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ABSTRACT 
Objective: To test the null hypothesis that administering misoprostol orally or vaginally will 
result in no difference in time to vaginal birth, and to determine whether different frequencies 
of tachysystole and hyperstimulation are associated with route of administration. 
Methods: Two hundred six women after 37 completed weeks' gestation who presented with an 
indication for induction were randomly assigned to receive misoprostol (50 fJg) orally or 
vaginally every 4 hours as needed to induce labour. Placebo use and-allocation concealment 
accomplished blinding until data analysis was completed. Sample size was calculated to allow a 
two-tailed a of .05 and power (1-~) of 80%. All fetal hean rate and uterine activity graphs 
were classified according to Curtis' criteria before the induction groups were unmasked. 
Results: Analysis involved 104 women in the oral group and 102 in the vaginal group. The 
mean time(± standard deviation) to vaginal birth with oral misoprostol was 1072 (± 593) 
minutes compared with 846 (± 385) minutes with the vaginal protocol (P == .004). There were 
no significant differences in cesarean rate, epidural use or neonatal outcomes. More frequent 
tachysystole for 20 minutes (P < .01) and hyperstimulation (P < .04) were observed with 
vaginal misoprostol. No neonatal asphyxia occurred in either group. 
Cond~tsion: Misoprostol effectively induces labour, given orally or vaginally. There is a shorter 
interval to vaginal birth with vaginal application; however, the more frequent occurrence of 
fetal heart graph abnormalities in this group suggests that, until the optimal dosing interval for 
vaginal use is determined, the preferred route of misoprostol administration might be oraL 
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Chapter 1 
INTRODUCTION 
Induction of Labour 
Induction of labour is the initiation of cervical ripening and uterine contractions 
before their spontaneous onset. Induction is often indicated for a variety of obstetrical, 
medical or fetal complications of pregnancy. Various mechanical and pharmacological 
methods are currently used to induce labour; however, no single method or agent has been 
suitable for all clinical situations. All available methods of induction of labour have associated 
medical risks; therefore, the decision to induce labour should only be made when the risk of 
continuing a pregnancy outweighs the risk of induction. 
For cenain clinical conditions such as severe preeclampsia, the decision to induce 
labour is straightforward. For other conditions, the point at which the risk of continuing 
pregnancy outweighs the risks associated with induction is not clear. Funhermore, the risk-to-
benefit ratio may be influenced by the methods used to induce labour, and by the methods 
used to assess fetal well-being when expectant management is chosen. Induction requires 
continuous electronic fetal and uterine contraction monitoring, which often reduces a woman's 
mobility md comfon. 
Ideally, induction agents should mimic spontaneous labour while avoiding e.""<cessive 
uterine activity. However, because the mechanisms that control the initiation of parturition are 
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not well understood, such goals are difficult to achieve. The major concerns associated with 
induction are ineffective labour and excessive uterine activity. Both problems may lead to an 
increased risk of cesarean delivery. Excessive uterine activity is defined as contractions of 
abnormally high intensity or frequency that lead to impaired uteroplacental circulation and 
consequently, decreased fetal oxygenation. When contractions of abnormally high intensity or 
frequency occur, insufficient recovery time resulting in fetal heart rate abnormalities could 
necessitate operative delivery or lead to fetal asphyxia. 
Cervical Ripening for Labour Induction 
In 1964, Bishop1 described a pelvic scoring system that predicted vaginal delivery in 
multiparous women. The five components of the score were: position, consistency, 
effacement and dilatation of the cervi.x and station of the fetal venex. A ma.ximum score of 
thineen described a ripe cervix. Bishop noted that with a score of nine or more the risk of 
failed induction was minimal. Bishop scores of 0-3 indicated a high likelihood of failed 
induction. This served as the basis for the concept of ripening the cervi.x for women whose 
score is unfavourable, before attempting induction with oxytocin. 
Since the discovery of prostaglandins and their use as agents for induction of labour, 
a wide variety of different formulations, routes of administration and dosage regimens have 
been investigated. Currently, prostaglandin PGE! (dinoprostone) is the most widely used for 
the purpose of induction, with the preferred route of administration per vagina. A variety of 
vehicles have been developed for the delivery of this agent, including lactic acid-based 
pessaries, water-soluble gels and most recently, a slow -release hydrogel polymer. 
13 
Cbapter 2 
THE ROLE OF PROSTAGLANDINS IN LABOUR 
Prostaglandins are lipid molecules that act as intermediaries in several physiologic and 
pathologic processes. Prostaglandins of theE (PGE1, PGE~ and F (PGF ~) series have potent 
uterotonic effects and are commonly used as labour induction and cervical ripening agents. 
Recent advances in molecular biology and biochemical techniques have allowed deeper 
understanding of the role prostaglandins play in the process of parturition. 
Prostaglandin Synthesis 
Biologically active eicosanoids are formed from polyunsaturated fatty acids. 
Arachidonic acid is the most common naturally occurring precursor and must be released 
from cell membrane stores, where it exists in an esterified form. The liberation of arachidonic 
acid from membrane phospholipids is generally considered the initial step in the synthesis of 
prostaglandins.~ This release from the esterified position is accomplished by the action of 
phospholipases, primarily phospholipase A2 (PLA~. PLA2 catalyzes the liberation of 
arachidonic acid from phosphatidylethanolamine, phosphatidylserine and phosphatidylysine . .! 
PLA2-type IT is the most abundant of four subtypes of the enzyme in the placenta, fetal 
membranes and decidua. The activity ofPLA2 is increased in the amnion and placenta during 
labour.3 The action of phospholipase C (PLC) is indirect, catalyzing the hydrolysis of 
15 
Oral administration of prostaglandins in obstetrics has virtually been abandoned 
because of the severe gastrointestinal side effects associated with existing preparations. 
Administration of prostaglandins for induction of labour has been limited to intracervical and 
intravaginal routes. An oral induction agent that is safe, effective, inexpensive and well-
tolerated by patients would likely be attractive to patients and health care providers. Several 
researchers have conducted randomized trials comparing vaginal misoprostol to standard 
therapy and have found it to be a safe and effective prostaglandin for induction of labour. No 
previous masked randomized comparisons of oral and vaginal misoprostol (SOJ.1g every four 
hours) for labour induction have been published in the English language literature. 
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phosphatidylinositol into diacylglycerol and inositoltriphosphate. Diacylglycerol is then 
metabolized by diacyl- and monoacylglycerollipases into glycerol and free fatty acids, including 
arachidonic acid. 2 At least ten distinct PLC isoforms have been cloned and sequenced." 
The second step in prostaglandin synthesis is the oxygenation and reduction of 
arachidonic acid to form an unstable intermediate, endoperoxide (PGH~. 5 This step is 
catalyzed by prostaglandin endoperoxide H synthase (PGHS). Two forms of PGHS have 
been identified: PGHS-1 and PGHS-2, each having cyclooxygenase and peroxidase activities.~> 
The principal feature distinguishing PGHS-1 and PGHS-2 is the regulation of their e.xpression. 
PGHS-1 is a gene product constitutively expressed under normal physiological conditions. 
Levels of PGHS-1 increase late in gestation and peak at term, but do not rise in response to 
labour/ PGHS-2 is an inducible enzyme that is expressed after stimulation of the amnion and 
chorion by cytokines, growth factors or tumour promoters.7 ,II Recent studies suggest that the 
increased production of prostaglandins by intrauterine tissues during labour results from an 
increase in the expression of the PGHS-2 isoform. 9"11 
The third enzymatic step in prostaglandin synthesis is the conversion of the 
endoperoxide intermediate to one of the biologically active prostaglandins (02, E2. F za, I~ or 
thromboxane A2• Individual cell types contain one primary isomerase, reductase or synthase 
that converts the endoperoxide to a specific prostaglandin characteristic of that cell. An 
additional factor involved in modulating levels of active prostaglandins is the regulation of the 
rate at which these compounds are metabolized. Chorionic cytotrophoblasts contain abundant 
levels of the prostaglandin-metabolizing enzyme prostaglandin 15-hydroxydehydrogenase 
(PGDH), which catalyses oxidative inactivation of E and F series prostaglandins. 12 
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Prostaglandin Receptors 
Prostaglandins exen their action through specific membrane receptors. The 
regulation of uterine smooth muscle contraction is controlled by the quantity and distribution 
of prostaglandin receptors as much as by the tissue concentration of biologically active 
prostaglandins. The prostaglandin E receptor has four subtypes: EP 1, EP 2, EP 3 and EP _.. 
These couple to two major effector pathways. 13 EP 1 and EP 3 receptors promote muscle 
contraction through mechanisms that include increased calcium utilization and inhibition of 
intracellular cyclic adenosine monophosphate (cAMP). EP 2 and EP _. act through increased 
cAMP formation to cause a relaxation of smooth muscle . H Prior to term, the action of EP 1 
receptor is a factor in maintaining myometrial quiescence. 
The expressiOn of myometrial prostaglandin receptors increases during late 
gestation. 15 At term, EP 1 and EP 3 receptors in the uterine fundus act to promote uterine 
contractions. EP 2 and EP _. receptors are concentrated in the lower uterine segment and 
cervix and may facilitate cervical effacement and dilation. Misoprostol is a synthetic 
prostaglandin E1 analogue that is rapidly absorbed following oral administration. It is de-
esterified to the active metabolite misoprostol acid. Misoprostol acid binds to EP 3 and EP,. 
receptors. l6 When used as a labour induction agent, it can effect contraction of the uterine 
fundus and relaxation of the lower uterine segment and cervix. 
Challis et al.17 described compartmentalization of prostaglandin synthesis and 
metabolism within the human fetal membranes, decidua and myometrium in late gestation. In 
the amnion, prostaglandin H 2synthase (PGHS) activity predominates, with an increase in the 
e..xpression of the PGHS-2 isoform at the time of labour. Prostaglandin E2 is the principal 
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prostaglandin formed in the amnion. The chorion contains high concentrations of PGHS and 
the prostaglandin-catabolizing enzyme 15-hydroxyprostaglandin dehydrogenase (PGDH). A 
reduced activity of PGDH has been shown to be associated with preterm labour. 18 
During labour, PGDH undergoes a reduction in activity in the portion of fetal 
membranes overlying the cervical os.19 The reduced activity of this enzyme in the region of 
the cervix is believed to potentially facilitate passage of active PGE1 from the amnion across 
the chorion, thereby facilitating cervical ripening. Funhermore, abnormal persistence of this 
enzyme might hinder the ripening process by diminishing the concentration of prostaglandins 
within the cervix. 10 The maternal decidua is a source of significant prostaglandin synthesis; 
however, the levels of PGHS-1 and PGHS-2 do not change during gestation or with labour 
onset. It has therefore been postulated that one of the phospholipases may be the primary 
rate-determining factor in decidual prostaglandin synthesis. 11 
Prostaglandins and Parturition 
Our knowledge of the mechanism of parturition in humans is increasing but not all 
relevant pathways have been completely elucidated. Prostaglandins clearly play an imponant 
role in the human labour process; however, a precise and complete description of their 
mechanism continues to be sought. They appear to be active in the triggering or facilitation of 
a complex sequence of events involving the fetus, fetal membranes and maternal tissues. tt-.u 
The role of the human fetus in initiating labour is not well defined. In animal studies, 
it has conclusively been shown that the fetal sheep triggers the onset of labour through 
activation of the fetal hypothalamic-pituitary-adrenal axis (HP A), resulting in increased 
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secretion of cortisol from its adrenal gland.11 Fetal cortisol acts on the placenta to upregulate 
prostaglandin synthesis, and to change the pattern of steroidogenesis, such that progesterone 
levels fall and estrogen levels rise. Once activated, the ovine myometrium is able to respond 
effectively to stimulation provided by the increased production of uterotonic agents such as 
oxytocin and prostaglandins. While a similar mechanism has not conclusively been 
demonstrated in humans, homology to the human parturition process is hypothesized. 
In humans, the bioactivity of circulating corticotropin-releasing hormone (CRH) is 
diminished during pregnancy by the presence of a high-affinity CRH-binding protein (CRH-
BP) in maternal blood.n This blocks the action of CRH in promoting ACTH release from 
pituitary cells and inhibits the stimulatory effect of CRH on prostaglandin production by 
intrauterine tissues. CRH-BP levels fall near term, with a corresponding increase in the activity 
of CRH. Studies in primatesn-29 have suggested that cortisol of fetal origin acts to promote 
delivery. Cortisol activates amniocytes, cytotrophoblasts and decidual cells to express CRH, 
further enhancing prostaglandin production by these cells. In addition, elevations in CRH may 
act synergistically with oxytocin or prostaglandins to stimulate myometrial contraction. 211 
Recent studies have demonstrated that exogenous glucocorticoid administration stimulates 
expression of CRH by placenta, decidua and fetal membranes, which in turn enhances 
prostaglandin synthesis and impairs prostaglandin metabolism in these tissues, promoting 
parturition. n 
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Prostaglandins and Cervical Ripening 
In 1947 Danforth30 characterized the connective tissue component of the cervi.x and 
recognized that changes in its structure and biochemistry were key elements of cervical 
ripening. The mechanism of cervical ripening involves a series of biochemical events distinct 
from those responsible for myometrial activation and similar to those observed in tissue 
inflammation.31 The trigger responsible for initiating the biochemical events that lead to 
cervical ripening has not yet been identified. Prostaglandins play an important role in cervical 
ripening; however, the molecular actions of prostaglandins to effect cervical ripening has not 
been fully defined. 
Smooth muscle and fibroblasts make up the cellular component of the human cervi."X. 
The extracellular matrix is composed of substances secreted by fibroblasts, such as collagen, 
glycosaminoglycan and glycoproteins. The glycosaminoglycans are comprised of repeating 
units of hexosamines or uronic acid linked as polymer chains. Chondroitin sulfate and 
dermatan sulfate are sulphated glycosaminoglycans while hyaluronate and chondroitin are 
unsulfated glycosaminoglycans. The glycosaminoglycans attach in branched patterns to 
glycoproteins to form very large molecules known as proteogylcans. 32 Elastin is another 
important component of the extracellular matrix of the human cervi.x. Elastin fibers are 
organized parallel to and between collagen fibers and are capable of being stretched in any 
direction. During pregnancy and particularly labour the uterine cervix undergoes dramatic 
changes in histological characteristics and biochemical composition. 
Early in gestation, cervical hyperplasia results from turnover of both smooth muscle 
cells and fibroblasts. As pregnancy advances, physiological cell death occurs, inducing 
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migration of neutrophils, macrophages and mast cells into cervical tissue.31 These cells 
produce inflammatory cytokines that are responsible for stimulating the production of 
metalloproteinases that cause collagen degradation at term. Nitric oxide may induce 
prostaglandin production by stimulating cyclooxygenase activity . n 
Ellwood et al. 3 .. described the production of prostanoids by the human cervix in 
pregnancy, demonstrating that the cervix produces E.:, I!, and F prostaglandins. The 
production of these compounds was furthermore shown to increase at term. Norstom et al.35 
postulated that prostaglandins might exen their effects on the cervix by modulating fibroblast 
activity, thereby controlling the biophysical and biochemical properties of the extracellular 
matri.~. They observed that cervical fibroblasts from women treated with prostaglandins 
undergo the same morphologic changes observed in women at the time of spontaneous 
labour. 
Murota et al. 36 demonstrated that prostaglandins are capable of stimulating the 
production of hyaluronic acid by cervical fibroblasts. The resulting tissue hydration alters the 
glycosaminoglycan/ proteoglycan composition in favour of cervical ripening. As pregnancy 
advances closer to term, multiple factors work together in comple.~ interactions that cause 
collagen dispersion and ripening of the cervix. At the onset of labour, these substantial 
changes in hyaluronic acid, cytokines and collagenases, combined with the mechanical force of 
uterine contractions extend cervical elastin and allow dilation of the cervbc required for 
parturition. 
21 
Cbapter 3 
MECHANICAL METHODS OF LABOUR INDUCTION 
Sweeping Membranes 
Stripping or sweeping of the fetal membranes was first described by James Hamilton 
in 1810.37 The technique involves mechanically separating the membranes from the lower 
uterus by sweeping a finger circumferentially around the interface of the fetal membranes with 
the lower uterine segment at the time of pelvic e.'<amination. Sweeping of the membranes aims 
to initiate labour through a cascade of physiological events, the exact mechanism of which is 
unknown. McColgin et al.311 concluded that membrane stripping causes acute elevation in 
plasma prostaglandin FJ.a and endocervical phospholipase AJ. activity. This release of local 
prostaglandins is believed to initiate cervical ripening and the onset of active labour. 
The Cochrane Library systematic review of stripping or sweeping of membranes for 
inducing labour or preventing post-term pregnancy assessed the effects of membrane 
sweeping to promote or induce labour on maternal and perinatal outcomes.39 Sweeping of 
membranes, performed in low-risk women at term, was associated with a decreased incidence 
of pregnancy continuing beyond 41 or 42 weeks' gestation (relative risk (RR) 0.42, 95% 
confidence interval (CI) 0.19-0. 93) but was not an effective induction method. The reviewers 
concluded that the routine use of sweeping the membranes at term did not seem to produce 
clinically important benefits. 
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Studies of sweeping membranes.f0-49 suffer from heterogeneity in study design and 
selection bias. Some of these studies have flaws in their design or analysis, as well as 
deficiencies in reporting of results. The frequency with which sweeping was performed 
varied from study to study. The first study by Swann et al . ..c described sweeping membranes 
daily for three days. The authors reponed an increase in the spontaneous delivery rate from 
26% to 69%. This study was not formally randomized and did not stratify based on parity 
or Bishop score. lvlcColgin et al.·41 examined membrane stripping performed weekly 
beginning at 38 weeks' gestation and found a significant decrease in the number of post-
dates pregnancies. Patient demographics were not described, making it impossible to assess 
comparability of the two groups. 
The study by Weissberg and Spellacy~l suffered from selection bias with an excess 
number of study group panicipants having documented Bishop scores greater than six. 
Several of the studies~3.~ enrolled only post-dates patients defined as beyond 40 completed 
weeks' gestation. Crane et al.~5 studied the effectiveness of sweeping membranes at 38-40 
weeks' gestation based on the ability to pass a finger through the internal os and strip the 
membrane by sweeping the examiner's index finger twice in a circumferential manner. No 
significant difference in the median number of days to delivery was detected between the 
groups (33% sweeping, 38% control, P - .39). 
Concerns may arise that membrane sweeping may not have been conducted 
properly in a number of these studies. As well, multiple episodes of sweeping potentially 
may be more effective than a single sweep. It is possible that sweeping membranes is more 
effective in post-dates than term patients or more effective in multiparous than nulliparous 
patients. The heterogeneity of results in published studies comparing sweeping membranes 
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to no intervention does not allow firm conclusions to be drawn about the relative merits of 
sweeping membranes for the purpose of labour induction with any degree of confidence. 
Balloon Catheters 
Obstetricians have used balloon catheters for more than 100 years to induce labour. 
Recently, Foley catheters have been used for this purpose. 50 After thorough cleansing of the 
vagina and cervix, the catheter is inserted into the endocervix and passed above the level of 
the internal cervical os. The balloon is then inflated with 30-50 ml of sterile saline and left in 
place for 24 hours or until spontaneous expulsion. ;r,s.:! Some authors suggest the application 
of traction to the catheter or the infusion of saline through the catheter to accelerate the 
ripening process.53"56 
The mechanism believed to be responsible for cervical ripening is direct pressure 
and overstretching of the lower uterine segment, causing local secretion of prostaglandin. 
This mechanism is attested to by an increase in prostaglandin levels in maternal blood.57 
Balloon catheters are absolutely contraindicated in patients with a low-lying placenta or 
antepartum hemorrhage. Other relative contraindications include cervicitis and ruptured 
membranes. No randomized trials assessing the Foley catheter for cervical ripening have 
included patients with a history of previous cesarean delivery. 
Several investigators compared the balloon catheter to intravaginal prostaglandin 
gel, finding the catheter to be significantly more effective than placebo, and as effective as 
prostaglandin in ripening an unfavourable cervix, as measured by the Bishop Score and 
duration of labour.58..(,1 No significant difference was found in the cesarean delivery rate. 
Spontaneous labour; however, occurred significantly more frequently in the prostaglandin 
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group. Atad et al.I,(J reported their experience with a special double balloon catheter and 
concluded that it was as good as prostaglandin E2 {dinoprostone) vaginal tablets and better 
than oxytocin in terms of change in Bishop score, interval to delivery and cervical ripening 
failure rates. 
St. Onge et al.61 compared 0.5 mg intracervical prostaglandin E2 gel (n- 30) with 
Foley catheter (n - 36) in a small randomized clinical trial. The authors concluded that there 
was no difference in efficacy between intracervical prostaglandin (n =- 28) and intracervical 
Foley catheter (n - 34) as measured by the mean change in the Bishop score. The induction 
to delivery interval was significantly shorter in the Foley catheter group (P - .01). 
Chamberlain et al.62 compared outpatient intracervical prostaglandin E2gel (n""' 
67) with intracervical Foley catheter insertion overnight (n - 62). Both the intracervical 
Foley catheter and the intracervical prostaglandin E2 gelled to similar changes in Bishop 
score. The Foley catheter was more commonly associated with cervical dilatation of three to 
four centimetres despite the requirement for significantly more oxytocin to induce labour (P 
= .003). There was no difference in route of delivery or adverse maternal events. 
A few randomized trials have compared intracervical Foley catheter plus extra-
amniotic saline infusion to intravaginal or intracervical prostaglandin E2 for cervical ripening 
in women with an unfavourable cervix. 53-56 The results of these studies were contradictory 
and inconclusive. In two studies, fewer ripening failures occurred in the Foley catheter 
group. 53.5-t L yndrup et al. 56 reported that prostaglandin E2 was more efficient in inducing 
regular uterine contractions in nulliparous women; furthermore, Foley balloon catheter 
ripening was associated with a longer latent phase of labour. Two of these trials 53.55 found 
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no difference in cesarean delivery rates and two reported an increased cesarean delivery rate 
in those patients randomized to the balloon catheter group. 54•56 
The advantages of cervical ripening with extra-amniotic balloon catheters include: 
simplicity, low cost, reversibility and lack of severe maternal or fetal side effects when 
compared with intravaginal prostaglandin E2_ The disadvantages include pain and 
discomfort, decreased maternal mobility and a greater need for oxytocin augmentation. The 
data further indicates that prostaglandin use is more likely to result in spontaneous labour 
and less likely to result in failed induction. The heterogeneity of results in published studies 
comparing prostaglandin E2 with Foley catheter does not allow firm conclusions about their 
relative merits to be drawn with any confidence. 
Synthetic Hygroscopic Dilators 
Hygroscopic dilators made from either natural or synthetic materials are inserted 
into the cervical canal under direct visualization using an aseptic technique. The dilators are 
placed in the endocervix and kept in place by sterile gauze placed in the vagina. These 
devices take up fluid from the surrounding tissue, gradually swell and ultimately cause 
dilation of the cervical canal. The stretching of the cervix causes local prostaglandin release. 
These devices are usually contraindicated in cases of ruptured membranes, cervicitis and 
vaginal bleeding. Their use in patients with a history of previous cesarean has not been 
studied. 
Research groups6J-M have investigated synthetic hygroscopic dilators such as 
Dilapan® (Gynotech, Middlesex, NJ) and Lamicel® (Cabot Medical Group, Langhorn, P A) 
to assess their effectiveness as cervical ripening agents. Dilapan® was shown to cause a 
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significant change in Bishop score within six to twelve hours of insertion. This change was 
comparable to prostaglandin and better than placebo. In a large randomized clinical trial of 
444 women at term, the use of prostaglandin was associated with a higher rate of successful 
induction, shorter labour, less use of oxytocin and fewer infections in the mother and 
newborn when compared to Dilapan®l>4. 
Natural Hygroscopic Dilators 
Natural laminaria are made from dried seaweed. In controlled studies, the 
overnight insertion of laminaria was found to cause significant change in the Bishop score in 
patients with unfavourable cervixes. 65-69 In two of these studies, patients with preinduction 
ripening with laminaria had higher rates of successful induction and shorter induction-to-
delivery intervals compared with controls receiving only oxytocin."5' 66 These findings were 
contrary to findings of two other groups. 67• 611 A recent randomized clinical trial comparing 
laminaria to extra-amniotic saline infusion reported that laminaria shortened the interval to 
delivery by eliminating the need for a preinduction ripening interval.67 No significant 
difference was noted in rates of cesarean delivery or adverse maternal or neonatal outcomes. 
Induction of labour is often indicated when the benefits to either the mother or the 
fetus outweigh the benefit of continuing the pregnancy. Obstetricians routinely use various 
mechanical methods to ripen the cervix; however, no single mechanical approach has 
enjoyed universally superior success or acceptance. The consistency of the cervLx is dearly 
related to the rate of success of labour induction and to the duration of the induction-to-
delivery interval. Women with the most unfavourable cervixes still face high rates of 
induction failure and cesarean delivery. The safety of mechanical methods for induction of 
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labour has not been established. There is a need for properly designed and conducted 
randomized clinical trials to evaluate the efficacy and safety of many of the mechanical 
methods of labour induction reviewed here. 
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Chapter 4 
PHARMACOLOGIC INDUCTION AGENTS 
Pharmacological Induction Agents 
Pharmacological techniques for induction of labour were first described over 400 
years ago. 70 One of the first recorded references described the use of juniper berries, cinnamon 
and castor oil to hasten binh. In 1906, Sir Henry Dale discovered uterotonic bioactivity in 
e.xtracts of the posterior pituitary gland. William Blair Bell administered a crude preparation of 
these extracts to pregnant women and reponed the first clinical studies on oxytocin use for 
induction of labour in 1909.71 Pierce and Du Vigneaud determined the structure of oxytocin 
in 1950, for which Du Vigneaud was later awarded a Nobel Prize in chemistry. Charles Liebn 
first discovered prostaglandins in 1930 but it was not until the late 1960s and early 1970s that 
prostaglandins E1 and E2 were first used clinically for induction of labour. 
Since the discovery of prostaglandins and their use as agents for induction oflabour, 
a wide variety of different formulations, routes of administration and dosage regimens have 
been investigated. Currendy, prostaglandin PGE2 (dinoprostone) is the most widely used for 
the purpose of induction, with the preferred route of administration per vagina. A variety of 
vehicles have been developed for the delivery of this agent, including lactic acid-based 
pessaries, water-soluble gels and most recendy, a slow -release hydrogel polymer. 
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Dinoprostone 
Dinoprostone (PGE.J intracervical and intravaginal gel has been the prostaglandin 
agent of choice for several decades and is currently the only pharmacological agent approved 
by the U.S. Food and Drug administration and the Therapeutic Products Program of Health 
Canada. It is available in three forms: a 0.5 mg endocervical gel {Prepidil®; Upjohn 
Pharmaceuticals, Kalamazoo, MI), a 1.0 mg or 2.0 mg vaginal gel {Prostin®; Upjohn 
Pharmaceuticals, Kalamazoo, MI) and a controlled-release prostaglandin vaginal insert 
available in the United States (Cervidil~; Forest Pharmaceuticals, St. Louis, MO), Canada and 
Europe (Propess®, Ferring Pharmaceuticals AB, Malamo, Sweden).71•74 
A meta-analysis of selected randomized trials comparing dinoprostone with placebo 
or with no treatment has concluded that the use of prostaglandins for cervical ripening is 
effective and reduces the induction-to-delivery interval as well as the operative vaginal delivery 
rate.75 There was a higher rate of uterine hypertonus and uterine tachysystole in those patients 
who received prostaglandin (PGE.J compared to oxytocin and a trend toward higher rates of 
abnormal fetal heart rate patterns. There are no randomized trials evaluating the required 
duration of fetal heart rate (FHR) and uterine contraction monitoring after prostaglandin gel 
dosing. 
Recent studies have noted a higher rate of successful induction, greater change in 
Bishop score and shorter induction-to-delivery interval with the use of vaginal gel (Prostin®) 
compared to intracervical gel (Prepidil®).76 There is insufficient evidence to make firm 
conclusions about the relative effects of prostaglandins and oxytocin on substantive maternal 
and neonatal adverse outcomes. 
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Controlled-Release Insert 
The controlled-release insert consists of a polymer base containing 10 mg of 
dinoprostone with a polyester retrieval system. The insert is placed in the posterior fornix of 
the vagina and releases 0.3 mg per hour of prostaglandin E2 over a twelve-hour period. It is 
removed with the onset of labour, at spontaneous rupture of membranes, with excessive 
uterine activity or after twelve hours. Theoretical advantages include ease of administration 
and the ability to remove the medication if excessive uterine activity occurs. 
Although widely used, these preparations may cause excessive uterine activity leading 
to placental insufficiency and abnormal fetal heart rate changes, and are associated with greater 
cost and more elaborate storage requirements. Dinoprostone must be refrigerated until shortly 
before administration. The average wholesale price ofPrepidil® is $48.98 per 0.5 mg dose, 
Prostin® $54.00 per 2.0 mg dose and $84.00 for the 10 mg vaginal insert. 
Several author?·79 have compared Cervidil® to placebo and demonstrated that it is 
effective in cervical ripening but is associated with a higher incidence of excessive uterine 
activity and hyperstimulation when compared to prostaglandin E2 intracervical gel. In a recent 
meta-analysis performed by our research group, 80 we e."<amined the effectiveness and safety of 
controlled-release prostaglandin for cervical ripening in nine randomized trials that compared 
controlled-release vaginal prostaglandin (with a retrieval string) with any other cervical 
ripening agent or with placebo. After assessing the homogeneity of results, the summary odds 
ratio and confidence intervals were determined. 
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Compared with placebo, controlled-release prostaglandin resulted in cervical change 
(summary odds ratio (OR)- 3.99, 95% (CI)- 2.71, 5.86), a higher rate of vaginal delivery in 
12 hours (OR- 29.01, 95% CI- 7.08, 118.87) and less need for oxytocin (OR== 0.14, 95% 
CI 0.06, 0.32) but a higher incidence of excessive uterine activity (P < .001) and 
hyperstimulation (P = .004). When compared with Prepidil®, there was a higher rate of 
excessive uterine activity with controlled-release prostaglandin (P == .03), but less need for 
oxytocin (OR - 0.09, 95% CI - 0.01, 0.53). With Prepidil® plus immediate oxytocin, there 
was a lower rate of active labour in twelve hours compared with controlled-release 
prostaglandin (OR - 0.27, 95% Cl== 0.10,0.72). 
There was a lower rate of vaginal delivery in 12 hours and a higher incidence of 
oxytocin use with controlled-release prostaglandin as compared with misoprostol (OR = 0.53, 
95% CI - 0.34, 0.83 and OR - 1.58, 95% CI 1.08, 2.32, respectively). The induction-to-
delivery interval was shorter with controlled-release prostaglandin than with placebo or 
Prepidil® but longer than with Prepidil® plus augmentation with immediate oxytocin or 
misoprostol. Although no differences in maternal or fetal morbidity were noted, the sample 
size was not adequate to evaluate these outcomes. Controlled-release prostaglandin is an 
effective cervical ripening agent as compared with Prepidil® but may result in an increased 
incidence of excessive uterine activity. Controlled-release prostaglandin may not be as 
effective as misoprostol or Prepidil® plus immediate oxytocin. The American College of 
Obstetricians and Gynecologists recommends that the fetal heart rate and uterine activity be 
continuously monitored electronically for the duration of insert placement.11 t 
32 
Misoprostol 
Misoprostol (Cytotec®; Searle, Oakville, ON), a synthetic prostaglandin (PGE J 
analogue, is marketed in an oral formulation of 100 ~-&g or 200 ~-&g tablets.82 It is currently 
approved by the U.S. Food and Drug Administration for use in the treatment and prevention 
of gastrointestinal ulcer disease resulting from non-steroidal anti-inflammatory use. 
Misoprostol is an inexpensive prostaglandin capable of initiating uterine contractions; 
therefore, it has been extensively investigated for use as an induction agent in pregnancy. A 
single 100 J,lg tablet costs $ 0.30; therefore, a single 50 ~g dose may cost as little as $0.15. 
Misoprostol is also temperature-stable and does not have special storage requirements. 
Vaginal misoprostol is currently widely used in the United States for cervical ripening and 
labour induction; however, investigations continue regarding the optimal dose, dosing regimen 
and route of administration. 
Review of Vaginal Misoprostol Literature 
Since the first clinical trial of vaginal misoprostol for labour induction reported by 
Margulies et al. in a letter to the Lancet in 1992, there has been growing interest in misoprostol 
for use as a labour induction agent.113 In this randomized trial, 64 women beyond 28 weeks' 
gestation undergoing induction of labour were given 50 ~g doses of intravaginal misoprostol 
or intravenous oxytocin. Successful induction was defined as vaginal delivery within 24 hours 
of the start of induction. More women in the misoprostol group achieved successful vaginal 
delivery within 24 hours than in the oxytocin group (79% compared with 62%). The mean 
time (± standard deviation) to vaginal birth delivery 407 (± 265) minutes in the misoprostol 
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group and 577 (± 605) minutes in the oxytocin group P = 0.02. There were no differences in 
mean birth weight or Apgar scores. No adverse fetal or neonatal outcomes were reported; 
however, this small study did not have sufficient power to form conclusions about maternal or 
fetal risks. The authors concluded that intravaginal misoprostol was more effective than 
oxytocin for labour induction in the third trimester of pregnancy. 
Several randomized trials 8>97 comparing vaginal misoprostol to standard therapy 
(dinoprostone) found misoprostol to be safe and effective for induction of labour. In 1993 
Sanchez-Ramos and colleagues8 .. compared 50 J.tg of intravaginal misoprostol administered 
every four hours to intravenous oxytocin in 129 women with uneffaced and undilated cervixes. 
The interval from the start of induction to delivery was significantly shorter in the misoprostol 
-treated group (11 versus 18 hours, P == .004); however, the frequency of uterine tachysystole 
(defined as six contractions in a 10 minute period, repeated over two consecutive 10 minute 
periods) in the misoprostol group was approximately three times that found in the oxytocin 
treatment group (34.4% versus 13.8%, P < .05). No differences were found in delivery route, 
neonatal or maternal morbidity. 
The authors concluded that vaginal misoprostol was safe and effective for labour 
induction and recommended further investigation to detail the optimal route, dose and dosing 
regimen. The frequency of excessive uterine activity was evaluated as a secondary outcome in 
the study, and did not form a basis for calculation of sample size. Investigators who reviewed 
fetal tracings were not blinded to group assignment. The non-blinded study design and the 
subjective nature of the evaluation and classification fetal heart rate tracings introduces bias 
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and raises concerns about inter-observer and intra-observer variation. This study did not have 
sufficient power to draw firm conclusions about the safety of misoprostol. 
In 1995, Winget al. 85 compared the administration of intravaginal misoprostol50 JJg 
every three hours with intracervical dinoprostone 0.5 mg every six hours in 135 women with 
unfavourable cervixes (Bishop score less than 4). Misoprostol was found to be more effective 
for labour induction. The mean time (±standard deviation) to vaginal birth was 903 (± 482) 
minutes in the misoprostol-treated subjects and 1410 (± 482) minutes in the control group (P 
< .001). The misoprostol-treated subjects required oxytocin augmentation much less 
frequently than those treated with dinoprostone 33.8% versus 65.7%, (P < .001). More than 
70% of women in the vaginal misoprostol group delivered vaginally within 24 hours compared 
with 47% of dinoprostone-treated women (P < .01). 
Misoprostol was associated with a 36% incidence of tachysystole (defmed as greater 
than six or more uterine contractions occurring in 10 minute window for two consecutive 10-
minute periods) compared with a 12% incidence of tachysystole in the dinoprostone treated 
group (P < .001). A 30% incidence of passage of meconium in utero was noted in the 
misoprostol group compared with a 10% passage of meconium in the dinoprostone-treated 
group (P < .05). No significant difference in maternal or neonatal outcomes was found 
between the two groups. 
The limitations of this study include, lack of blinding, an empiric dosing regimen and 
lack of rigor in defining the treatment of study group and controls. The 50 f.lg dose of 
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misoprostol every three hours was extrapolated from a previously published study of 
misoprostol. 8.. There was a difference in the time intervals from last dose of medication to 
allowable administration of oxytocin which could have potentially biased the primary outcome. 
Oxytocin administration was permitted three hours after the last dose of misoprostol and six 
hours after the last dose of dinoprostone. The frequency of excessive uterine activity and 
meconium staining were evaluated as secondary outcomes in this study. Investigators who 
reviewed fetal tracings were not blinded to group assignment. The non-blinded study design 
and the subjective nature of the evaluation and classification fetal heart rate tracings introduces 
bias and raises concerns about inter-observer and intra-observer variation. This study did not 
have sufficient power to draw firm conclusions about the safety of misoprostol. 
In 1996, Mundie et al.116 compared 50 !Jg vaginal misoprostol administered every 
four hours to standard labour induction methods (dinoprostone and or oxytocin) in 222low-
risk women undergoing cervical ripening and labour induction at term. The mean time to 
vaginal delivery (±standard deviation) was 753 (± 588) minutes for vaginal misoprostol versus 
941 (± 506) minutes for intracervical or intravaginal dinoprostone. Oxytocin augmentation 
was used less frequendy in the misoprostol group (RR = 0.48, 95% CI 0.31, 0.7 4). There were 
no significant differences in cesarean rate. Maternal and neonatal outcomes were not 
significandy different. 
The major weaknesses of this study were lack of blinding and rigor in defining the 
standard protocol. The control group could receive one of several options: Prepidil® 0.5 mg 
intracervically every six hours, Prostin® 1 or 2 mg intravaginally every six hours or a dilute 
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solution of oxytocin administered intravenously. The choice of the agent to be used in the 
control group was to be chosen by the individual attending physician caring for that patient 
based on whichever option the physician felt was optimal for the care of that particular patient. 
This study did not have sufficient power to draw firm conclusions about the safety of 
misoprostol. 
In a subsequent clinical trial involving 276 women, Winget al. 87 used a lower dose of 
misoprostol, comparing 25J,lg of intravaginal misoprostol every three hours with 0.5 mg of 
dinoprostone administered intracervically every six hours in an attempt to reduce the 
occurrence of tachysystole and meconium passage noted in the misoprostol group in their 
earlier trial.85 Misoprostol was found to be effective for labour induction in women with 
unfavourable cervi.xes (Bishop score less than 4). The mean time (± standard deviation) to 
vaginal birth was 1323 (± 844) minutes in the misoprostol-treated subjects and 1532 (± 706) 
minutes in the control group (P < .05). The misoprostol-treated subjects required oxytocin 
augmentation much less frequently than those treated with dinoprostone 46% versus 73%, (P 
< .001). 
The dosing regimen of misoprostol25 !Jg every three hours was associated with a 
17% incidence of tachysystole (defined as greater than six or more uterine contractions 
occurring in 10 minute window for two consecutive 10-minute periods) compared with 14% 
incidence of tachysystole in the dinoprostone treated group (P ==0.08). A 17% incidence of 
passage of meconium in utero was noted in the misoprostol group compared with a 14% 
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passage of meconium in the dinoprostone-treated group (P > .05). No significant difference in 
maternal or neonatal outcomes was found between the two groups. 
Limitations of this study include lack of blinding and a discrepancy in treatment 
between the study and control groups. Allowable dosing intervals from last dose to start of 
oxytocin differed in the investigational protocol, 6 hours for dinoprostone and three hours for 
misoprostol. Pharmacokinetic studies would have strengthened this study considerably. The 
primary outcome was the achievement of successful induction. All other outcomes were 
secondary. This study did not have sufficient power to draw firm conclusions about the safety 
of misoprostol. 
Sanchez-Ramos et al. ~8 studied the safety and efficacy of vaginal misoprostol for 
cervical ripening and labour induction in a meta-analysis of trials published up to 1997. Of 16 
trials identified, eight 8"· ~s. 87' 89-?J met their criteria and included 966 patients, 488 of whom 
received vaginal misoprostol for labour induction. Controls received oxytocin or vaginal 
dinoprostone. Those who received vaginal misoprostol had a higher incidence of vaginal 
delivery within 24 hours of application (OR 2.64, 95% Cl 1.87, 3.71) and a lower cesarean rate 
(OR 0.67, 95% CI 0.48,0.93). Use of vaginal misoprostol was associated with a higher 
incidence of tachysystole (OR 2.70, 95% CI 1.80, 4.04) but not ofhyperstimulation (OR 1.91, 
95% CI 0.98, 3.73). 
The number of subjects allocated to the misoprostol group ranged from 24-138 with 
control groups of similar size. Five of the eight trials included were conducted in the United 
StatesS-t.ss.B7. 92.93 while the other three were conducted in South America.ll9-91 The proportion of 
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nulliparous patients were similar and all patients enrolled in the control group received 
dinopro~one or oxytocin with the exception of one small trial where control patients received 
placebo. 
The primary problem with this meta-analysis was the heterogeneity in study design. 
The dose of misoprostol varied from 25 J.tg every two hoursn to lOO J.Lg119·'}0 as a single dose. 
There was no one standard treatment for the control groups. In one study, placebo was used 
in the control group. 89 In two studies, s ... 91 dinoprostone 0.5 mg intracervically could be used 
with or without oxytocin. In the remaining four studies controls received dinoprostone 0.5 
mg intracervically. 85' 87' n. 93 In one study the dose of intravaginal dinoprostone was 3 mg.'JC 
Continuous electronic fetal monitoring was performed on all patients in si-x studies 
while the other two studies used fetal monitoring intermittently.119' 90 None of the individual 
trials had sufficient power to detect a reduction in cesarean delivery rate; however, a reduction 
in overall cesarean rate was observed when the studies were considered together. The 
reduction in cesarean rate in this meta-analysis depended heavily on one study.91 When the 
analysis was repeated after e.xcluding each trial, it appeared that the Campos study was an 
important contributor to the overall heterogeneity due to its large discrepancy in cesarean rates 
between the misoprostol (3.8%) and control groups (25.3%). 
In an attempt to define the optimal dosing regimen of vaginal misoprostol, Winget 
al.9• compared 25 J.Lg of intravaginal misoprostol every three hours with 25 J.Lg of intravaginal 
misoprostol administered every six hours in 522 women with unfavourable cervi-xes (Bishop 
score < 4). In this trial, the six-hour regimen was found to be less efficacious than the three-
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hour regimen. The mean time (±standard deviation) to vaginal binh was 903 (± 482) minutes 
in the three-hour dosing group and 1410 (± 869) minutes in the si."<-hour dosing group (P < 
.001). The overall frequencies of uterine contraction abnormalities were 14.6% with the three-
hour dosing interval and 11.2% with the six-hour dosing interval (P < .05). A low incidence of 
uterine hypenonus and hyperstimulation was observed with both regimens (4.2% with the 
three-hour dosing and 4.6 with the six-hour dosing regime). The frequency of meconium 
passage was lower with the longer dosing interval than that observed in earlier studies (10%). 
No adverse fetal outcomes were reported; however, there was one maternal death from 
amniotic fluid embolus and two cesarean hysterectomies for uterine atony. This study did not 
have sufficient power to draw conclusions about maternal or fetal safety. 
Sanchez-Ramos et al.95 compared 50 f.lg of vaginal misoprostol with the slow-release 
dinoprostone vaginal insert. The vaginal insert was administered as a single application for a 
maximum of 12 hours. Misoprostol-treated women delivered in a shorter time interval than 
the dinoprostone treated women (P < .001) but e."<perienced more tachysystole (21.3% versus 
7.0%, P =- .004). No differences in route of delivery, intrapartum complications or adverse 
neonatal outcomes occurred between the two groups. The authors concluded that both agents 
were effective and safe but that misoprostol appeared more effective and offered substantial 
cost sav10gs. 
Winget al.96 compared the efficacy of 25 f.lg of misoprostol administered every four 
hours to a 24-hour exposure of the dinoprostone vaginal insen. Two hundred women were 
enrolled. There were no significant differences in the interval from stan of induction to 
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delivery. There were no significant differences in delivery route or use of oxytocin between 
the two groups. Approximately 50% of women in both treatment arms delivered vaginally 
within 24 hours. Uterine tachysystole and hyperstimulation occurred more often in the 
dinoprostone-treated subjects (18.4% versus 7.1%, P = .02). 
The Cochrane Pregnancy and Childbirth Group'~7 reviewed twenty-six selected 
randomized trials of vaginal misoprostol. They studied the effectiveness and safety of 
vaginal misoprostol compared with placebo, oxytocin or prostaglandin E1 for cervical 
ripening or induction of labour at term. The primary outcomes were the rate of vaginal 
delivery within 24 hours, the incidence of uterine hyperstimulation with associated changes 
in the fetal heart rate, the rate of cesarean delivery and the incidence of serious adverse 
effects in the fetus or the mother. 
When compared to dinoprostone, failure to achieve vaginal delivery within 24 
hours was reduced in four of five trials (RR 0.70, 95% CI 1.17-1. 99). The reported incidence 
of uterine hyperstimulation was increased with misoprostol (RR 1.59, 95% CI 1.02-2.48) as 
was meconium staining of the amniotic fluid (RR 1.38, 95% CI 1.06-1.79). Rates of vaginal 
instrumental delivery and cesarean delivery were inconsistent between trials. Overall, there 
was a reduction of instrumental deliveries with misoprostol (RR 0.75, 95% Cl .58-.97). 
There were no significant differences in perinatal or maternal outcomes. 
When comparing low dose regimens of misoprostol to higher doses regimens (25 
J.lg every six hours compared to every three hours or 25J.lg compared to 50J.lg every three 
hours) neither group showed significantly more failures to achieve delivery within 24 hours 
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(RR 1.08, 95% CI .93-1.25). There was significantly more use of oxytocin for labour 
augmentation in the low dose group (RR 1.32, 95% CI 1.11-1.56). There was a trend toward 
less uterine hyperstimulation, fewer low Apgar scores at five minutes and fewer admissions 
to neonatal intensive care units. There were no differences in mode of delivery, meconium 
stained amniotic fluid or maternal side effects. 
The Cochrane collaborative group concluded that in dosages of 25 J.Lg every three 
hours or greater, misoprostol is more effective than dinoprostone and oxytocin for the 
induction of labour at term. No differences in perinatal outcomes were shown; however, the 
studies were not sufficiently large to exclude the possibility of uncommon serious adverse 
effects. Although vaginal misoprostol showed promise as a highly effective, inexpensive 
and convenient agent for labour induction, it could not be recommended for routine use at 
this time.9M 9 
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Table 1: Summary of Randomized Trials of Vaginal 
Misop_rostol for Labour Induction 
Author Year No. Misoprostol Control group Results Pts. Dose 
Indue-delivery time 
Margulies83 1992 64 50 J,Lg q2h Oxytocin shorter (miso.) 
(P- .02) 
Sanchez8 .. Oxytocin 
Indue-delivery time 
1993 129 50 J,Lg q4h shorter (miso.) +PGE2 (P == .004) 
Indue-delivery time 
Fletchers9 1993 45 100 J.lg Placebo shorter (miso.) 
(P < .001) 
Fletcher90 1994 63 100 J,Lg PGE2 (3 mg) Indue-delivery time not different (P = n.s.) 
Indue-delivery time 
Wing 115 1995 135 50 J,Lg q3h Prepidil ® shorter (miso.) 
(P < .001) 
Indue-delivery time 
Wing9-4 1995 276 25 J,Lg q3h Prepidil ® shorter (miso.) 
(P < .001) 
Indue-delivery time 
Varaklis92 1995 68 25 J.lg q2h Prepidil ® shorter (miso.) 
(P .... 006)_ 
Indue-delivery time 
Chuck93 1995 103 50 J,Lg q4h Prepidil ® shorter (miso.) 
(P < .001) 
Indue-delivery time 
Mundle86 1996 222 50 J,Lg q4h PGE2 shorter (miso.) 
(P- .04) 
Indue-delivery time 
Wing87 1996 522 25 J,Lg q3h 25J,Lg q6h shoner (miso. q3h) 
(P < .001) 
Wing96 1997 200 25 J,Lg q4h Cervidil® Indue-delivery time not different (P - n.s.) 
Indue-delivery time 
Sanchez95 1998 223 50 J,Lg q3h Cervidil® shorter (miso.) 
(P < .001) 
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Review of Oral Misoprostol Literature 
Only a few randomized trials assessing oral misoprostol for induction oflabour at 
term have been published.1c:o-107 Ngai et al.100 compared 200 J.lg oral misoprostol to 50 mg oral 
vitamin B12placebo for cervical ripening in 80 women with prelabour rupture of membranes at 
term. Twelve hours after receiving the assigned treatment, oxytocin was administered as 
necessary. There was a significant difference in Bishop score 5.7 (± 1.8 SD) in the misoprostol 
group and 6.1 (± 1.9 SO) in the placebo group P< .05. The sample size was calculated to 
detect a difference in Bishop score 12 hours after administration of medication. The 
assumptions were a of .05 and 1-(3 = 95. The sample size was initially calculated to be 100; 
however, an interim analysis was conducted after 80 patients were enrolled and the difference 
in Bishop score was found to be highly significant in both nulliparous and multiparous 
participants. 
The strength of this study is its design as a double blind placebo controlled trial. The 
weaknesses include the choice of primary outcome. More clinically imponant and objective 
outcomes such as time to delivery would have been more relevant in this population of 
women with prelabour-ruptured membranes. The authors do not explain their decision to do 
an interim analysis after eighty patients were enrolled. An additional twenty patients would 
have met their sample size requirement. All patients in the study received oxytocin twelve 
hours after enrolment. This is a more aggressive approach than the current standard of care, 
which involves administration of oxytocin within 24 hours of membrane rupture. 
Windrim et al. 101 studied the effectiveness, safety and gastrointestinal tolerance of 
misoprostol used orally for induction of labour and compared its use to established induction 
protocols. The primary outcome measure was time to delivery. Two hundred seventy-five 
women who presented for induction of labour were randomly assigned to receive either 50 #'g 
of misoprostol orally every four hours or treatment with physician-chosen combinations of 
either intracervical or vaginal prostaglandins every 4 to 6 hours or artificial rupture of 
membranes followed by oxytocin infusion. The mean time (±standard deviation) to vaginal 
birth was 926 ± (521) minutes compared to 909 ± (585) minutes with the established protocol 
P =- 0.81, a non-significant difference. There were no clinically or statistically significant 
differences in maternal secondary outcome measures (cesarean rate, frequency of epidural use, 
perineal trauma or manual removal of the placenta). There was no difference in maternal 
gastrointestinal side effects. Neonatal outcomes including cord blood acid-base analysis were 
not different. This study identified oral misoprostol as a new option for labour induction and 
recommended further studies to confirm the safety and efficacy and to determine optimal dose 
and frequency of administration. 
The sample size was calculated using a two-tailed a of 0.05 and a 1-P of95. This is a 
smaller type two error than the 13 0.20 usually chosen in similar trials. These authors chose this 
J3 of 5 to reduce the chance of missing a true difference between the two groups if a difference 
actually did exist. The major clinical consequence of conducting a trial with insufficient power 
to detect a difference in the time to delivery interval might be that patients could be offered a 
new induction agent that performed less well than the standard induction agent dinoprostone. 
The primary outcome was time to delivery, which is less substantive than more important 
clinical outcomes such as cesarean delivery rates and fetal asphyxia. To test such outcomes 
using misoprostol would require large sample sizes. A study of this nature would need to be 
multi-centred and would be prohibitively e.~pensive. 
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The major weaknesses of this study were lack of blinding and lack of rigor in defining 
the standard protocol. The control group could receive one of several options: Prepidil® 0.5 
mgs intracervically every six hours, Prostin® 1 or 2 mgs intravaginally every six hours or a 
dilute solution of oxytocin administered intravenously. The choice of the agent to be used in 
the control group was to be chosen by the individual attending physician caring for that patient 
based on whichever option the physician felt was optimal for the care of that particular patient. 
Toppozada et al. 102 compared vaginal and oral misoprostol for induction of labour in 
a small-randomized trial. Twenty patients assigned to receive lOOf.lg of vaginal misoprostol 
were compared to twenty assigned to lOOf.lg oral misoprostol. When no response was noted 
three hours following the first lOOf.lg dose, 200J,lg was then administered every 3 hours until a 
ma.ximum dose of 1000f,1g was reached. Doubling the dose via the vaginal route was only 
needed in one instance. One subject in the vaginal group and three in the oral group had 
cesarean delivery because of failed induction. The authors concluded that vaginal misoprostol 
resulted in a shorter time to delivery (P < .005). However, more abnormal fetal heart rate 
patterns and uterine hyperstimulation occurred (P < .05). The validity of the results of this 
study is limited by its small sample size and the heterogeneity in misoprostol dosing regimens. 
The study does not have sufficient power to draw conclusions about maternal or fetal safety. 
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Table 2: Summary of Randomized Trials of Oral Misoprostol 
for Labour Induction 
No. Misoprostol Misoprostol Comparison Author Year Pts. Vaginal Oral Dose Group Dose 
NgailOO 1996 80 200 ~gonce Placebo 
PGE2 gel Windrim101 1997 275 50 ~gq4h q6h 
T oppozada102 1997 40 100 ~gq3h 100 ~g q3h 
Bennett1CJ 1998 206 50 ~gq4h 50 ~g q4h 
Adair10 .. 1998 178 50 ~g q6h 200 ~gq6h 
Wingtcs 1999 220 25 ~g q4h 50 ~gq4h 
Butttc6 1999 108 50 ~gq4h Oxytocin 
Results 
Change in Bishop 
score greater 
(miso.) 
(P < .05) 
Time to delivery 
not different 
(P = .81) 
Time to delivery 
longer in oral 
(P < .005) 
Time to delivery 
longer (oral) 
(P = .004) 
H yperstimulation 
lower in oral 
(P = .04) 
Time to delivery 
not different 
(P = .12) 
Tachysystole 
greater (oral) 
{P < .01) 
Time to delivery 
longer (oral) 
(P - .005} 
Tachysystole not 
different 
(P - .39) 
Time to delivery 
longer (miso.) 
cP- .007) 
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Chapter 5 
RESEARCH QUESTION AND METHODS 
Research Question 
The primary research question in this study was whether there existed a four-hour 
difference in the interval to vaginal birth with oral misoprostol (50 J.Lg} compared with vaginal 
misoprostol (50 ~g) administered every four hours for induction of labour in women at term 
with intact membranes. As a secondary outcome, we also studied whether the route of 
administration influences the frequency of excessive uterine activity resulting in abnormal fetal 
heart rate tracings. Other secondary outcomes included neonatal morbidity (as determined by 
cord blood acid-base disturbances and American College of Obstetricians and Gynecologists 
criteria for binh asphyxia.), cesarean binh, maternal gastrointestinal side effects and patient 
satisfaction. 
Scientific Rationale and Originality 
Prostaglandins are known to be effective induction agents when administered 
vaginally. A meta-analysis of randomized clinical trials found vaginal misoprostol to be safe 
and effective in cervical ripening and labour induction in women at term with intact 
membranes.88 No masked randomized clinical trials comparing oral misoprostolSO J.Lg every 
four hours to vaginal misoprostol50 ~g every four hours were found in a Medline search of 
the English language literature. 
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Research Design 
This study was a masked randomized placebo-controlled trial. 
Sample Size Calculation 
For the primary outcome, time to vaginal binh, a sample size of 172 was calculated 
using a two-tailed a = .05, f3 = .20, .!\ = 240 minutes, and cr derived from pooling of results 
from a cohon of women who received vaginal misoprostol 86 (588 minutes) and the oral 
misoprostol intact membrane stratum 1c1 (521 minutes) in previous studies by our group 
(PEPI, Version 2,1995; Computer Programs for Epidemiologic Analysis, Stone Mountain, 
Georgia). Since our previous studies had consistent cesarean rates of 12.2% with 99% 
confidence interval (CI) {8.8, 16.5%), we added 20% {34 patients) to allow for anticipated 
cesarean binhs in our sample. A sample size of 206 was deemed appropriate to detect the 
clinically imponant difference {240 minutes), determined by a survey questionnaire of patients 
and medical personnel. 
Setting 
The study was conducted at the Grace General Hospital, St.John's, Newfoundland, 
Canada, from March 3, 1997 to October 8, 1997. This referral centre for perinatal care serves 
an almost entirely white population of 500,000 and is the site of 2500 of the province's 6000 
annual births. Our induction rate is just over 20%, with approximately 520 inductions per 
year. 
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Inclusion and Exclusion Criteria 
Patient inclusion criteria were: an indication for induction, single live fetus, gestation 
longer than 37 completed weeks, intact membranes and cephalic presentation. Patients who 
presented with any one of the following were ineligible: non-reassuring fetal bean rate tracing 
(FHR), previous uterine surgery, known hypersensitivity to prostaglandins, age less than 18 
years, contraindication to vaginal birth or unwilling to consent. 
Recruitment 
Before staning the trial, the research protocol and study design was presented to 
obstetricians, residents and labour and delivery nurses at the annual Obstetrical Resident 
Research Day. The research nurse provided in-service education to the labour and delivery 
staff and prenatal educators who were involved in the study. All pregnant women who 
attended prenatal classes were informed of the study and given written information about the 
protocol. Eligible patients were informed when induction of labour was indicated. At 
presentation for induction, patients were enrolled in the study by the attending physician, who 
explained the protocol and potential risks and benefits before obtaining written consent. 
Randomization 
Opaque envelopes containing a card indicating group allocation were prepared by an 
administrative staff member using computer-generated random number tables with 
randomization in blocks of four. Stratification was based on parity and Bishop score. 
Allocation of each consenting patient to the induction method was determined at the time of 
induction by opening the next sequentially numbered envelope. A pharmacy technician 
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prepared study medications and placebos. For each patient, eight powdered SO J.lg doses of 
misoprostol were placed individually in paper packets and stored in an airtight plastic 
container. Eight doses of an indistinguishable powdered cellulose placebo were similarly 
prepared and separately packaged for each patient. Oral or vaginal use was specified on the 
label. 
Allocation Concealment 
To conceal appearance and taste, all oral powders were mixed with 30 ml of apple or 
orange juice according to patient preference. Vaginal powders were suspended in 
hydroxyethyl gel just before use and delivered to the posterior fom.L"< using a vaginal applicator. 
When a subject required more than eight doses, another identically prepared medication and 
placebo package was provided. To maintain allocation concealment, research personnel who 
prepared the envelopes and medications were not involved in any other aspect of the study. 
The induction method was concealed from all caregivers, participants and investigators until 
data analysis was completed. The code for group assignment was not broken until data 
analysis was complete. 
Intervention 
After enrolment, subjects were e."<amined to determine Bishop score and stratified to 
either the low Oess than 7) or high (7 or more) Bishop score group, and according to 
nulliparity or multiparity. Each patient was then randomly assigned to receive either oral 
misoprostol (50 J.l&) and vaginal placebo or vaginal misoprostol (50 J.Lg) and oral placebo every 
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four hours until the occurrence of one of the following: a contraction frequency of three per 
10 minutes, a non-reassuring FHR tracing, spontaneous rupture of membranes or delivery. All 
study inductions were conducted immediately after randomization on an inpatient basis, to 
allow continuous electronic FHR and uterine contraction monitoring for at least one hour 
after each dose. Decisions regarding amniotomy, analgesia, epidural anesthesia and oxytocin 
augmentation were made by the attending physician. 
Compliance 
All participants enrolled in the study were accounted for, with none lost to follow-up. 
After each delivery, the study package was returned to the pharmacy technician to ensure each 
participant had received the assigned treatment. 
Primary Outcome 
Substantive maternal and neonatal primary outcomes, such as rates of cesarean birth 
and binh asphyxia, are relevant when evaluating any induction agent. To test such outcomes 
using misoprostol would require sample sizes of 3400 and 5300, respectively because of the 
infrequency of these events. A study of this nature would need to be multi-centred and would 
be prohibitively expensive. For this study, the primary outcome measure was chosen to 
address clinical effectiveness. The primary objective was to compare the efficacy of 
misoprostol administered orally to misoprostol administered vaginally in patients requiring 
cervical ripening for the induction of labour at term. The purpose was to determine if route of 
administration impacts upon the induction-to-delivery interval. 
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Secondary Outcomes 
To determine whether hypertonus, tachysystole or hyperstimulation were asS<..'Ciated 
with route of administration of misoprostol, all FHR graphs were reviewed before study 
induction groups were unmasked. Each of the physician authors {two maternal fetal medicine 
attending physicians and two senior obstetrical residents) independently classified monitoring 
strips using terminology defmed by Curtis et al.1::1 as follows: hypertonus, a contraction lasting 
more than 90 seconds; tachysystole, a contraction frequency of more than five in a ten-minute 
period; hyperstimulation, exaggerated uterine response with late FHR decelerations or 
tachycardia greater than 160 beats per minute. Planned treatment of tachysystole and 
hyperstimulation included change in maternal position to the left lateral decubitus position, 
oxygen administration by nasal prongs and intravenous ritodrine as needed. Fetal scalp blood 
sampling was performed when indicated by non-reassuring FHR graphs, at the discretion of 
the attending physician. 
To assess fetal safety issues, cord blood samples for arterial and venous acid-base 
analysis were taken after each delivery. Neonatal outcomes such as Apgar score at one and 
five minutes were recorded. All neonates were evaluated to assess if they met the American 
College of Obstetricians and Gynecologists (ACOG) criteria for birth asphyxia. 1cs To assess 
patient satisfaction, all patients enrolled in the study were asked to complete a modified labour 
agentry scale questionnaire. tC<J 
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Data Analysis 
Data were analyzed on an intent-to-treat basis by parametric and nonparametric 
statistics, using Statistix 4.1 (Analytic Software, Tallahassee, Florida). Decision levels and 
hypotheses to be tested were preset to minimize bias. Hypothesis testing was performed on 
the primary outcome. Other comparisons were considered hypothesis-generating. Statistical 
significance of the primary outcome measure was assessed using Student's t-test and was 
considered significant at P < .05. Rank order nonparametric statistics using the Mann-Whitney 
U test, where cesarean birth is a failure to deliver vaginally and ranked longer than any vaginal 
birth, allowed inclusion of all births in a secondary analysis with median time to vaginal birth as 
the measure of central tendency. 
Secondary outcomes were analyzed by parametric and non parametric statistics as 
appropriate. Descriptive statistics were used for demographic baseline data. The significance 
level for all secondary and hypothesis-generating analyses was set at P < .001 to account for 
multiple testing, a conservative approach. 
Confidentiality and Ethical Issues 
Specific steps were taken to protect the rights of participants in the clinical trial. All 
pregnant women who attended prenatal classes were given written information early in their 
pregnancy. All participants who presented at the time of induction were given written 
information sheets explaining their participation in the clinical trial. The physician responsible 
for initiating the induction obtained written informed consent. Members of the research team 
reviewed records concerning labour, delivery and hospital stay. No records bearing the name 
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of any research panicipant was provided to anyone other than the research team involved in 
the study. No panicipant was identified in publication. 
The risks associated with the study were carefully explained at the time of obtaining 
written consent. All patients were informed of the potential risk of excessive uterine activity 
associated with the use of prostaglandins. The planned medical treatment available and the 
possibility of cesarean delivery were explained in detail. Participants were also informed of the 
potential gastrointestinal side effects associated with administration of oral prostaglandins. 
The Human Investigation Committee of the Faculty of Medicine, Memorial University of 
Newfoundland, and the Grace General Hospital approved the research proposal. 
Study Protocol for Misoprostol Induction 
The study protocol for this randomized controlled trial was posted in the labour and 
delivery area and served to guide medical and nursing personnel involved in recruitment of 
patients and administration of study medications. 
Misoprostol (Cytotec®) is a prostaglandin E1 methyl analogue with potent cervical 
ripening and uterotonic effects. Randomized clinical trials in our centre have found 
misoprostol to be more effective than standard induction regimes. Patients being delivered by 
a family physician require consultation with an obstetrician before recruitment. 
Contraindications 
• Major uterine surgery 
• Cephalopelvic disproportion 
55 
• Non-reassuring fetal heart rate tracing 
• Fetal malpresentation 
• Known hypersensitivity to misoprostol or prostaglandins 
• Any contraindication to vaginal delivery 
• Age less than 18 years. 
Note 
The use of prostaglandins for cervical ripening or induction in a patient with a history 
of a previous cesarean delivery has not been approved by the Society of Obstetricians and 
Gynecologists of Canada (SOGC) or by the American College of Obstetricians and 
Gynecologists. (ACOG). 
Procedure 
1. The patient should be fully informed of the indication for induction. 
2. The proposed use of misoprostol should be explained. 
3. Written informed consent should be obtained. 
4. All misoprostol inductions will be done as in-patients. 
5. A written order is necessary for the initiation of the induction by misoprostol. 
6. A specific order is necessary for each additional dosage of misoprostol, after physician 
evaluation of the appropriateness of this dosage. 
7. Vital signs are to be checked prior to administration of medication. 
8. Fetal heart rate tracing (FHR) prior to misoprostol should be obtained. 
9. All patients should have a Bishop Score determined and recorded prior to the start of 
the induction. 
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10. The data sheet should also be stamped with the patient's admission card. 
11. Fetal heart rate tracings should be done continuously for two hours after each dose of 
misoprostol. 
12. Repeat misoprostol dosage may be continued until one of the following occurs: labour 
is established, a contraction frequency of 3 per 10 minutes. 
13. Amniotomy (ARM) can be performed in either group at the discretion of the attending 
physician. 
14. Following ARM, misoprostol can no longer be used. 
15. Augmentation with oxytocin is permitted following the use of misoprostol. 
16. Oxytocin should not be started within four hours of misoprostol administration. 
17. Misoprostol may be ordered in a dose of 50 micrograms up to every four hours as 
needed. 
18. All newborns should have cord blood gases obtained (venous and arterial). 
19. The misoprostol induction data sheet should be completed for ongoing monitoring 
and quality assurance of our misoprostol protocol. 
Budget and Grant Applications 
In an attempt to procure funding for this study, our research group submitted a 
proposal to the Medical Research Council of Canada (see appendi..x F). Unfortunately, this 
application was unsuccessful. A subsequent research proposal submitted for the Memorial 
University and Health Care Corporation research award was successful and resulted in a 
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research grant of $25,000. The Health Care Corporation hired a departmental part-time 
research nurse to assist with the study. The Budget is attached as appendix G. 
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Chapter 6 
RESULTS 
Study Population 
During the study period, 393 patients presented for induction of labour, of whom 
308 were eligible. Seventeen patients refused enrolment because they did not want to be 
involved in a research protocol and the remaining 85 were not invited to participate because 
alternate methods of induction including amniotomy, oxytocin or dinoprostone were preferred 
by their attending physicians. Among 206 women enrolled, there were 104 in the oral group 
and 102 in the vaginal group (Figure 1). No panicipant or neonate was lost to follow-up. 
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Figure 1: Study population 
308 
Eligible 
17 
- Patient refused 
85 
- Not invited to participate 
206 
- Enrolled 
I 
I I 
104 102 
Oral misoprostol Vaginal misoprostol 
Primary Outcome 
The mean time (±standard deviation) to vaginal binh with oral misoprostol was 1072 
(± 593) minutes compared with 846 (± 385) minutes with the vaginal protocol, a statistically 
significant difference (P - .004). The median time to vaginal binh in the oral misoprostol 
group was 1125 minutes compared with 926 minutes in the vaginal misoprostol group (P = 
.38, Mann Whitney U test). When given orally, a median of two and a ma.ximum of nine doses 
were used. Only seven subjects took more than five oral doses. When misoprostol was placed 
vaginally, a median of two and a maximum of five doses were used. Maternal preinduction and 
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neonatal demographic data are given in Table 3. There were no significant differences in 
demographic characteristics between the two groups. 
Table 3: Demographic characteristics 
Vaginal Misoprostol Oral Misoprostol 
n =102 n = 104 
Nulliparous 74 69 
Maternal age (years) 28.7 4.9) 27.5 5.0) 
Gestation (days) 284.2 (8.3) 285.4 (7.6) 
Gravidity 1.6• 0.8 1.7~ 1.0 
Parity 0.3 I 0.61 0.5 I 0.8 
Bishop score < 7 81 79 
Postterm 65 69 
Hypertension 18 12 
Oligohydramnios 8 13 
Other 11 10 
Birth weight (grams) 3645 (566) 3585 (612) 
Data given as number or mean (standard deviation) 
Peripanum data are given in Table 4, with relative risk (R.R) and 95% Cl. There were 
no significant differences in oxytocin (RR 0.67, CI 0.38, 1.18), epidural (R.R 0.89, CI 0.51, 1.56) 
or other analgesia use (RR 0.59, CI 0.21, 1.64). No significant differences were observed in 
meconium staining of amniotic fluid (RR 0.78, CI 0.41, 1.47), frequency of need for 
episiotomies {RR 1.23, CI 0.62, 2.42) or tearing of the perineum (RR 0.98, CI 0.72, 2.33). 
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Table 4: Peripanum data 
Vaginal Oral Relative 95°/o Confidence (n = 102) (n = 104) Risk Interval 
Intrapartum _frequency_. 
Oxytocin use 59 70 0.67 0.38, 1.18 
Epidural use 61 65 0.89 0.51, 1.56 
No analgesia use 6 10 0.59 0.21, 1.64 
Meconium 21 29 0.78 0.41, 1.47 
Episiotomy 22 19 1.23 0.62, 2.42 
Laceration 54 59 0.98 0.56, 1.69 
Third or fourth degree 2 0 Laceration 
Intact perineunn 34 29 1.29 0.72, 2.33 
Data for mean vaginal birth intervals are given in Table 5. There was a significant 
difference in time to vaginal birth depending on route of administration. Those subjects 
randomized to the vaginal misoprostol route had a significandy shorter time to delivery (846 ± 
385 minutes versus 1072 ± 593 minutes in the oral misoprostol group, P = .004). 
Furthermore, the induction-to-full dilatation interval was also significantly shorter in the 
vaginal misoprostol group (763 ± 361 minutes versus 1003 ± 578 minutes in the oral 
misoprostol group, P - .002). There were no statistically significant differences in the time of 
first, second and third stages of labour between the two groups. This indicates that the 
observed difference in time to delivery was not simply due to an increased time pushing during 
the second stage of labour. 
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Table 5: Labour interval to vaginal birth 
Vaginal Oral 
Misoprostol Misoprostol 
Induction to vaginal birth 846 385) 1072 (593) 
Induction to full 763 061) 1003 (578) dilatation 
1st stage of labour 342 204) 365 223) 
2nu stage of labour 83 891 69 76) 
3rd stage of labour 12 ( 14J 9.9 I 8.4) 
Data given in minutes as mean (standard deviation) 
~:· Student's t-test 
Secondary Outcomes 
Birth Route 
p~· 
.004 
.002 
.48 
.26 
.21 
There was no significant difference in binh route between the two groups (x., ~ = 
2.53, P - .47). With oral misoprostol, there were 58 spontaneous vaginal deliveries, 21 
vacuum deliveries, 9 forceps-assisted deliveries and 16 cesarean births (15.3%}. With vaginal 
misoprostol, there were 56 spontaneous vaginal deliveries, 15 vacuum deliveries, 8 forceps-
assisted deliveries and 23 cesarean binhs (22.5%). Non-reassuring FHR tracing was the 
indication for two cesareans in the oral misoprostol group and six cesareans in the vaginal 
misoprostol group (RR 2.47, CI 0.49, 12.49}. 
Excessive Uterine Activity 
Fetal heart rate and uterine activity tracing data were analyzed using non parametric 
statistics based on number of masked physician reviewers making that classification of a given 
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tracing (Table 6). The inherent subjectivity involved in analyzing fetal heart graph and uterine 
contraction monitoring strips led us to analyze the data based on agreement between 
physicians. All four physician-reviewers blinded to group assignment agreed that 25 women in 
the vaginal misoprostol group and 5 women in the oral misoprostol group e.xperienced 
tachysystole (P - .01), and four women in the vaginal misoprostol group and no women in the 
oral misoprostol group experienced hyperstimulation (P == .04). 
Table 6: Classification of excessive uterine activity 
0 1 2 3 4 
Reviewers Reviewer Reviewers Reviewers Reviewers 
classified classified classified classified classified p ::· 
graph as: graph as: graph as: graph as: graph as: 
Tracing classification 
Hypertonic > 90 sec 
Oral misoprostol 1 8 15 26 54 0.68 
Vaginal misoprostol 0 12 11 29 49 
Hypertonic > 120 sec 
Oral misoprostol 7 22 24 20 31 0.57 
Vaginal misoprostol 8 21 22 28 22 
Tachysystole > 10 min 
Oral misoprostol 23 14 18 25 23 0.21 
Vaginal misoprostol 16 15 18 21 31 
Tachysystole > 20 min 
Oral misoprostol 52 21 16 10 5 0.01 
Vaginal misoprostol 41 17 7 11 25 
Hyperstimulation 
Oral misoprostol 84 14 5 1 0 0.04 
Vaginal misoprostol 70 17 6 4 4 
~-Mann-Whitney U test. 
64 
Although there was more frequent 20-minute tachysystole (P < .04) in the vaginal 
misoprostol group, these results were not statistically significant by our preset level for 
secondary analyses, but the trend warrants attention. 
Neonatal Outcomes 
Neonatal outcomes in both groups were similar (Table 7). Umbilical cord arterial 
and venous blood acid-base analysis was performed on 89 of the 104 participants in the oral 
misoprostol group and 92 of the 102 participants in the vaginal misoprostol group (90% of 
neonates}. Two neonates from the vaginal misoprostol group had cord pH less than 7.00; 
however, no neonate met the American College of Obstetricians and Gynecologists (ACOG) 
criteria for birth asphyxia. ICll While it is reassuring that no neonate experienced an adverse 
outcome, this study did not have sufficient power to draw conclusions about fetal safety. The 
significance level for all secondary and hypothesis-generating analyses was set at P < .001 to 
account for multiple testing. 
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Table 7: Neonatal outcome 
Vaginal Oral 
Misoprostol Misoprostol 
A COG criteria for birth N N 
asphyxia: 
Apgar 5 min < 3 0 0 
CordpH < 7 2 0 
Base deficit > 16 2 0 
Cord blood: Mean Mean 
Cord pH 7.28 0.10 7.30 0.09 
Base deficit 5.28 4.14 4.44 3.32 
Apgar scores: 1\1edian Median 
Apgar 1 minute 9 (8,9) 9 8,9) 
Apgar 5 minute 9 (9,10) 9 ( 9,10) 
N N 
Apgar 1 minute < 7 17 7 
Apgar 5 minute < 7 0 1 
::-Fishers' exact test 
t Student's t test: mean (standard deviation) 
+Mann-Whitney U test: median (1st and 3rd quartile) 
x Chi square test 
p 
.16::-
.16::-
.08t 
.13t 
.59:!: 
.23:!: 
.03;{ 
.32::-
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Labour Satisfaction 
Ninety women in the oral group and 83 in the vaginal group completed a labour 
satisfaction questionnaire administered 24 hours postpartum (84% response rate). Analysis of 
the responses to all questions failed to detect any statistically significant difference in patient 
satisfaction or overall score. All participants in the study reported positive labour and delivery 
experiences. None of the panicipants reported adverse gastrointestinal effects. There was no 
reported diarrhea in either group and no difference in occurrence of vomiting (18 in the oral 
and 19 in the vaginal group, P - .81). 
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Cbapter 7 
METHODOLOGICAL ISSUES AND DISCUSSION 
Design Problems 
The results of this study are convincing because of the strength of its masked 
randomized design and the lack of protocol violations. The problems encountered in 
conducting the trial stemmed from two major sources: financing the trial and accomplishing 
blinding. From the point of view of financial support, it became apparent very early that the 
Canadian manufacturer of misoprostol (Searle Canada, Oakville Ontario) was not interested in 
supporting research on induction of labour. This related to medicolegal liability inherent to 
research in pregnancy and a potential adverse effect on pharmaceutical marketing in the event 
of publicized complications or lawsuits. Because of its reticence to be involved in pregnancy-
related research, the manufacturer declined to provide a placebo. Estimates obtained from the 
manufacturer placed the cost of placebo production at more than $200,000. 
Even if misoprostol was identified to be an ideal pharmacological induction agent, 
the market size and additional generated revenue would be small, as each potential patient 
would require only small doses briefly, during an infrequent event in her lifetime. For these 
reasons, the manufacturer is unlikely to ever be proactive in this area of research or to seek 
Canadian Health Protection Branch approval of misoprostol for induction of labour. This 
approval will have to be sought by investigators once more evidence is obtained 
68 
Since a major expected benefit of using misoprostol for labour induction is cost 
savings, it was decided to pursue the possibility of realizing such a cost savings to obtain 
financing for this trial from the Health Care Corporation of St. John's. A review of pharmacy 
records from previous misoprostol studies conducted at the Grace General Hospital provided 
data to suppon an expected savings by using misoprostol instead of dinoprostone for labour 
induction, justifying financial suppon of this trial by the Health Care Corporation. 
The Corporation approved the hiring of a part-time pharmacy technician to work 
exclusively on the trial to provide a placebo for the study and to maintain records, ensuring 
that each panicipant received the appropriate treatment. This technician was responsible for 
the preparation of code-labelled indistinguishable drug-placebo packages according to the 
specifications of the study protocol. Study drug packages contained eight doses of the 
designated treatment, as the ma.ximum number of doses required by any subject in our prior 
research studies was seven. The induction method was concealed from all caregivers and 
investigators until data analysis was completed. 
The Health Care Corporation also approved the hiring of a pan-time research nurse 
to provide suppon to the Department of Obstetrics and Gynecology for the duration of the 
trial. The research nurse reviewed all aspects of the study protocol and acted as a liaison with 
the pharmacy department. Educational sessions were arranged for prenatal instructors, 
residents and attending physicians to familiarize all participating caregivers with the study 
protocol. Data collection, including the administration of a postpartum labour satisfaction 
questionnaire to all participants, was the primary responsibility of the research nurse. 
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In addition to financial suppon from the Health Care Corporation, funding was 
sought from the Medical Research Council of Canada. Two separate grant applications were 
submitted; unfortunately, neither application was successful. An application to the Memorial 
University of Newfoundland Faculty of Medicine was successful in securing a $25,000 research 
grant, and was awarded the Cox Research Award. These additional funds were instrumental in 
financing the remainder of the projected costs of the trial. Efforts to secure financing for this 
trial delayed its stan date by approximately one year. 
Recruitment 
During the study period, 393 women presented for induction of labour. Of this 
group, 85 were ineligible according to the study protocol, 17 did not wish to panicipate in a 
study and 85 were not invited because the attending physician chose alternate methods of 
induction. Two hundred and six of the 223 women (> 90%) invited to participate agreed to 
panicipate in the study. Since only 206 of a potential308 were recruited, a possible selection 
bias is introduced into the study. Non-participants were documented but their demographic 
characteristics were not. This is because physicians other than the investigators were 
providing primary medical care. We did not have permission from non-panicipants to review 
their medical records. 
Differences are widely acknowledged to exist between patients who agree to 
participate as subjects in research studies and those who do not. Significantly different 
outcomes have frequently been documented even between non-participants in studies and 
participants randomized to an equivalent control arm. Therefore, one must interpret these 
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results (and those of most trials) bearing in mind that generalizability to the clinical population 
may not be complete. In this case, 85 patients were not invited to participate in the study 
because their attending physician preferred alternate methods of induction including 
amniotomy, oxytocin or dinoprostone. It is likely that several of these women had a 
favourable cervix (high Bishop score) at presentation, leading the attending physician to 
believe that an amniotomy followed by oxytocin was a more appropriate treatment than 
randomization to either form of misoprostol induction. Thus, any conclusions reached 
concerning the relative merits of the forms of misoprostol induction studied here must be 
understood to apply to a relatively similar population to that randomized. 
Classification of Excessive Uterine Activity 
Although there is no direct relationship between continuous electronic fetal 
monitoring and fetal well-being, non-reassuring fetal heart rate changes associated with 
excessive uterine activity warrant intervention either to reduce uterine activity or to deliver the 
fetus. Because of confusion stemming from inconsistent definitions of excessive uterine 
activity, Curtis recommended a standard terminology. While it allows for classification of 
labour graphs, the terminology is nevertheless arbitrary, particularly with respect to 
tachysystole and hypertonic contractions. 
Despite concerns of possible uterine hyperstimulation, substantive adverse newborn 
outcomes such as neonatal acidosis, meconium aspiration, and birth asphyxia have been rare 
and have not differed between misoprostol and control groups in previous published studies. 
In our study, two neonates in the vaginal misoprostol group had cord blood pH less than 7.00 
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but no asphyxia occurred. Among the 39 cesarean births, six of the eight done for fetal safety 
reasons were in the vaginal misoprostol group. While these differences ace not statistically 
significant, the question is clinically relevant, making it a worthwhile primary goal in the design 
of a future clinical trial. The frequency of excessive uterine activity associated with route of 
administration was evaluated as a secondary outcome in the present study, and did not form a 
basis for calculation of sample size. 
Inherent in the evaluation of excessive uterine activity is the concern about inter-
observer and intra-observer variation. We believe that agreement about the occurrence of 
hyperstimulation among all four reviewers blinded to each others' results and to group 
assignment provides strong evidence for the e.xistence of four cases of hyperstimulation in the 
vaginal misoprostol group and no cases of hyperstimulation in the oral group. The finding 
that two neonates in the vaginal misoprostol group that had a cord pH less than 7.00 further 
supports the conclusion that vaginal misoprostol has a greater propensity to cause excessive 
stimulation of uterine contractility. 
Pharmacokinetics of Crushed Misoprostol 
The pharmacokinetics of misoprostol suspended in gel and given vaginally has not 
been directly evaluated. No study has evaluated the pharmacokinetics of crushed misoprostol 
given orally. In our study, this group had the lowest incidence of tachysystole and 
hyperstimulation. Understanding the timing of e."<cessive uterine activity is important because 
it addresses concerns about fetal safety. Appropriate and timely intervention can then be 
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initiated. Such information is also essential for the rational design of further trials to determine 
the safest dose, form, and route of misoprostol administration. 
A Future Study of Excessive Uterine Activity 
To further study the relationship between misoprostol and excessive uterine activity, 
our research group has planned a cohort study. The primary objective is to determine the 
incidence and timing of excessive uterine activity with induction of labour with misoprostol. 
Different routes and formulations of misoprostol will be compared to prostaglandin E1 
intracervical or intravaginal gel, oxytocin, and spontaneous labour. 
Study Design 
The study will include women enrolled in each of three randomized trials evaluating 
misoprostol for labour induction. tct,tOJ, tcs The studies were conducted from March 30, 1994 to 
September 22, 1994 and October 25, 1996 to December 19, 1997 at the Grace General 
Hospital in St. John's, Newfoundland. A cohort of women who presented in spontaneous 
labour during the same period will also be evaluated. 
Inclusion criteria are: a single live fetus in cephalic presentation, gestation longer than 
37 weeks and fetal heart rate and uterine activity graphs available for review. Exclusion criteria 
include: non-reassuring fetal heart rate tracing prior to induction (or on admission in the 
spontaneous labour cohort), prior uterine surgery, contraindication to vaginal birth, age less 
than 19 years and known hypersensitivity to misoprostol or other prostaglandins. 
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One of these trials enrolled only women with term premature rupture of 
membranes106, while the other two trials included only those women with intact 
membranes. 101' 1ru The details of the three trials are previously published. For those women 
undergoing induction oflabour, the cohorts will be as follows: misoprostolSO ~tg crushed and 
suspended in hydroxyethyl gel given vaginally every four hours, misoprostolSO ~-&g crushed and 
mixed with juice given orally every four hours, misoprostolSO ~-&g tablet given orally every four 
hours for premature rupture of membranes [PROM], intravenous oxytocin beginning at 2 
milliunits (mu) I min and increasing by 2 mu/ min every 15 to 30 minutes for PROM, 
misoprostol tablet 50 ~-&g vaginally every four hours, prostaglandin E! intracervical gel 0.5 mg 
every six hours or prostaglandin E2 intravaginal gell mg or 2 mg every 6 hours. The cohort of 
women in spontaneous labour in the study will include a group of women who had at least si.x 
hours of fetal heart rate and uterine activity monitoring and who would have otherwise met 
the criteria for induction of labour. 
Methods 
The fetal heart rate and uterine activity graphs will be independendy and individually 
analyzed by three maternal fetal medicine specialists and one physician enrolled in a Maternal 
Fetal Medicine Fellowship. Tachysystole will be defmed as a contraction frequency of more 
than five in a ten-minute period for two consecutive ten-minute periods. Hyperstimulation 
will be defined as tachysystole with late fetal he-.ut rate decelerations or fetal tachycardia greater 
than 160 beats per minute. Tachysystole or hyperstimulation will be noted if at least two of 
those reviewing the graph agree with the diagnosis. 
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For those women receiving the crushed forms of misoprostol, reviewers were 
blinded to group usignment and the code was not broken until completion of analysis of 
graphs. For the other cohorts, although the reviewers were not blinded, they will not actively 
seek to reveal the cohon allocation until analysis of graphs is completed. The timing of the 
excessive uterine activity will be determined relative to the misoprostol dosing schedule. If 
tachysystole or hyperstimulation occurred after subsequent doses of misoprostol, the timing of 
each episode will be determined relative to the number of doses given. Those women who 
experience tachysystole or hyperstimulation only after oxytocin augmentation is initiated, or 
during the second stage of labour with pushing, will not be included in the determination of 
timing of excessive uterine activity, as this may lead to confounding. 
Sample Size Calculation 
The sample size required is based on the estimated incidence of tachysystole in the 
misoprostol and oxytocin cohorts. 101' 103' 1c6 Using a two-tailed a = .05 and ~ = .20. fifty-one 
women in each cohon will be needed to detect a significant difference between 35% incidence 
in one cohon and a 10% incidence in another cohon. Data will be analyzed using Statisti.x 4.1 
(Analytical Software, Tallahassee, FL). Continuous variables will be assessed using Student's t 
test and analysis of variance, while categorical variables will be analyzed by "land Fisher e.xact 
test where appropriate. Statistical significance will be set at P < .05. Because of multiple 
testing, all comparisons other than the primary outcomes will be considered only as hypothesis 
generaung. 
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Chapter 8 
IS ORAL MISOPROSTOL THE IDEAL INDUCTION AGENT? 
Obstetricians routinely use various mechanical methods and pharmacological agents 
to induce labour, however, no single approach has been universally successful. Oxytocin is an 
effective induction agent; nonetheless, it is not optimal therapy for a patient with an unripe 
cervix. Administration requires an intravenous infusion with continuous monitoring of fetal 
heart rate and uterine contractions. Prostaglandins are effective cervical ripening agents, 
achieving a shorter induction-to-delivery interval and a lower rate of operative intervention 
when compared to oxytocin. 
Oral administration of prostaglandins has essentially been abandoned because of 
undesirable gastrointestinal effects, which have limited their use to vaginal and intracervical 
routes. Termination of prostaglandin-related e."'{cessive uterine activity remains problematic. 
An oral induction agent that is safe, effective, inexpensive and well tolerated by patients would 
likely be attractive to patients and health care providers. Anticipated benefits include 
avoidance of intravenous lines in some panurients, less frequent need for vaginal e."'{amination 
and greater freedom for upright positioning. Ambulation might even facilitate labour progress. 
Misoprostol 
Misoprostol (Cytotec®; Searle, Oakville, ON), a synthetic prostaglandin (PGEJ 
analogue, is marketed in an oral formulation of 100 f.lg or 200 f.lg tablets.82 It is currently 
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approved by the U.S. Food and Drug Administration for use in the treatment and prevention 
of gastrointestinal ulcer disease resulting from non-steroidal anti-inflammatory use. 
Misoprostol is an inexpensive prostaglandin capable of initiating uterine contractions; 
therefore, it has been exten.sively investigated for use as an induction agent in pregnancy. A 
single 100 J,lg tablet costs$ 0.30; therefore, a single 50 J,lg dose may cost as little as $0.15. 
Misoprostol is also temperature-stable and does not have special storage requirements. 
Pharmacokinetics of Oral and Vaginal Misoprostol 
Misoprostol is primarily metabolized in the liver, with less than one percent of its 
active metabolite excreted in urine. Misoprostol has no known drug interactions and does not 
induce the hepatic cytochrome P-450 enzyme system. The most common adverse effects of 
misoprostol are nausea, vomiting, diarrhea, abdominal pain, chills, shivering and fever, all of 
which are dose dependent. Although other prostaglandins (prostaglandin E 2 and 
prostaglandin F 2a) can cause myocardial infarction and bronchospasm, misoprostol does not. 
Toxic doses of misoprostol have not been determined. 
Zieman et al. 110 compared the pharmacokinetics of misoprostol (400 J.tg) 
administered by vaginal and oral routes to 10 non-pregnant and 10 pregnant first trimester 
volunteers, concluding that significant differences exist. Among women who were 9 to 11 
weeks pregnant and given misoprostol before a surgical abortion, intrauterine pressure began 
to increase an average of 8 minutes after oral administration and 21 minutes after vaginal 
administration and was maximal 25 minutes after oral administration and 46 minutes after 
vaginal administration. Uterine contractility initially increased and reached a plateau one hour 
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after oral administration whereas uterine contractility increased continuously for four hours 
after vaginal administration. Maximal uterine contractility was significandy higher after vaginal 
administration. Systemic bioavailability of vaginally administered misoprostol was found to be 
three times that of misoprostol administered orally. With vaginal administration, peak plasma 
levels were reached more slowly but were sustained in excess of four hours. 
In a confirmatory study, Danielsson et al. 111 reponed that uterine activity increased 
continuously for four hours after vaginal administration of misoprostol, and warned that this 
could lead to a cumulative effect with subsequent dosing. When contractions of abnormally 
high intensity or frequency occur, insufficient recovery resulting in FHR abnormalities could 
necessitate operative delivery or lead to fetal asphyxia. It could reasonably be argued that the 
greater frequency of abnormal fetal bean rate patterns observed in patients who receive vaginal 
misoprostol are a result of excessive uterine activity, reflective of this greater bioavailability. 
Induction agents, ideally, should mimic spontaneous labour while avoiding e."~Ccessive 
uterine activity. Inherent in the evaluation of excessive uterine activity is the concern about 
inter-observer and intra-observer variation. We believe that agreement about the occurrence 
of hyperstimulation among all four reviewers blinded to each others' results and to group 
assignment provides strong evidence for the existence in this study of four cases of 
hyperstimulation in the vaginal misoprostol group and no cases ofhyperstimulation in the oral 
group. The finding that two neonates in the vaginal misoprostol group that had a cord pH less 
than 7.00 further supports the conclusion that vaginal misoprostol has a greater propensity to 
cause e."~Ccessive stimulation of uterine contractility. Uterine hyperstimulation was a secondary 
outcome and was not considered in calculation of sample size. The significance level for all 
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secondary and hypothesis-generating analyses was set at P < .00 l to account for multiple 
testing. 
Misoprostoi-Current and Future Use 
Despite accumulating evidence of effectiveness and obvious cost advantage in over 
44 randomized clinical trials, the U.S. Food and Drug Administration and the Therapeutic 
Products Program of Health Canada have not yet approved misoprostol for induction of 
labour. However, they do recognize that in certain circumstances, off-label uses of approved 
products are appropriate, rational and accepted medical practice. Misoprostol administered 
vaginally for labour induction is currently in widespread use in the United States. Its use in 
' 
most Canadian tertiary care centres is limited to research protocols. 
The American College of Obstetricians and Gynecologists (ACOG) Committee on 
Obstetric Practice recently concluded that vaginal misoprostol administered appears to be 
effective in inducing labour in pregnant women who have unfavourable cervi.'Ces; however, the 
initial dose should be limited to 25 !Jg every three to fours hours because of concerns of the 
greater incidence of tachysystole observed with the use of higher doses. It further concluded 
that prospective studies are necessary to define optimal dosing regimens. 111 The Society of 
Obstetricians and Gynecologists of Canada (SOGC) has not published a recommendation on 
the use of misoprostol as an induction agent. 
Misoprostol is an effective induction agent whether it is given orally or vaginally. 
Misoprostol is much less expensive than dinoprostone and, unlike dinoprostone, which 
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reqwres refrigeration until just before use, it is stable at room temperature. Oral 
administration of misoprostol is appealing for several reasons, including convenience and a 
non-invasive mode of delivery. Fewer cervical exams could also potentially result in lower 
peripartum infection rates, particularly in women with prelabour-ruptured membranes. Oral 
administration of misoprostol, if proved s~e and effective, could potentially reduce overall 
hospitalization time by permitting administration of the medication in an outpatient setting. 
No studies using misoprostol as an outpatient preinduction cervical ripening agent have been 
published. Use for this indication is not currently recommended because of the need for dose 
surveillance of uterine activity after administration of misoprostol. In addition to these 
potential benefits, oral misoprostol shares with vaginal misoprostol the advantages of cost-
effectiveness and efficacy in labour induction. 
The oral route of misoprostol administration is an important one that has not been 
fully investigated, and the question of whether oral may be the preferred route of misoprostol 
administration remains to be answered. Sanchez-Ramos et al. 99 conducted a systematic review 
of published randomized trials comparing oral and vaginal misoprostol administration for 
cervical ripening and labour induction. In total, 1,191 patients were randomized to receive 
misoprostol orally (n - 602) or by the vaginal route (n - 589). The oral doses ranged from 50 
J.lg to 200 J.tg every four to six hours. Vaginal misoprostol was administered in doses ranging 
from 25 f,lg every four hours to 100 J.tg every three hours. 
No significant difference was noted in the proportion of patients who delivered 
within 12 and 24 hours. Similarly, the intervals from start of induction to vaginal delivery were 
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not different. No difference was noted in the incidence of abnormal Apgar scores or rates of 
admission to neonatal intensive care units. Interestingly, the rate of cesarean delivery was 
significantly lower in the oral misoprostol group (15% versus 22%, Mantel-Haenszel pooled 
odds ratio 0.64). 
Although meta-analysis provides a systematic and explicit method for demonstrating 
early evidence with regard to the effectiveness of treatments, it is not as valuable as a large 
randomized trial. Three principal concerns must be addressed when assessing the validity of a 
meta-analysis: publication bias, quality assessment of the randomized clinical trials included 
and study heterogeneity. Several sources of inter-study heterogeneity can be identified in the 
Sanchez-Ramos review. There were variations in treatment protocols, small sample size in two 
of the seven studiestco,tct and a lack of uniform stratification according to Bishop score and 
parity. It is imponant that the results of a meta-analysis not depend excessively on the results 
of a single study. To assess inter-study heterogeneity, the analysis should be repeated after 
sequentially excluding each trial, seeking to determine whether any one trial contributed 
excessively to the overall reduction in cesarean delivery rate. 
The enormous economic and clinical advantages of misoprostol for cervical ripening 
and labour induction suggest that the unanswered questions about the impact of oral 
misoprostol on cesarean delivery rates and fetal safety should be addressed in a properly 
designed, well-conducted multi-centre trial. Our research group has planned such a trial, and is 
currently seeking funding to allow it to proceed. 
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Mi5oprostol (Cytotec; Se.ule. Oakvillt!. Ontario, Cana· 
da). a synthetic prostaglandin (l"G} E1 analogue cur· 
rendy used for treatment of gastric and duodenal 
ulcus, can initiate uterille contractions. It is mMketed in 
an oral formulation of 100. or 200-~&g tablets with a 
maximum recommended dose of 1600 ,.g per day.1 
lnduction of Llbor by placing a portion of 5UCh a tablet 
in the vagina has been studied extensivelyl-1; however. 
few randomized tn.Js9.1° asse55ing oral misoprostol for 
00l9-71Mf/98/SI9.0D 411 
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induction of labor at term have been published. Our 
research group compared oral misoprostol to vaginal 
dinoprostonc (PCE2) and found oral misoprostol to be 
an effective induction agent with no important adverse 
maternal or neonatal outcomes ... The median medica-
tion cost per patient receiving misoprostol wil5 at least 
100 times lower than the median medication cost per 
patient in controls receiving dinoprostone.119 
Despite accumulating evidence of effectiveness and 
obvious cost advantagr. misoprostol is not yet ap-
proved for induction of labor at term in most North 
American health care centers or by a national agency. 
Some authors have reported that tachysytole11 might be 
a frequent occurrence when vaginal misoprostol is u~ 
to initiate uterine activity,5·o.1:.13 which has led to con-
cerns about potential increased rates of operative deliv-
ery and neonatal asphyxia. Any new induction tech-
nique must address these Stlfety concerns. 
Substantive maternal and neonatal primary out· 
comes. such as rates of ces.lrean birth and birth as· 
phyxia, are relevant when cvilluating any induction 
agent. To test such outcomes using misoprostol would 
require Stlmple sizes of 3400 and 5030, respectively, 
because of the infrequency of these events. Before 
conducting such a lnge and costly project, it is neces-
Stlry to determine the most appropriate route of miso-
prostol administration. For this purpose, we designed a 
masked randomized trial with time to vaginal birth as 
the primary outcome measure. 
Our primary research question wu whether there is 
a -l·hour difference in the interval to vaginal birth with 
oral compared with vaginal use of SO ,.g of misoprostol 
administered every -1 hours for induction of labor in 
women at term with intact membranes. We also deter-
mined whether the frequency of excessive uterine ac-
tivity resulting in abnormal fetal heart rate (FHR) 
tracings is influenced by route of administration. Other 
secondary outcomes included neonatal morbidity (as 
measured by cord blood add-base analysis and ACOG 
criteria for birth uphyxia 1~). cesarean birth, maternal 
gastrointestinal side effects, and patient Stltisfaction. 
Met/rods 
The study was conducted at the Grace General Hospi-
t;:d. St. John's, Newfoundland, Canada, from March 3. 
1997 tu October 8, 1997. This referral centerfor perinatll 
care serves an almost entirely white population of 
500,000 and is the site of 2500 of the province's 6000 
annual births. Our induction rate is just over 20'ro, with 
approximatcly 520 inductions per year. The research 
propos.ll was approved by the Human Investigation 
Committee of the Faculty of Medicine, Memorial Uni-
versity of Newfoundland, and the hospital 
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Patient inclusion criteria were indication for induc-
tion, single live fetus, gestation longer than 37 com-
pleted weeks, intact membranes, and cephalic presen-
tation. Patients who presented with any one of the 
following were ineligible: nonreassuring FHR tracing, 
previous uterine surgery, known hypersensitivity to 
prostaglandins, age less than 18 years. or contraindica-
tion to vaginal birth. All pregnant women who attended 
prenatal classes were informed of the study and given 
written information about the protocol. Eligible patients 
were informed when induction of labor was indicated. 
At presentation for induction, patients were enrolled in 
the ~tudy by the attending physician, who explained the 
protocol and potential risks and benefits before obtain-
ing written consent. 
Opaque envelopes containing a card indicating group 
allocation were prepared by an administrative staff 
member using computer-generated random number 
tables with randomization in blocks of four. Allocation 
of each consenting patient to induction method was 
determined at the time of induction by opening the next 
sequentially numbered envelope. Study medications 
and placebos were prepared by a pharmacy technician. 
For each patient, eight powdered so.,.g doses of miso-
prostol were placed individually in paper packets and 
stored in an airtight plastic container. Eight doses of an 
indistinguishable powdered cellulose placebo were 
similarly prepared and separately packaged for each 
patient. Oral or vaginal use was specified on the label. 
To conceal .tppearance and taste, all oral powders 
were mixed with 30 mL of apple or orange juice 
according to patient preference. Vaginal powders weN 
suspended in hydroxyethyl gel just before use and 
delivered to the posterior fornix using a vaginal appli-
cator. After each delivery, the study package was re-
turned to the pharmacy technician to ensure each 
participant had received the assigned treatment When 
a subject required more than eight doses, another 
identic;llly prepared medication and placebo package 
was provided. To maintain allocation concealment, 
research personnel who prepared the envelopes and 
medications were not involved in any other aspect of 
the study. The induction method was concealed from 
.til caregivers, participants, iUid investigaturs until data 
analysis wu completed. 
After enrollment, subjects were examined to deter-
mine Bishop score15 and sb:ttified to either the low (less 
than 7) or high (7 or more) Bishop score group. Each 
patient was then randomly il55igned to receive eithu 
oral misoprostol (50 l'g) and vaginal plicebo or vaginal 
misoprostol (50 ,.g) and oral placebo every 4 hours until 
the occurrence of one of the foUowing: a contraction 
frequency of three per 10 minutes, a nonreassuring FHR 
tracing, spontaneous rupture of membrane, or deliv-
96 
ery. All study inductions were conducted immediately 
after randomization. on an inpatient basis, to allow 
continuous electronic FHR and uterine contraction 
monitoring for at least 1 hour after each dose. 
Decisions regarding amniotomy. analgesia. epidural 
anesthesia, and oxytocin augmentation were made by 
the attending physician. To assess patient satisfaction, 
all patients enrolled in the study were askLod to com-
plete a modified labor agentry scale questionnaire.'~ 
Planned treatment of tachysystole and hypetstimula-
tion included change in maternal position to the left 
lateral decubitus. oxygen 01dministration by nasal 
prongs. and intravenous ritodrine, as needed. Fetal 
scalp blood sampling was performed when indicated 
by non reassuring FHR graphs. Cord blood samplt.os for 
arterial and venous acid-base analysis were taken after 
eao:h delivery. 
To determine whether hypertonus. tachysystole. or 
hyp:rstimulation were a.~sociated with the route uf 
administration of misoprostol. all FHR graphs were 
reviewed before study induction groups wen: un-
masked. Each of the physician authors (two maternal 
fetal ml!dicine attending physicians and two senior 
residents) independently classified monitoring strips 
using terminology defined by Curtis et al11 and Winget 
al" as follows: hypertonus. a contraction lasting more 
than 90 seconds or more than 120 seconds; tachysystole. 
a contraction frequency of more than fiw in a 10-minute 
period or two consecutive 10-minute periods; hyper-
stimulation, exaggerated uterine response with lah! 
FHR decelerations or fetal tachycardia greater than 160 
beats per minute. The code for group olS.~ignment was 
not broken until completion of data analysis. 
For the primary outcome. time to vaginal birth. a 
sample size of 172 was calculated tilling a two-tailed a .. 
.OS. 13 • .20, ;1 = 2-10 minutes. and u derived from 
pooling of results from our" vaginal misoprostol cohort 
(588 minutes) and our previous oral misoprostoloJ intact 
membrane stratum (524 minute!~) (PEPI, Version 2. 
1995; Computer Programs for Epidemiologic Analysis. 
Stone Mountain, GA). Since our previous studiesu had 
consistent cesarean rates of 12.2'ro with 99~o confidence 
interval (C[) 8.8, 16.5o/o we added 20'Yo (3-& patients) to 
aUow for anticipated cesarean births in our 5amplc. A 
sample size of 206 was deemed appropriate to detect 
the clinically important ditrenma: (2-10 minutes) deter· 
mined by a survey questionnaire of patients and med-
ical and nursing personnel. 
Dilta were ilnillyzed on an intent-to-treat basis by para-
metric and nonparametric statistic;, using Statistix .U 
(Analytical Software. Tallahassee. FL). Ol!dsion levels and 
hypothese to be tested were preset to minimize bias. 
Hypothesis testing was perfurmed on the primary out· 
come. Other comparisons were considered hypothesis 
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Table 1. Demographic ~racteristics 
V.gin.a! 
misoproslol 
Owxmistic (II • 102) 
Nullip•""'-" 
M.tlrm.ll ~so: (y) 
CeltAtion (d) 
Gr.avidity 
PJnty 
Bishop ocore lea th.ln 7 
lndiclnon tor induction 
Post-term 
Hypermt.""'n 
Oligohydr.amnom 
Oth« 
Birth w~ght lgl 
7-6 
:!11.7("-9) 
2llol.l (8.3) 
1.6(0.11) 
0.3(0.6) 
81 
6S 
I! 
8 
It 
J6o&5 (566) 
D;ara Rlvm a numbrr or me•n (stuldud ctev;..Jion). 
cma 
misoprosiOI 
(II • 104) 
69 
27.5 (5.0) 
:!a$.4(7.6) 
L7(1.0) 
0.5(0.8) 
~ 
69 
12 
13 
10 
l585(6Jl) 
generating. Statistical significance of the primary outcome 
measure was assessed using Student's t·test and was 
considered significant at P < .05. Rank order non paramet-
ric statistics using the Mann-Whitney U test, when a 
Cl!Silrean birth is a failure to deliver vaginally and ranked 
longer than any vaginal birth. aUowed inclusion of an 
births in a !iC.'CQndary ilnillysis with median time to vaginal 
birth as the measure of centralllmdency. Secondary out· 
comes were analyzed by parametric and nonparametric 
stltistics. as .1ppropriate. 
Continuous variables were examined for normal dis-
tribution (Wilk·Shapiro/Rankit Plot) before using para-
ntetric statistics.17 Desc:riptive statistics were used for 
demographic baseline data. Baseline data from non-
volunteers were analyzed to assess generalizabUity. 
The significance for aU secondary and hypothesis-
generating analy5e5 was P < .001 to account for multi· 
pie testing. a conservative approach. 
T.able 2. l'eripartum Oatil 
95'!1. 
V~gin.ll Or.ll Rd.lliv~ CDIIfodencr 
Vuubk! (II • JQl) (rr • 104) nslt inlerv~ 
lntnp.artum fmtumcy 
(h~;n ... S9 i'tJ 0.67 0.38. J.IJI 
Epidural usc 61 6S 0.89 051. 1.56 
No ouoalgew II3Cd 6 10 1).59 0.21. 1.64 
:1.1.-cuniwn 21 29 0.78 0 .• 1. 1.47 
P•onlWilltn~ 
Ef!i.'iotomy Z! 19 l.lJ 0.62..:t41 
l..acn~ S4 S9 11.98 0.56. 1.69 
Third· or fourth· l 0 
dqtft l«uallon 
Intact pmrcum l4 29 l-29 0.12.l.ll 
lanett et II MisoprostDl for Uzbor lrrducticn 4IJ 
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Tible 3. l..Jbor !ntervm to V;~ginal Birth 
Induction to votpn:al birth 
lnductlan ro full diLation 
First s~p: of LJbor 
5«ond stage of Llbor 
Third s~c of t..bor 
V•gmal 
misoprustol 
846(3851 
:'63(361) 
3-l2 <:W..I 
8.1 (119) 
12(1-1) 
10'72(593) 
1003 (3711) 
365(223) 
69(76) 
9 .q(8.-l) 
0.~ .anr givt:n in m111utes .u rnc:an (sund.vd dni.lriunl. 
• ~lcuY~ by Student t rorst. 
Results 
.001 
.002 
. .as 
.:!6 
21 
During the study period, 393 patients presented for 
induction of labor, of whom 308 were eligible. Seven-
teen patients refused enroUrrumt because they did not 
want to be involved in 01 research protocol and the 
remaining 85 were not invited to participate because 
altem:~te methods of induction, including ilmniotomy, 
oxytocin, or dinoprostone, were preferred by their 
attending physicians. 
Of 206 women, there were 104 in the oral group and 
102 in the vaginal group. No participo:~nt or neonate wo:~S 
lost to follow-up. The mean time (!:standard deviation) 
to vaginal birth with oral misoprosto1 was 1072 {!:593) 
minutes compared with Sl6 (!:385) minutes with the 
vaginal protocol. a statistically significant diJFerence 
(P = .004). ("The median time to vaginal birth in the oral 
misoprostol group was 1125 minutes compared with 
962 minutes in the vo:~ginal misoprostol group [P = .38, 
Mann-Whitney U testJ.) Maternal preinduction and 
neonatal demographic data are given in Table 1. Peri-
parium data are given in Table :!. with relative mk (RR) 
and 95'Yo CI. There were no significo:~nt dilferences in 
T1ble 4. Cli155ifiation of ExCI!Ssive Uterine Activity 
Tracing dua&f&e.ailun 
Hypertoni.: >'ill S« 
Oral misup~rol 
V.agin.ol nusopmsrol 
H)l"'fllNC >120""" 
Oral mixlpruMOI 
v .. pna~~ 
T.adlysystolc > 10 min 
Oral milop-tol 
ValiN! nusoprD11tul 
T.adlysystolc >20 min 
()r;a! milopi"Dl'llDl 
Vaginal 11\UoprastDI 
Hypcn!Unulallon 
()r;a! mi5uptollol 
Vq~NI mi5opt"oltol 
7 
8 
23 
16 
52 
41 
M 
70 
Rnlew~ 
cl.ullifird 
graph a 
8 
12 
~ 
21 
1-1 
15 
21 
17 
1-C 
17 
Table 5. Neonatal Outcome 
ACOC criteria for birth 
.asphyxia 
Appr .at 5 min :sJ 
Coni pH <7 
IJ.uoe ddicit >16 
Mean CURl pH 
Mr.an b;uor dclicit 
Mectw. Appr .11 1 
minute 
V.agiN! 
misoprustol 
0 
7.28(0.10) 
5.2JI(U4) 
q(8.9) 
a 
0 
0 
7.30 (0.09) 
U4(3.J2) 
'1(8,9) 
p 
.16' 
.16' 
.08' 
.ll' 
59' 
q (9. lal 'l(q,101 ~ Apg;u .11 5 .231 
minurc 
Apew .11 1 nun <7 17 mt 
Appr .11 5 min <7 a .32' 
• F".stwr ...w:t ret 
• Studl!flt r ret: """"" (st;an.Urd dev~tioa). 
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' .r' lftt. 
oxytocin, epidural. or other analgesiil use. Data for 
mean vaginal birth intervals are given in Table 3. 
There was no significant difference in birth route 
between the two groups (X,1 = 2.53, P = .-17). With oral 
misoprostol there were 58 spontaneous vaginal deliv-
eries, 21 vacuum deliveries, nine forceps-assisted deliv-
eries, and 16 cesarean births. With vaginal misoprostol 
there were 56 :;pontaneous vaginal deliveries, 15 vac-
uum deliveries, eight forceps-assisted deliveries. and 23 
cesarean births. Nonreassuring FHR tracing was the 
indication for two cesareans in the oral misoprostol 
group and six cesareans in the vaginal misoprostol 
group (RR 2.-17, 95.,-o a 0.-19. 12.49). 
Fetal heart rate and uterine Ktivity tracing data were 
.. 
Reviewft!' RcvicWt'I'J illr'v...,en 
cl.aulfied d.IA.•II'Wd dalsi!Md 
gr;aph.as sraphu graph .as po 
15 :!6 5& .611 
II 2IJ 
"" 
:!-I ::!0 31 S1 
~ ~ 21 
IS 25 :0 .21 
Ill 21 31 
16 10 5 .a1 
7 11 :!5 
0 .Ool 
6 .. 
analyzed using nonparametric: statistic:s based on num-
ber of masked physician reviewers making that classi-
fication of a given tracing (Table -1). Although there was 
more frequent 20-minute tac:hysystole {P < .01) and 
hyperstimulation (P < .04) in the vaginal misoprostol 
group. these results were not statistically significant by 
our preset level for secon~ry analyses. but the trend 
warrants attention. Neonatal outc:omes in both groups 
were similar (Table 5). Umbilic:al cord arterial and 
venous blood acid-base analysis was performed on 89 
of the 104 participants in the oral misoprosto1 group 
(86% of neonates) and 92 of the 102 participants in the 
vaginal misoprostol group (90'Yo of neonates). Two 
neonates from the vaginal misoprostol group had c:ord 
pH less than 7.00; however, no neonate met the ACOC 
criteria for birth asphyxia.'• 
A postpartum questionnaire was c:ompleted by 90 
women in the oral group and S3 in the vaginal group (84'Yo 
response rate). Analysis of the responses to the -49 ques-
tions failed to deb!ct any statistically !!ignificant dift.'f1!1\Ct! 
in patient satisfaction or overall score. All participants in 
the study reported positive labor and delivery experi-
ences. None of the p;uticipants self-reported adverse gilS-
trointestinal elects on the questionnaire. There was no 
dianhea nctl!d in either group, and no diference in 
~"CUffee''IZof vomiting (18 in the oral and 19 in the vaginal 
group. P = .81). When given orally. a nwdian of two and 
a maximum of nine doses were used. Only seven subjects 
took more than five oral doses. When misoprostol was 
placed vagiNlly, a median of two and a maximum of five 
doses were used. Bl5eline data from nonvolunteers did 
not difer significantly from volunteers. 
Discussion 
Obstmicians routinely use various mechanical methods 
and pharmacologic agents to induce labor; however, no 
single approach has been universally successful ()l(ytoc:in 
is an ektive induction agent but it is not optimal for 
patients with an unripe cervix. uu9 Administration re-
quire intr.aveNNS infusion with continuous monitoring 
of FHR and uterine cattr.Ktions. When campan!d to 
oxytocin. prostagLandins (dinoprostone) are e6«tive cer-
vial ripening agents, 1c:hieving a shorter induction-
delivery intftVal and a lower rate of operative interven-
tion. :zo Oral admini5tration of prostaglandins ~11tiaUy 
has been ab.ndoned because of undesirable gastrointesti-
nal d'ects, which have limited their use to vaginal and 
intracervical routes. 1' Tennination of prostaglandin-
relatll!d excesaive uterine activity remains problem.ltic. :n 
An oral induction agent that is safe. e~ective. inex-
pensive. and weD-tolerated by patients would be attrac· 
tive to patients and health care providers. Anticipated 
benefits include avoidance of intravenous lines in some 
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parturients, less frequent need for vaginal examination, 
and greah!r freedom for upright positioning. Ambula-
tion might even facilitate labor progress.::z Induction 
agents shouJd mimic spontaneous labor while avoiding 
l!xc:essive uterine activity. When c:ontractions of abnor· 
maUy high intensity or frequency oc:c:ur, insufficient 
recovery resulting in FHR abnormalities could necessi-
tate operative delivery or lead to fetal asphyxia.11 
Several r .. ndomiud trials2"' comparing vaginal mi-
soprostol to standard therapy found misoprostol to be 
safe and c!«tive for induction of labor. Sanchez-Ramos 
and colleagues'~ studied the safety and effiacy of 
vaginal misoprostol for cervial ripening a:ld labor 
induction in a meta-analysis of published trials to 1997. 
Of 16 trials identified, eight met their criteria for inclu-
sion and included a total of 966 patients. 488 of whom 
received vaginal misoprostol for labor induction. Con-
trols received oxytocin or vaginal dinoprostone. Those 
who received vaginal misoprostol had 3 higher inci-
dence of vaginal delivery within 24 hours of application 
OR 2.6-1, 95~ .. Cl 1.87. 3.71) and a lower cesarean rate 
(OR 0.67, 95'l'o Cl 0.48, 0.93). Use of vaginal misoprostol 
was associated with a highe1' incidence of tachysystole 
(OR 2.70, 950ft. CII.SO. 4.04) but not ofhyperstimulation 
(OR 1.91, 95% Cl 0.98, 3.73). 
Only a few randomi:~:ed trials assessing oral m~ 
prostol for induction of labor at term have been pub-
lisht!d.9•10 Toppozada et al13 compared vaginal and oral 
misoprostol for induction of labor in a smo:U random-
ized trial. Twenty patients assigned to receive 100 I'S of 
vaginal misoprostol were compared to 20 assigned to 
oral misoprostol. When no response was noted 3 hours 
after the first lQO.I'K dose, 200 l'g was administered 
every 3 hours until a maximum dose of 1000 l'g was 
reached. Doubling the dose administered .. -aginally 
only occurred once. One subject in the vaginal group 
and three in the oral group had cesarean deliveries 
bec:ause of failed induction. The authors concluded that 
vaginal misoprostol resulted in 3 shorter time to deliv-
ery (P < .005), but more abnormal FHR patterns and 
uterine hyperstimulation occurred (P < .05). 
Zieman et al23 r.ompared pharmac:okinetics of miso-
prostol (400 ~£8) administered by vaginal and oral 
routes to ten nonpregnant and ten pregnant ftrst-
trimester volunteers and conc:luded that significant dif-
ferences exist. Systemic bioavailability of vaginally ad-
ministered misoprostol is three times that of 
misoprO!Itol administered orally. The greater bioavail-
ability of vaginal misoprostol might explain why we 
observed a shorter time to vaginal birth in the vaginal 
group. The greater frequency of abnormal FHR patterns 
observed in this group might be the result of excessive 
uterine activity because of this greater bioavailability. 
Although there is no direct one-to-one relationship 
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between continuous electronic fetal monitoring and fetal 
well being. nonreassuring FHR changes associated with 
excessive uterine activity warrant intervention. either to 
l'l!dua! uterine activity or to deliver the fetus. BecaWJe of 
confusion from varied definitioN of excessive uterine 
activity, Curtis et iil11 recommended a standard ll!nninol· 
ogy. Although it allows for classification of labor graphs, 
the terminology is arbitrary, particularly with respect to 
tachysystole and hypertonic rontriM:tiol1s. 
Despite concerns of po551ble uterine hyperstimulation. 
substantive advene newborn outcomes such as neonatal 
acidosis, meconium aspiration, and birth asphyxia have 
been rare and have not difered between misoprostol and 
control grt111ps.•-•o.tl..l3 1n our study, two neonates in the 
vagirlal misoprostol group had cord blood pH less than 
7.00, but no neonatal asphyxia occurred. Among the 39 
cearean births, six of eight done for FHR abnonnalities 
were in the vaginal group. Although these difeteN:eS are 
not statistically significant, the quetion is clinically rele-
vant, making it worthwhile to design a clinical trial to 
answu this question. 1l1e fn!quency of exce55ive uterine 
activity ISIOCiated with route of administration is a sec· 
ondary outcome in the present study and did not fonn a 
basis for cakulation of sample size. 
Misoprostol is elective in inducing labor whether it is 
given orally or vaginally. There is a shorter interval to 
vaginal birth with Vilginal application; however, the 
more frequent FHR graph abnormalities in this group 
might be attributable to excessive uterine activity. Oral 
administration is an appropriate alll!miltive for labor 
induction with misoprostol. considering fetal safety and 
the ongoing study of optimal vaginal dosing interVal. 
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APPENDIX B: HUMAN INVESTIGATION COMMITTEE APPLICATION FORM 
MDIOIUAL lJNIVDSII'Y OF NEWIOlJNDL\ND • PACIJLTY 01' MmiCINE 
HJIMAN INYf.STIGA'DON COMMrJTEE - c\PPUCATION FORM 
11lis fimD is delia-1 10 cover • lqe a vlriely of propollb • poaible: DOt all quCitioaa ~L-.~Ij.~i= 
bowever, please coalider CICb qaeatioa cuefidly befOre writiDc it off • •Not Applic:able• 
l. Name of Priacipllllaveaipor: ----..al.u«lbru...;:t .. ,_, __ L----------
Mailill1 Addraatrel...,_ No.: 13 un 1qy Rpqtl a , •. , Nl ang.J221 
2. Name(s) of Co-1aveati,.0r(s): .~P.:~'-...acDqyl4aall.llr-~~~~...,, -------------
3. N..,. of supervisor, if Priftcipallavestiptor is a studall: Dr PaWl YOMIJC 
4. Title of investiption: (PI I&SJ HHJGIII' 1JY WI!IQS) 
Vsrtnql Hl.rwmpql Vmw Orpl HLrtpwtqt For lrttl¥Q1911 Q(IMqer· A Rqadqm4td Owrqi/M Tripi 
S. Whal is die proposed startial dale? (Must be iL.Ja1S 4 weeb larer dian !bee of receipt of tbis 
applia~~ion by tbe H.I.C. Office.) 
'!qpgry ,. 
6. Whal is lbe amiciplled dale of oompleion of dae study? 1411HQ1Y 1227 
7. Please fill in dae lfProprille informallon: 
a.,~~a~~c-•., ...... laftlftl ...... s.lllalu.llo Parddpadna 
Sealaa laftlftlll ......, ._. Flellllls lbpltal Eabia Commlu.a 
........ 
Grice Geaeral Hosp. Yu r~.r Yu Yu 
Labour a: Delivery 
Uait 
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Pqe2 
J7w ,.,., obJ«<iw of tills llll/ly II ID CClfi9JCft dw t/lk«J of lfllsDprom1l (CI pi'MIQJi4lltlbl) adlrtlltsluN 
DNil1 ro Mlsoprollol ~11111,_, lit ptllilllll f'Wllllrilll arvtctll rlpalltJ.ftJr rtw lltdut:ttolt ofhlbor. 
J7w tJII'1ID# 1110 tlnmlfllv 1/rtlfM of~,.,.., MJliOII dw time ofilttbM:Itoft ID dlllwry. 1111 
ow COfWIIdoll dtlll e111 orGl lflltllcodofl Wlllfll4 be ~ to MIIIWII tu II coflld tl«ntu~ dw ,.,..,. of 
W111M1 ,.,., 1/wy """" raJflft llrnlfllll * llttl¥altJfa prtJUD. 
9. Wlllt is die scitlllifk: bal:qrouiMI..a ndoalle fDr tbeiiiUIIJ? Wlllt beaeftll may be IDliclpated'P Have aay 
reiiVIIII tmm. or aaiJIIII lllldielllrady bela """"'"""" Pleae specify. (Aaadl aaodlcr s1aeet of paper, if 
required.) 
P'ro.rtllrl4alllu tW boMI ro be qftalw bttlwrltJia .,a. Slwralltllllln haw shmm 11111J1U IIWoprostol 
ro be "* Gild~ lit anta~~ f"'palltrtlllll ,._, btdMt:rlott lit ptllkra """ illltiCIIIItJ!Iblau, iltdudbtr 
011T mar's RCT. Mlsoprostollltlbofltl DIW pntnl tu costly tu Ollwr GfalS. 
A """' RCT compi«ld ell tlw CiNe~ Gtltmll Hosp#IQl hCI.r shoMI ortllllflsoprostol ro be 1111 ejfocttvt! 
l1tdualoll CIJtltl. No rtUfdolrtlud lrillls llcM Cl1lllptUftl ONl lldlrtbtLrlrellloll to 1111111N11 adlnlltlstratlo11. 77W 
study GllllllpU ID dJu1fy Wdwr 111111111C1l or ONl GdlllllllstrGif II 1M pnftmd rOIIU of #UIIwry. 
10. Wbicb of die followiq are 10 be employ.a iJt tbe iavesdplion? List only tbose tbat are NOT part of normal 
pllieal care. 
(a) S1111pa. 10 be taken from subjecu: Sraae type of sample, frequau:y 11111 IIIIOWil. 
No 
(b) List die proc:edura IIIII IDY t1111 or subiCIDCa co be admiJlislend ro plliems: spec:ill dieu, dnap (stae dose 
IIIII fnlquacy), isoeo~Jic tncen, «e. 
Grotip I. 
~II. 
Mtsopronol 25 111 PO ~ry two ltolln IIIIIU loboflr ~stllbllsMd. spoNIUWDIIS ruprur~ of 
trWIIfbrtuws ordlllwry. 
MtsoproSIOI 25 111 PV Cr~ery 1W0 ltotln IIIIIU loboflr tsl4bllsMd, SROM or tUilvt!ry. 
(c) Questioaaaira: Aaadl copy of qucstioDDaire 10 be used. 
Ml«<ttd. 
(d) Is tbia IPPiicatioD for a cliftical trial? ( K) Yes ( ) No 
If ya, wbll •p~~aae• of dle trial does tbis saady repraenc? Wha is tbe delip of tbe trial (e.g. opea. double 
blind, ell:.)? 
Opm. 
l¥tlw J. 
~ CDiflroiiTial 
ll. Doa dle study involve tbe use of my radioactive llllhrial? 
If ya, specify. 
( ) Yes ( .r) No 
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12. Give a brilfcr.cripdoDofdaedaip ofdae llUdy. (PI- abo lllldl ma.copy of a prococol if available.} 11lis 
sbould iad1lde c111aiJa of subject selection. .-pie size c:alculllioa (if appliclllle), OUCQHDe measuraaeat IIIII 
clllaiJa of lllllysil. 
l7lt llttlallfiiiD'.r .,_, 10 COitlbla 41 1'GNlolrUud COIIII'Oiltd trl4l ctJ1f111Grl111 orQ/ tUtti WIIIMI mlsoprostol as 
bttlaalorl ~. /11 orrlu 10 e1mJ11111 for dw ~ of PGrllY Oft lltdMaloll of,., ~ wUI 1¥ 
.rnwiJI«l. 1\lo f'OIIPI will - ntllbll.rlttd, fllllllptJtuar ptlllnD lllfllllflllllptlnHu potlal.r. 10 JIDII 
tlltd ...,.lfllloptwlol WDIII4 '- dtJtwiiJ "'*" .,.,..,U, ,.,.,rei optlqlltt mwlopa wllh Rudy tlll«tlllotl. 
l7ltu WOfll4 - pwptrttliiJ ~ .rlll/1 .. lllwJiwrllla pGIIal Clll'e MJiltl ,..,.,. ......,.14bla """ 
~ Ill biDd:J of /Dflr. GnHip 41111,.,.,., Wllfll4 '- ct1ltt:4tlltd /fotlt Clllf! rtwn lllftU tlw lilll4 of 
,.,.,.,. All Rudy p4IMitl.r will - odlrtllt«lto /wplltll tllflll1ttiMerlole will - Cllrrlal 0111 011 all llfpollal basi.r 
wllh ~ frtiiii'IIOIIllortJII for CNW 1tow tl/t6 ~ of t1w pronar141tdlll tUtti dwtltr atllblulwd 
lllbotr. 
13. Number of sultjecu: Sr.e bow subjects will be selected. 
780 lllbj«t.r wUI br rKn~Jttd j'rt1lfl ~ p~ tllfll obnmlcQ/ praatc~.r ill St. Jolul's. Pa*nn will 
'- ~llflbl~ lfdwy pn.r~llt wllh a11 btdictllloltfor lltdiiCI#oft of labor, a sillrl~fonu, c~pMJic pnsnuattollllltllllltaa 
IIWJIIbrG~VS. 'lPien """' br 110 COIIITtJbtdllaloiiiO WIIIMI blnh. 
14. Number of coaaola: State bow dlcy will be seJcc:ted. 
Euhuloll crilutG will I¥: lfDIIIYIWIITilllfntJI /won trru:1111, prior llleriM surr~ry. dot:JIIfwllud ~n~111ilivity 
to llll.ropronol or otlwr prosiGfltUtdLIU or COIIITGittdlcad011to WIILMI blnh. 
15. W1la (a) risks, (b) discomfons or (c) inconvcnicnca are iawlved? 
(1) Po.r.rll* ra.rti'OUWitilttll.rlde qJ'«u assodtllttl will& pronGrltutdbt illcliiM: t~GUSN, vom~~tnr. dlllrrMt~. (2J 
A rrn COIIIpllaJtlofl of pro#llfl4ltdlla use 1.1 •rllw ~ A MedlCQI Protocol for lllldres.rblr this 
slnMJdolt I.J uttlbli.rlttd. 
16. Are lbere uy imlllediale beaefiu atiliq out of !be audy for the subjects? (Specify) 
FrMT pelvic ~ Mirltl ullilll4ldy fWd to br pnfonrwd. Data from a Sillily diNw Gl our lllsLtllllo11 
~a ntlllnktll tUtti dllalallly slpljfcallt mhlaiDft of owr tJwe ltolln (p=0.0/8) ill tiiM frotra Utdw:rio11 
to variNII blnla wiiiJ WJflltGIIffUDptollol tlll1rtbllsurtd 50 "' every four hofln PV. 
17. What sups will be takca to preserve coafideatiality? 
l7lt llnlatlftiiOn II.JIId wUl br tlw Dilly peopl~ to llluttiU dtllru tllld lwalth rrcord.r. No pGII~IIl /MIIIiflilll 
~ wUI br rrletiMI for publlCIIIIoll or P'f#III4IIOII. 
ll. Espa.ia pmc:eduae em obtaiaiq c:oDICDt. 
Wbo will make !be iaitial co.act wida liNt subject? Alrgdlnr Plmlr:fa 
Who will oblaiD die COIIICDI of die subject? '"""''flfllrJ 11m4 Ml[nn ml4ptplrclcm twac 
(If ftllldi1al .ruppon obtabttd) 
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19. wm lllbjectl illdude ...,. 
leplly incoalpltlat periOIII 
If 10, ........ will be raba to probiCt daeir riafds? 
21. (I) Will ¥Oiullleal receive ~ for apenMS 
time 1o1t from wort 
Pap4 
)Yes (.I')No 
)Y• (.I')No 
) Yea ( .1') No 
)Yea (.I')No 
) Yes ( .1') No 
) Yes (X) No 
•• Pleae speeify oa separa IbM Kemdina to GuideUDea for die Remuneraion of Research Subjects. 
(b) Will dlere be 1DJ dlird pany remuaeraion for referral of pllieacs? ( ) Yea (X) No 
•• Pl ... ll*ify oa scp ... sb• accordina ro Guidelillll for Payment ofFiDders' Fees. 
•• AVAILABLE IN 'DIE OmCE OF RESEAaCH • GRAOOATE S'llJDID (MEDICINE) 
22. PI_. enclose 1 copy of die buda• for dlil mady, iadudina an iDdicaion of source of fuadina. 
Will die budpt be .tministered dlroup dae UDivcnity Fiaance Office? ( ) Yea (X) No 
If no,ll*lfy. 1/mNI'dl/flltdlllr obftlbtalll t4IOII/d 1» ~,llwllrll 1M Ulllwntly. 
WUI die iJmltiplor accrue my beDefiU by virtue of plfticipalion in tbis saady? ) Yea (X) No 
23. Is tills pan of 1 aaulti-cenlre study? )Yes (X)No 
24. Will d• bec:o.- dle exdusive propeny of 1 pbiiiiiiCeUtical company or otber ouaide 
apacy?lf yes, please elaborate. ( ) Yes ( X ) No 
25. It is tbe relpOIIS1bUily of die u.v.dpcor to IIIIUre Ill• permission is obcained from dillicians, depanments, 
illltiUioaa or COIDIIIIUiitiel wbose plliellcs/reaidenll will be involved in tbe study. Have tbe app1011rialc colllai:U 
.,_ llllde? 
Yn 
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Office ol Raarda and Graduate Sclldia tMcdicillel 
Faculty of Mtdicine 
The Health Scialca Centre 
1997 Olll KEYED 
Dr. Kelly Beaneu 
Deputment or Obstetric:s/Gynec:ology 
Grace General Hospilll 
Dar Dr. Bennett: 
Thank ,au for llldna tbe time to complcce the annual update form ror 1he raan:h study 
entitled •v..-. Mllopnl1al Vtm11 Onl Mileprostal for laductioa or Lahor: A 
Ra•do..a.d Coatroled Trial". 
At a meetiftl held on Pebna1'7 17, ltt7, the Human lnvestiprion Committee granted 
approval oftllia study Ulllil febnw'J 1991 at which time yau wiD be ccmlaCicd for a 
fUrther update. 
Human lmaliption Committee 
HBY\jalo I 
c:c: Dr. K.M. W. Keou&h, Vice-Piesidenl (Jlacarch) 
Sc. rc*a•L Nf'. Cmada AlllV6 • Td. : 17091 737-6762 • Fu: 110!11 7l7·50ll • auol: rpeiiiOfpA.IICI.mua.ca 
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APPENDIX C: DATA COLLECTION FORMS 
Group 
Chart## 
Ap 
Gravida. Para 
Gestation (clays) 
Bishop - Position 
- Ccmsiltence 
- Efliccment 
-Dilation 
-Station 
##Doses ofNarcodc 
Epidural 
PG##ofDosea 
Ma.Miso-Vq. 
Ms. Milo. 0n1 
Oxytocin ## miaates 
Indication for Induction 
Type of Delivery: SVD Vacuum Forceps LSCS 
Indication for OR: NR.T FTP None 
Episiotomy: Nil Lat. Midline 
Lacerations 
Manual Remcml ofPiaccnta 
Blood Loss: Normal or 
Scalp pH 
Side Efl'ects: Nausea 1/1 .. Diarrhea 
QUES110NN.AIRE SENT _YES NO 
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-R.O.M. (Time) 
t.feconium: Yes No 
1st Sla&e (mins.) 
2nd St.qe (mins.) 
Induction to deliwry (mills.) 
Induction to fully (mins.) • 
saaaem 
Apprl 
Appr5 
Cord Pb 
Cord B.E. 
Gender 
Weight 
I Pelvic Exams 
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INITIAL BISHOP SCORE· PLEASE CIRCLE 
Parwnelers 
Cervical Position 
cervtca1 COnsistency 
Cervical Effacement ~) 
cervtca1 Dilatation (em) 
Station of Fetal Head 
Total Score • 
Time and date: 
Assessment by: 
1 
2 
3 
4 
5 
e 
7 
a 
Oxytocin: 
Time Started: 
Bishlp Score: 
Dose: 
Gravidity: 
Parity: 
Geslallonal Age: 
Time of Delivery. 
0 
Posterior 
Firm 
0.30 
0 
·3 
1 2 
Mid Anterior 
Medium Soft 
40-50 80-70 
1-2 3-4 
·2 ·110 
Dos!p! Time 
3 
>10 
>5 
+1 
Date 
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APPENDIX D: POSTPARTUM MISOPROSTOL QUESTIONNAIRE 
( ( 
Appllcanc's Name : Kelly Ansela Bennect 
POST-PART\."M MISOPROSTOL STl.l)\' SATISFACTIOS SlltVE\' 
Please r:ate the rollowint narements on the basis of srrontiY qne • 10 and stronfly 
~isatne • I . 
• . I was very sarisficd with the care we received 
~urint labor and delivery. I :! 3 4 S 6 7 8 9 10 
.:. Sufficient anention was paid ro the safety of 
:norher and baby durin1 labor and delivery. 2 3 4 S 6 7 8 9 1 0 
3. The staff rave us &II the care and attention they 
:ould durin1 labor and delivery. 2 3 .a S 6 7 8 9 I 0 
~ . Some unnecessuy inrervenrions were carried our 
on modter or baby durin11abor and delivery. 2 3 4 ~ 6 7 8 9 10 
~- Our wishes were always respecred durintlabor 
and delivery. 2 3 4 S 6 7 8 9 10 
6. I feel happy about this labor and delivay nperienc:e. 2 3 4 5 6 7 8 9 10 
i . I fell in c:annol of whal bappened duriq labor 
And delivay. 2 3 .. 5 6 7 8 9 10 
8. I fell some mistabs were made in the care received 
:Tom thc staff durinl Iabar and delivery 2 3 4 S 6 7 a 9 I 0 
~ . If rhe staff had been more capable durin& labor And 
delivery I would have ben happier with the care received. 2 3 " S 6 7 a 9 I 0 
I 0. I would be feeliftl befter aow if the Slilff had been 
more considerale durin& lllbar and delivay. 2 3 4 S 6 7 8 9 10 
11. 'The nune pve us all 1M can and aaenrion l1nnced 
durina Iabar and delivay. 2 3 " ~ 6 1 8 9 10 
12. 'The doctor pw all 1M anenlion needed durina labor 
and delivery. 2 3 • ~ 6 7 • 9 10 
13. I would haw lilrad die IDif 10 haw n ; ided 10 me 
differently durin& llllor and cleli'"'Y. 2 3 4 S 6 7 I 9 I 0 
I 4. Sufficient anention wu paid 10 comfort durin1 labor 
and delivery. 2 3 4 S 6 7 I 9 10 
!5. I would have libd the~ of llbor and 
~elivery ro have been dane diffemnly. 2 3 4 S 6 7 I 9 10 
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( 
Applicant's Name: Kelly Angela Bennett 
16. There was 100 much equipment used durint labor ~'1d 
<i.eiivery . 
l 7. The surf ,.,·ere sometimes rude to me durin, labor 
and defi,·ery. 
I 8. There were 100 many sraif or studmu involved in 
the labor and deli"ery. 
I~- Staif treated me as if this was just one more delivery. 
::0. The suif helped me ro reel like tJus was ~ very 
speciu event. 
~ 1. The appropri~te amounr of equipment was used 10 
monitor the labor and delivety. 
::. There were occasions when no one e~;tlained to me 
what was lolftl on. 
23. There were unnecessary restriction on mochen 
walkin& around durina labor. 
2.&. The most comfonable position was used for lhe 
actual delivery. 
:s. The lhinas done 10 the baby immediately aner binh 
were all necessary. 
~6. I held the baby as soon as I wmted. 
:7. They cried to deliver the placenra IDO quickly. 
~8. I ,.,.as liml all die information needed about 
PfOITtSS in labor. 
:9. The nurse was with me as much as I wanted. 
30. I saw the doctor as often u I wanted. 
31. I was satisfied wilh the way pain was relieved 
durin1 labor. 
31. l was dissatisfied witb the way paift was relieved 
durin1 delivery. 
33. There were too many vqinal elWirinations. 
3.&. Our biM plans were ipoted. 
~ ] " 5 6 7 8 9 10 
2 ] . 5 6 7 8 9 10 .. 
2 ] 4 5 6 7 8 9 10 
2 ] " 5 6 7 8 9 10 
2 3 J 5 6 i 8 9 10 
2 3 " s 6 7 8 9 10 
l 2 3 4 5 6 7 8 9 10 
l 2 3 4 s 6 7 8 9 10 
2 3 4 s 6 7 8 9 10 
2 3 4 5 6 7 8 9 10 
2 3 " 5 6 7 8 9 10 
2 3 4 s 6 7 8 9 10 
2 3 4 5 6 7 8 9 10 
2 3 4 s 6 1 8 9 lO 
2 3 4 s 6 1 8 9 10 
I 2 3 4 S 6 7 8 9 10 
2 3 4 5 6 7 8 9 10 
2 3 4 s 6 7 8 9 10 
2 3 4 s 6 7 8 9 10 
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( ( 
Applicant's Name: Kelly Anaela Bennett 
)~. Rec;overy time in labor and delivery was roo rushed. 
36. The nurse made tile labor and delivery a bener 
e~perience. 
3i. I wish all docrors were as aood as ours. 
38. The doctor made the labor and delivery a beuer 
experience. 
39. I did nor ellperience diarrhea durina my induction. 
labor and delivery. 
40. I did noc experience stomad: cramps durinJ my 
induction. labor and delivery. 
-------------- . . -·· .. -- - ~ . . 
ADDITIONAL COMMENTS: 
( 
~ J ~ 5 6 7 8 9 10 
~ J 4 s 6 7 8 9 10 
~ 3 4 s 6 7 8 9 10 
2 3 4 s 6 7 8 9 10 
~ J 4 s 6 7 8 9 10 
2 3 4 s 6 7 8 9 10 
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APPENDIX E: CONSENT FORM 
ft~ 
FACULTY OF MEDICINE 
MEMORIAL UNIVERSD'Y OF NE1WF4DU1111DIJ,\NID 
ST. JOHN'S, NEWFOUNDLAND Alii3V6\\. 
CONSENT TO PARTICIPATE IN BIO.MEDICAL 
Dr. K. Bennett and Dr. D. Young 
You are beina asked to putic:ipate in a researdJ study. Panic:ipation in the study is entirely 
volunary. You may decide not 10 participate or may wilhdraw from the study at any time without 
affecting your normal ueatment. 
Confidentiality of information concerning participants will be maintained by the investigators. 
1be investiplln will be available during the study at all times should you have any problems or 
questions about the study. 
You underscand you have been scheduled for induction of labour. You arc aware that 
pn:111111mlins, altbou&h primarily used as cervical ripening agents, also stimulate labour. These 
mcdic:alions can be administered ci1her by moudl or vaginally. 
Misoprosrol is a prostaaJandin used for the ueauncnt of stomach ulcers. Recent research has 
shown that misoprostol placed vqinally effectively induces labour. Our own research has 
demoMtrated that misoprostol by mouth is no less effective or safe than usual labour induction. 
This trial will attempt to dec:ide if misoprostol by mouth can be used as effectively as vaginal 
misoprosrol. 
If you cboase to enta' dlis SlUdy you will be randomized (chosen as if by flipping a coin) inco one 
of two poups. All patients will receive a pill by mouth and a vaginal preparation. One of chese 
prepantiom will contain misoprouol, the ocher preparation will not contain any medications. 
Every palient will receive an active mcdicaDon either by moudl or vaginally. Neidler patients nor 
investiaauxs will know aroup assipment. There will be no additional cxamirwions or blood 
cem. After delivery your chart will be reviewed by die research team for information reprding 
your delivery and baby. You unclcntand that you will remain under the care of your physician 
who will manage your labour/delivery as deemed necessary. Your participation is voluntary. 
112 
You may choose to withdraw from study at any time. Prior to discharge we will be asking you 
to complete a brief questionnaire on the satisfaction of care during your stay in hospital and 
throu&hout the labour and delivery. 
The alternative sllould you choose not to enter the study. would be induction via prosraalandin 
concainiq cream given per vagina. 
You have discussed the information provided with your physician a'1d he/she has answered any 
questions about your care. 
You undentand d1at records concerning your labour, delivery and hospital stay will be reviewed 
and you give your permission for this. No records bearing your name will be provided to anyone 
other than the research team in this study. You will not be identified in publications in any 
manner. 
lJabUity se .. eanaa: 
Your signature on this form indic:ar.es that you have undencood to your satisfaction lhc 
information reprding your participation in lhc research project and agree to participate as a 
subject. In no way does this waive your legal rights nor release the investigators, sponsors, or 
involved institutions from their legal and professional responsibilities. 
(5.......,. or Partidpaat) (Date) 
(S ...... ofWIIals) (Dale) 
(Siplllun of laftldplor) 
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·Memorial 
University of Newfoundland 
Humaa lft..-iptiaft Caamirta 
~ and Craduale Studila 
Facuhy oi PoWidM 
'llle Haith~ eaaa. 
29 April 1996 
""" ... 
Dr. Kelly&-. 
c/o Dr. n.ws v--. 
Oblllaica a O,aecolo&Y 
Once a.-.1 Holpilll 
DarDr ........ : 
1'hil will Kbo•Jedae ndipl of' your reviled COIIICIII f'orm for tbe ~ study enlided 
.._ .... ...,,._,, CNIIIIII, ..... •iaedTriiiCe• ...... OniVenuV ...... 
Mllapn!ICII PwiA ... r t.diJCIIM•. 
I haw miewed tbe reviled couena form llld 6nd it to be lllil&ctory. We wiD keep a copy iD tbe 
IDCOflice. 
cc: 
St. Jolla'•· Plcuf 'Jed Clalda AlllV6 • T&: 17'1191 TJ7411• • Faa: 110111 TJ7·~ 
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APPENDIX F: MEDICAL RESEARCH COUNCIL GRANT APPLICATION 
........ 
Youq. David 
~:=r=.e~OIIWI 
=.tiiis- =-
Youy. David 
Crane. lou 
MJSOPROSTOL 
LABOtJiliNDVCTION 
"'·=-mJr--7Q.tJ ..... 
t. Dr. Mary lflnnah 
Associate Professor 
FICUlty of Medicine 
University of Toronto 
2. Dr.Jermne o.a.ereau 
A.aociace Profeaor 
17 
Facul afMedicine 
Uaiv:.ty of Brililh Columbia 
3. nr. area a,... 
AuiltUI Profeaor 
~- ofQblf(Jya 
Unawnity of 'toronto 
C!!!,.,, ................ _ ......... (! ___ , 
s 11,522 
=:::u==:=.:-~ ......... , y_., .. , 
.-,.....,...... 
1947 03/0t/97 
1965 
C·=~-~ REPR 
REPROOUcnONIPREGNANCY 
l!·c!ar..==~ 
,.....,.,., ..... ..-..c., 
..... , ..... , Naa •tallfiMIW 
Depr. of ObsiGyn 
76 Grenville Street 
Toronto, Ont. M5S 182 
(416) 323-7317 
B.C. Women's H0111ital 
IT62-4500 Oak St. 
Vancouver, B.C. V6H 3NI 
(604) 175-2424 
Mount Sinai Hospital 
775-600 University Ave. 
Tor011to, OnL M5G IXS 
(416) 516-1415 
St. Joseph's Heallh Centre 
PO &ox sm. stn ae esc 
LGndGn. OnL N6A 4\'l 
(519) 646-6091 
Cliaic:ll hMslipion 
Clinic:ll Trilla 
Clo!NiMe. 
"''"*"'== 
Perinatal Ctinic:al Trials 
Maternal Fetal Medicine 
Maternal Fetal Medicine 
Maternal Fetal Medicine 
Maternal Fetal Medicine 
Q.lf_.,,...__...._ ...... ,.. ... .....,_ 
,_ __ MO'f ...... .,.... ........ 
M-e ........ r •••-- e ••- a~ 1• =• Dr. Kelly 8ennla. Resident V, Dept. aiObiGyn., Memorial University ofNewfoundJand 
Dr. Rary Windrim, Pratasor, Dept. ofObiGyn., Memorial University aiNewroundland 
Dr. Kim Bult.ltesident lV, Dept. of"Ob/Gyn., Memorial University of Newfoundland 
1-0IN--~-·---= .. ~ .... -· ===--.............. _ .. . ..
c 
c 
ll5 
~ c..._.~ 
Yogq. David 
C~~DC.Io.t 
.......... ,. CJAA 
Maaarial Uaivenity ofNcwt-illal 
Induction of Llbour with Oral Misoprostol. 
=r.:.'~--..... c.,... ........... flwLiiUiii&Wt ....... : 
,... ® NcM ... 
lt-.1 0 
"-*"·· ''~r" .,..& ............ •c01w11 ............. 
Mdi .......... CIICitll: 
~--· ........ ==:· ...... IYN,N , ... ,,..... 
Y• .... Te-a. a...,. 
·-..._ 
~ ........ ~ 0 
...-----· 
__ ...... 
Alilllll 0 .. , •• 11 0 0 
.pelllll .. l ....... 
A~IIW 
--· 
0 :-c:r.-. 0 0 
N":..~-....._ 
I =:=•-: .;; , ... .,..d .ca~. ..... 0 
a.....• ........ - .... =--- "-' ® Ia--·-- - ,...0 ,... .. • .... 
----· 
DEMANDE DE SU8VIN110N DE 
FONC11~ 
_,_ 
a.--tao.- oc 
Prvf .t Clulir Obsaacl(iyn 4Cl Medicine 10 I 
Aslt Pial Obsaacl(iyn « Medicine l 0 I 
"'=._... ..... ~ ............ --. CJAA .. ...  ............ ,....... .. 
McmoriW University ofNcwf'ouadlad 
~~ 
lnflrwtUy- ~a:::...-= e. .. 
~-- s 81,522 .... tcaCIIIIW'Nmell E.._. .... 
Talll s 81,522 Taq~ 
-
=--.....- =.:.r--@10 2 0 3 0 5 y_,_...._ 
........ ...... 
.......... := ........ 
Dr. David Yound, 
Gnce General pi tal 
241 LeMan:hant Road 
SLiobn's.NF 
AlE 1P9 
T ....... ......... 709-771-6157 NIIIMir ......... 
,_ T ........ 7CJ9.7S3-1162 
EoftiCI C8lllllr obtYftmua@public.nftd.com 
.... ...... 
............. 
....... _... 
_. ... a 1ft: 
4 •a• r..-® , ..... : 
LJa ........... ,_. 
IMC/CMI ttatvwt.t) 78iaaat= ---_,_ 
Office ~f Research 
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·--Youaa. David 
t-~"'L-, 
&:..'if =-
Yauy.DaYid 
Crane. Joan 
MISOPROSTOL 
LABOUR INDUcnON 
, . .,.J:" .. ,t:;tt ..... 
t. Dr. Muy Hlnnah 
Associaac Pral'euar 
FICUity afMidicine 
Univwsity of Taranto 
~ Dr. JIRtllle DIDiaau 
Alloci ... Praleuor 
17 
FICUity ofMedicine 
Uniwnity ofBri1ilh Columltia 
1 Dr. <ina Rya Assistant Prafasor 
~ ofObii(Jya 
Unavwsity afToran10 
Dr.RenatoNatlle 
4 Pralaaar 
n.-otObs/Gya 
tJ;rvwsiay otw ...... On11rio 
C!!l,.,,,... .. ~--·-....... (!!r--t 
s 81,522 
=-~=-·CIIM ....... t 
y_ ...... , 
............... 
=--' =-
1947 03/01./97 
1965 
t:-t=tl.\. ,.,.;_. REPR 
R!PRODUC'nONIPRECiNANCY 
I·~=.S:.tfa'a 
e--..,., ...... ~, ..... ,....._, ___ ___ 
Dep1. of Obs/Gyn 
76 Grenville Street 
Toronto, One. MSS 182 
(416) 323-7317 
B.C. Women's Hospital 
IT62-4SOO Oak SL 
Vancouver, B.C. V6H lNl 
(604) 175-2424 
Mount Sinai H ·w 
775-600 Univ= Ave. 
Tcr01rto, Ont MSG 1X5 
(416) 586-8415 
St. Joseph's Health Centre 
PO Box sm. Stn Cte esc 
London, Om. N6A 4V2 
(519) 646-6091 
Cliaical hMIIipion 
CJiaic:al Trim 
O.......e 
=·"'*"'== 
Perinatal Clinical Triats 
Malemal Fet1l Medicine 
Ma1emat Fecal Medicine 
Ma1emaJ Fetal Medicine 
Mllemal Fetll Medicine 
H-C ...... IIJ&._.. C: •••- • 1• a Dr. Kelly 8eanlft. Resident V, DlpL ofObiGyn., Memorial University afNewf'oundland 
Dr. Rary Wiadrim. Professor, Dept. ofObiGyn., Memcrial University of Newfoundland 
Dr. Kim 8uft.llaiden11V, Dept. ofOb/Gyn .• Memorial University oCN.wf'oundland 
c 
c 
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(! .. _,, ................... _~., ...... , 
Yaun& David 
,..fl ............ ,,,.. ............. ___, 
S ll.Sl2 
Tll.NIIf .... lllrtllllllllrtNI·W.--. ..... 
709-71WI57 
'•IT ....... 
709-753·1161 
lt ..... 
<' ...... _. .......... ..._., ... w:w:~•..-1 
......... £ ............. .._ .. _.... ,.........,. ....... ,_ .... lUll.-•-==-~=-
....... - .......... - ........................................................ .. 
............. ifiiCMieltlla ....... ., .... ....... 
Labor induaion is a &equena obstdric: intervention (=201'/t). Prostaglandins (PGs) are 
ettective apnts. but pstroinlestion&l (GI) intolerance has limited use to non-oraJ routes. The 
tnditioMI oxytocin .. drip" requires intravenous (IV) use and discourqes mobility. Misoprostol. a 
modified PG. is nwkeced for onl UtabiiCld of Gl disorders. but initiases uterine c:ontrac:tions. an 
undelinble Gllide e&c:t. Recently. there hu been a research "boom• on misoprostol in prepancy 
to eft'ectively and safely empcy me uterus. by usina this .. side etrea··. Almost all this research has 
been per vqina. We are oae of two or three sroups worldwide who have published on oral 
misoprallol to induce term llbor to IIUdy efl'ectiveness, Gl tolerance. and safety for mother/ baby. 
Cost per patient has been less than one hundredth that of other PGs. even less than IV oxytocin. 
This project wiU advlnce our research for term labor induction w;th two randomized 
conlrDIIed trials (RCTs): one msr=iac oral to vaaiftal rnisoproaol w;th unniotic membranes ilact. 
the other onl misoprosaol to IV oxy~ocin with prellhor ruptured membranes. We will assess time 
to Vlliftll binb. mott.A»aby wd ' · .. motber•s satisfiction. and any Gl effects. With 6uther 
...-rdl we hope to fiDd nUipiOIIUia d coli etrectiYe oral induclion qerst . 
........... ,.._ .............. ..... 
-· ...... ----= 
...... Dill/ u.• a. 
S\-~.J-.1~ I ~ 
-----.... . .,.. ..... _, .... ,., 
c...•-..-.---:n_~·-
====w:=a::=r .. ,.:.. .. 
181 ... ,...... ....._ ... .... 
181 ·::==: ....... :.diMft ....... ~ 
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..... ., ..... 
Yauna.DDid s 81,522 
.......... ...-. .... -.,_ ..... l._._....._......, • ........_ ....... ,z .... 
,. ..... 
--
• I '::Sf:tu I s 39,172 s 9,961 $49,140 
=J=: I $22,600 s 5,650 s 21,250 
===== s TOTAL 'IRSCINNIL I .... TOTALI POUlt Ll 'lllSCINNIL Dl RlCHEJlCHE 
1 w::.-=:·m=o.:o•' 
I -- ' tiC.) 
I l a.a.. .... ,~ ........... 
j .,... ... l ....... ~ .. 
I 
TOT A&. 1'WAINEES I TaTA&. STAGIAIRII 
....... ,.._ 
.. , ~~--
·--
...... 
CIW.......__..,,.._If ........... l 
TOTAL 
... 
.. 
s 
s 
S SIS 
s II 
s 2,759 
TOTALS I TOTAUX 
s 71,090 
I 
I 
I 
I 
I s 
s 3,432 
s 11,522 
J 
J 
I 
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·---
Yauq.David s 11,522 
.._._.. 
·--............. A.,. ........................... .. 
.............. fiiiii!L 
IOhnlwk 
20hnlwk 
a. _,.., ..... 11 ...... .,,._ 
................ 
....... ___ ._ ......................... 
.. ..... .,_, _ _ 
,. ................ _ .. ,.ir= ..... .. 
...... , ... _,..., •• CUft. ..... ,
... ,...._.,..._ 
.... ................... , ..... _. ......... .. 
......... (1 ....... - ....................... , ... 
..... , .... l:r--' 
c. ..... ., ....... &. 
-··= .. 
Slilaylllllft 
s 
PERSONNEL 8-Ril 6 n'mr1 
Position: a-dt Assisunt 
Credentials: BllcMiar ofNunina. Level n pay scale (source: Collective 
AiJWW NLNU, NHNHA and Treuury Boud) 
Dep11 D'MIIl: Obllltrics A GyftecoloiJY, Faculty of Medicine. MUN 
r.,.,.. !aR'N rs r: 
This is a p;ufi I" aMI polition providina racudt 1Upport to the office of 
Oblletrica A G7IIICDioaY· The polilion llllintainl a liaison with ofticills of 
the Faculty ofMedicine. Nuniftl. Pharmlcy and lfosPtaJ Adminisuation. 
General supervision is provided by research applicant and Discipline Chair. 
..... 
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Youna, David s 81,522 
Qulia: 
• FllftCiian u full-time project co-ordinaror. 
• Collect_, collllla eft0111phk:, iiiD'Ipll'tUm and ourcome dala. 
• lftpul dlla ., aapuw. 
• Ift(ann P*ftdal puticipuiS about raeardl project al prenalal 
clules. 
• Partici.,.. ill informed consent process. 
• Ad~ pollplrtUm Salisfaction quatiol\11aft. 
• Educare nuniq and medical staff such as family physicians, 
houseslllf, llld cuaoom nunes, reprdina study proux:ol. 
• Conduct lilaabU'e teUChes on relaled topics. 
• Prepare presentations ie. slides. 
Salaries: 
Nunina (screeniJ• a: moni1orins). overtime, scandby, beeper. 
milcqe. IMUIIIeave S 39,872.10 
Benefits (25% 1'011 salary· CPP, PSPP, UIC, WCC, etc) 9,961.00 
D.ereUJ 'tr' ' ''I 
Position: Pbumacy Technician I 
Credenbals: Phlnnlcy Technician Certifiwe. Level III pay scale (source: 
Collective Ajlee111ent NAPE HS, NHNHA and Treuwy 
Bolrd). 
Deputment: ........_,, School ofPhannacy, MUN a: Health Care 
CCJI1MX'IIion (HCC) of St. John's 
r..., eq.,. . 'Hir: 
This ila psof'wllioall poliliaft pnMclina resarch support ro rbe oflice of' 
Obt&etrics a 0, 1 .a..,. The position m8intains alilison with ofticiafs of 
the Facuky ofPIIIrmlcy and Hospilll Adminisualion. Oenenl supervision is 
pnwided by r.-rch appliclnt, Obstetrica a: GynecoJoay Cblir, and Director 
of'Pbumlcy, HCC. 
Qulia: 
• FuactioD u ftdl-dme pharmal:y project miiiiJU. 
• Preplle ave c1n1a 11111 pllclba u per andomizalion schedule. 
• Mliallia records of pllilnt usipment. 
Ada phumlcy liailon with Once Hospital lite, HCC. 
Saluiel: 
OYenime. standby, beeper, milap. annual lave 
Bene6ts (25% paullluy- CPP, PSPP, Uie, wee, etc) 
6.2 
22,600.00 
5,650.00 
'71.190.10 
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EXPENDABLE 
Total prior to taxes 50.00 
HST (10.31%) 5.16 
Total posa.p 55.16 
Eltllultd cost of pHMifu (SW ... da). 
$40.00/rnouth X 12 mondls 410.00 
HST (10.31%) 49.49 
total phone/fix 51t.4t 
SERVICES 
$0.02/copy x 4,000 copies 80.00 
HST (10.31%) 8.25 
tow photocopyins 11.2! 
OTHER EXPENSES 
MataialaadSuppiJa 
Trani 
Estmlated cost et •lleproecal (Rcr 1). 
SO. 77/patient x 206 patients I 51.62 
HST (10.31%) 16.35 
tow misoproaol (RCT I) 114.9'7 
~COlt etplaah (RCI' 1). 
Sl.OO/paliem" 206 palients 206.00 
HST(l0.3We) 21.24 
total pllcebo (RCT 1) 12'7.24 
Eltbuted COlt ............ al (RCI' D). 
$0.77/paaient X 54 patien&s 41.51 
HST (10.31%) 4.29 
tow miloprostol (llCT D) .t5.17 
Eadluted c..a.r • .,... (Rcr m. 
SS.l2/pllient X 54 palientl lll.U 
HST (10.31%) 29.06 
toal oxycoc:ift (llCT D) liO.t4 
EftieatM celt rortnml r.r p.-tatiH et resulas aad 
uplou1 r. .. n '*led ,....a epport.aitia. z.•.oo 
TOTAL EXPENSES saa.sp.n 
6.3 
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1be conniaee wa c:oftCIImlal that misoprosaol wu not beina compared to current ltUidard 
of care. c.vicll prullllllndin (PG) widl or without IV oxytocin. and that thouah labor duration wu 
an outcome of interest. safety should be the preenUent outcome. 
AI is stated in our research proposal. we..,_ thalsubstantiw nwemal (e.J. Caeslrans) 
and newtan (e.a. birth uphyxia) are the prd'ernd primary outc:omc meuures. however, the lllftllle 
siza ...ted to 1pp1upialdy evaluale clinically impoRint dlanaes in these (see RATIONALE PIP 
12.6) would require 3400 and 5030 subjects respectMiy. Such a c:linical trial would need to be 
multicenter and. lhere(ore. cosdy. Belore bep.ail• a naalticemer RCT, the most appropriale 
misoproscol interveftrion needs to be defined. Oral misoprostol would offer a new approach that 
would appeal to many pelients and Clfe8ivers. The RCTs we propose here are to evaluate an oral 
nd:lpiDihll ptatocol in labor induction qainsl V11inaJ misoprostol with membnnes intact (RCT I) 
and .... .....,.oxytocin with prelabor-IUpCW'ed membranes (RCT U). We feel our public:alions lUI 
haw ahown Vllinal rniJOIWOilOI u c:osa-eS"ective c:ompared with a cervical PO/IV oxytocin protocol 
and ani misoproltol no less. lfthe proposed orallllisopro•ol RCTs suppon existing evidence. then 
a multic:emer RCT of sufficient sample size would be tppropriate. with a primary outcome such u 
Caesarean or birth asphyxia. and versus the cumnt standard of care. 
Rnllwer II "DIIed Dea.ber 9, 1996" 
Our proposal has been extensively revised (RCT I and RCT II). and we believe is bener 
orpnized and not repclitively presented. The demonstration of a cost-effective and safe onl 
induction apnt is clinically relevant. The other two reviewers support this. Peer miewers for our 
oral misoprostol publk:ldon 21 • have sugesaed that this may lead a dwlge in saandanl of care in 
NOftll America. after fUrther evidence. 
Onl milopioal is likely to be leu c:osdy even than IV oxytocin induction. where our co•s 
ror IV liae. ftlbint. e~ecuo~y~e solution and oxytocin awnae ss.22 per pllient. 
'Jbec..diln IIIINI&charerofnUoproslol (Searle Canida. Oakville. Onlario) hu not been 
interelled in IUppoft of research in labor induction or prepancy tcnninalion. This relates to 
IFW& I 1 ' llbilicia inbennl to raan:h in pi....,ICf, and muketina liabilities ofbeina IR«'Ci••ed 
with a potllllill'"lborlion" dNa. Even if misoproltol became the ideal pharmlcoloaical induction 
..- and the fine line appfOICh, the multet size and lddilional pnerated revenue would be small, 
coaapaed to the present ..r. and secure Gt market. Unless the company adopcs a .. for the aood of 
women" laamaniwian attiblde. it will never be proiCtive in this uea of research and IMMr .t 
Hllllh Procection Branch IPprGval for investiplion of this new indication. Our research hu been 
wowd by CU" umncy llld ....-. human investipaion llld edlics committees. and subjecU ue 
filly nbrnwl W'dh Airther ~ e\idalce we would leek such HPB IPJI'Oval, in defauace 10 
die IIIUU&ctunr. ['TheR is a rwnour that the company may beain mulcetina misaprolcol oaly in 
comlrinarian with a nonsteroidll Ulli-in8ammalory aaent in a siftale piU (AilTHROTEC). which 
would eliminate use in prepancy.) 
.. 
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A two-tailed sample size calculation was used because eft"ecc may be in either direction. 
Excessive uterine activity vuiables wiD be coUected. u well u substantive newborn outcomes. 
Oxytocin use in our study and control JrOUPS have been specified. 
Ia lbe put yar we have been invited to lftl8ll our raan:h at national (SOOC) and reaional 
_..in Cllllda (Adallic and Ontlrio).llld It IMnlteniuy c:eaten • Calpry, Halifax, Toronto 
and Bllrimore. Raean:ll with misoprostol in obstecrics Uld IYftMCOIOIY in Canada is underway in 
V111couver llld Toronto. I hope this woufd persuade this reviewer of the general interest in the 
Canadian obstetrical community reprding misoprostol. 
Reviewer 1¥2 "Review of Protocol by YOIIDJ D. 9609 cr -34561 • cr B" 
This review was quite encounsinl to us. llld made a number ofbeneficialsugestions. The 
reviewer felt that oral misoprostol is "a potentially imponant addition". and that "misoprostol may 
became the tratnlellt of dloice" for induction oflabor. Our difficulties with obtaining funding from 
the manu&cturer and through MRCJPMAC were understood. 
Concern reptdinJbreWy ofthe resareb plln. clarity of inclusion criteria. and stratific:arion 
wriables have aD been addressed. We have not specified a maximum Bishop score. however. u we 
are explorina misoprostol use for the tWI specuum of cervical .. ripeness". 
We have darifled how side affects will be assessed. by c:aJe11ivers and subjects, and referenced 
our Jatil&ction queslionnaire. 
Because, foUowina revision. the projecc will be completed within one year, we have not 
atllllished an edemll Safety Monitorinl Cc1rnrNaee, however, any in11ance of neonatal asphyxia will 
be brauafll to llllnlion of die study team within 24 boun of its occurrence. for ongoin1 rnonitoriJI&. 
'I"M reviewer hu • ...,....., addition of a trials design expert to our team. Dr. Joan Crane is 
now added a a ~principii imoeslipaor. She is alllltanll fecal medicine subspeciality graduate wflo 
hu now joined our ficulty lnd is at present~ her M.Sc thesis in c1inicll epidemioiOSY at 
Dllhaulil. Tile two colllboratil• .aior resideab, Da. Kimberly Butt and Kelly Bennett are enroUed 
in the cliaicll ~ M.Sc prup~m at Memorill Univenity ofNewfoundland. The resources 
cltbe C&aical Raeardl Group in C1inical EpidemioloaY at MUN are available to us. The principal 
invesciptor hu 111 M.Sc in Desian. MeuuRment, llld Evaluation fiom McMaster University. 
Dlputment of Clinical EpidemioloiY and Bioswislics. 
Reviewtr 13 Oa a ro,. eadtled C.._ittee Review's Report 
We were pleased wilh this very positive review. Throup the revision for resubmission. our 
.... a. bu t.n reduced so that completioft widin 1 yar u a sinal• c:enaer study is now !euillle. 
We f'eel that followinl this project we will proceed with a mulricenler trial u mentioned above. 
I Wll deeply traubled by the &nil line clthis review. It is.....- that the reviewer's oripw 
raq Wll •excellent'" with a score of' 4.4, but this is penciOed over to '"aood" and 1.0, with no 
iDdicldon u to who made this chanp. Presumably the committee hu this autflority. 
9. l 
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Llbor induction is a &equent obstetric ilarlentioa (•20%). Prostqllndins (PGa) .. 
e&1:1ive......, but plllodalilill (GJ) inlolaanc:e hu limited their use co intr.cervical and vqjnal 
ldninillnlian ofPGEa aels. 
Miuprual. POE. lftlloaue, is rnukelecl Cor oral treabnent of upper Gl disorders. The put 
tMt yan hu - mUnomifta Utmaure on iu .-to initiate uterine coatractioas f'or prepiiiCY 
tan· •;,., n in the &It lnd .and trimestas. and llbor induction in the third. Vqiaal administration 
hu bem llmolt m:ln6ely Ulal. hll beal ccsc4'eclive (lell than oae hundredth PGEJ and without 
hlnn co mocher or newbcm. We have published a randomized comrolled erial (RCT) on vqinal use 
ll. An onlllbor inductioa 11ent would be ltti'ICiiw to many patients and care providets. A sinaJe 
ptE hldlt.CT IIIIIIUICripc 11hu evaluated onl 11ilap011d u • one dose cervical Primina aaent prior 
to oxytocin induction, and our RCT" (in press) with 27S subjcc:u addressed an induction prot~cJI 
with repeat oral doses compued to a nditional induction rqime (physician chosen combirwions of 
intracervical or vaainaJ P<i~, intravenous (IV) o"Ytocin. and anific:ial membrane rupture). Both 
acr·s found oral misoprottol effective. well toleraacd. and without harm to mother or newborn. 
Bef'ore a.._kiic on a costly and necessarily ndticenter R.CT to evaluate more subsuntive 
outcomes (Caauans or neonual asphyxia) with sample sizes pacer than 3000, we seek tUndiq 
fbr 1WO RCT"s. fi:lr labor inlb:lion 11 term. RCT 1- • double blind comparison of oral venus vqinal 
niqlroltul, widt intact UGIIi)nws and R.CT U - oral misoproSiol versus IV O"Ytocin with prelabor 
ruptured membnnes (PROM). 
~ ltaaldt Quldoal 
RCT I · When COIIIpwed with vqinal rnisoprcmol (SO~~ ~ 4 houn u needed) for labor 
inlb:lion • term with illlaCt ••••a•w:s. does ani adminislntion dift'er by more thwJ 
4 houn in time &om induction to vaainaJ binh? 
RCT D - When compared with our escablilhed IV oxytocin llbor induction prot~l for term 
PROM. does oral misoproslol (dose a above) difFer by more than 4 hours in time 
&om induclion to vqinsl birth? 
Secol•y researdl questions address harm to the newborn (mcludins cord blood acid base 
...,. a ACOG birth uphyxia crileriaa.u) and mo&ber (Caesareans. peripartum interventions). 
mMemll Gl inlolennce. and excessive uterine ICiivity. 
Raardlftu 
Subjca in bolb lt.CT"s wil be 11 psaltionl.-er dian 37 completed weeks. with a cephalic: 
presenti.., 1M linale &:Ius. who bave an iacfic:laion f'or induction. and no c:anuaindic:alion to 
iaduc:liaa. Yllinal binh. or PG ua 
Rladam elloee«m wil be bloc:Jced and Slnlificd (on Bishop ICOI'e Uld parity). In RCT I, Ill 
IUbjlcll wil naiw a vqinll Uld oral applicalion (misoprollol or p&.cebo). In R.CT D. the conaal 
lfOUP will rwceiYI IV oxytocia, bued on recen1 TER.MPROM ma&JU'. Blindins otR.CT 0 is not 
ttuil* for our center • present. 
Semple U. C'h""DMD were baed on a • 240·miruta. ca (2 tailed) • o.os. p • 0.20. wiah 
o &am our pt& "o•lft2L· Adjustment Cor lnlic:ipad c..rans (<20%) were made. Sample size 
for R.CT I is 206 and RCT D is 101. This recnaitment within a year is supported by our prior 
resarch.'w 
·• 
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Our pnviOUJ wort or 111011 direct relevance to this application hu reaalted in tbrw 
pulllicllions in the puc ,.Vt.1' 21 • These papers ,..,an our two prior randomized c:omroDed trilla 
(RC'I's) al\'llinll1• IIIII c:nl milup0110121 wru a widely esubJished tenn labor inducdon pratOCDI. 
IIIII a liclralure ~'~View" IIIII ........ayu ofvqinal miloproltollt.CI's. These papers are llucribed 
in the lt.aan:h Proposal. paps 12 to 12.10 ofrhis applic:ldon. with the complete papers in the 
Appendix. Data on vqjM1 binh interval (VBI) in the membnna intact llld membranes rupcured 
(PROM) scraaa of our onl misaprostol publication:• will be preseaaed and discussed here. Some or 
this clara cloa not app11r in the paper, but will be praented at the SOGC ACM 1997. 
Of' the 275 IUbjeetJ I'IJiduuWed. 56 were in the PROM llnlUm. VBI (cesuans aducled 
ftam lllllysis) was an-. (a SCindard deviuion) of7l4 :t 461 min with oral misoprosco1 venus 557 
:t 312 min for control subjects (1V oxyrocin) (P-0.13). Nonparameuic analysis wins the Mann 
Whitaey U test fancludina c:aare&lll u the same VBI. but pater than any actual VBI) Jives a 
median VBI utiOO miD with onl misoproscol and 796 min for cunuols (P-0.96). No newbom in 
either poup hid binh uphyxia., •. 
11oe intiCt nwuDw•lb'IIUm coaaiaed 219 subjecls. The control poup permitted phylician 
c:tm.n combinllions af~ prosllllandins.lrtificial membrane rupture. and oxytocin 
infillion. n. VBI (c:e.•as excluded) wu a mean of974 2: 524 with oral misaprosaol venus 1002 
a 606 min in controls (P-0. 73). Nonparamctric analysis fandudins cesuans) siva a median VBI 
afl030 min with oral miloplostol and 994 min with controls(P-0.34). Apin. no newborn in either 
IJ'OUP hid birth aphyxia. 1ft neither sanrum wu a dift'erence in VBI found. Even direction in eft'ea 
time is not tpparalt. 
Our vaainal milaproaal RCT .. for tenn Iabar induction included only intact membrane 
.... =v &y cm.ia ... euentially the same u for the intact membranes straCUIIII or our onl 
milopiCIIIIDIIt.CT21• W'11b doe control poup (as for intact membranes scraaum above) mean VBl wu 
941 a 506 min (excbina ccsarana). with a median lime of931 min (includins cesareans). Very 
1imiJar clara to 1hll in till prwvioul puaaraph. Vqinal misaprostollead to a mean VBI of'753 :t Sll 
min. wilh a median lime oL611 min. Campara~ with the cunuol poup, these VB Is durations are less 
(P-0.011 t-tat, and 0.017 U-tat rapectively). 
'l'lil.-dl.,..-will describe two RCTI. RCT I will be a double blind compuiloa or 
ani venus vqinal rMDproaol for term induction with inciCt neubriDD. It would be loaillic:IQy 
noon ciUIIcult. if not q a 1libll far our cent• to carry out a double blind RCT or oral or wain~~ 
llliloprollol Yaaas Uldidonal induction melhocls. without placebos provided by phamaceutical 
IIIUUfactunn (Sarli Canida far niluprolao1 and Upjoluo for diaoprostone). which is not 
fonlscomina II ,..__ The above dale .,.aas onl misoproslal .-.Its ue very ....,. to die 
c:oattol ..., ,..liadarly with nmbranes intact. A double blind trial of oral venus Vllfnal 
miJoproaol is f'eaibll for us and would pn:Mde unbiased outcome data. particularly on the mon 
IUbjectiw uterine aaivicy. 
RCT U will be clesiped with sufficient power to come to a conclusion reprdina oral 
llliiapiOIIOI wrsas IV oxytocin (no better method yet~- Blindins of this RCT is not feasible 
forUI. 
\ 
.. ,. 
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Induction of labor nar term is fiequently necessary. (more than 20% of labors in many 
Canadian tertiary centen) for 1 variety of obstclric and mediQJ indic:alions. PGs. panicularly 
dinoprostone (P(i~). have bela prown effective c:erYical ripenina and labor induction lplll. u 
Since 1971 there hu been evidence from randomized c:onuoUed trials (JlCTs) that oral PG 
&dministntion is an efFective merhod of labor induction. 2 Unfortunately. oral POs. includifts 
dilloprostone tablets. lad to uucceptallle pstrointestinal (GI) side efFects. with up to a 101.1. 
incidence of vomitifts and diurhca2• Wilh the development of commercial tel PG preparations 
dllial*l for Vllinal or intr~~C~enical application. without such side etfects,the oral PG approiCh for 
labor induction has been virtually abandoned. 
Milo ......... 
Miloprostol (~ Sarte Canada. Oakville. Ontario. Canada) is an inexpensive synthetic 
PGE, analope marketed in North America in an oral tablet form. which is liable It room 
tempenaure. Two formulaaions. I 00 tal llld 200 talo are aYiilable on physician prescription for 
pm•IDon and bllln•ll oe ..... II'Oidll lllli-irdllmmaa dNJ induced pstric ulcers and b'atmem 
of .. ,' .. u1cen. 1 ne hqueacy ofGI side efl'ects is low with oralldministnlion of up to 1600 
"' per clay. U• in PI¥W"Y is Silled to be cofttrlindicated because of its uterotonic etrects and the 
lilt otauiaaai;p. Then bu been no evidence offctotoxic. teruopnic. or carcinopnic etfecu in 
animal studies. 1 Misoprollol COlli less than one hundredth the price per dose of commercial PGs 
curnndy used in llbor iDduclion. 
A role for Vl8inll miloproslol has t.n established in second trimester terminalion of 
pr..-r:). U1ina its utaocoaic e8'ects u in divided doles oC 400 to 2200 ,., per clay. An RCT hu 
canpll'ld llliloprostol &vanbly to clinoproaaone•. Our JRIUP &rst studied misoprostol in second 
trimester tenninalioa ofpi.WCj c:omplicaled by lethal r.taJIIIOIUiies, and found vqinaiUie I 
co•-e&c:Dve to intrumniocic llypertoftic aalifte.' Misoprostol is allo eft"ective in ftnt triiMMcr 
llldcll ws;Waau. but only folo ... ailistration of another abortifacient. such u mileprislone' 
or methotrexate'. 
v..-.a ~.a fer La1Mrl8d•ctio• 
Sewral RCTs have now shown vqinal plKemcnt of misoprostollablets to be an cft'ec:IM 
lllllhod ofua.cina llbor. wilhout Ul increue in adverse maternal or neonaw outcomes ... ,, In 1993. 
Slnchc&-ltlmossal. reponed • RCT of ,..maa misoprostol venus intravenous oxytocin ildbsion 
with dea wd time to v.p.l cleliwry. Subtequent trials have compared a variety of controlpoups 
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iri ... ilmcervical and vqjnal dinoprosc~••. In 1ft RCT iAvolvina 222 subjects at term with 
membrlna intact. our JI'OUP'• fouad deaaled time to Yl8iNl delivery (by approximalely lhne 
baun). lela hqucat ~ ..... Ilion, & ~Croft~ trald (or less use Of epidunlt'lllpPI, end 110 
difl'awcc in Caesarean births witb llliloproslol. Median PG cost per patient with miloprostol wu 
one lluadnldth lhlt in the COIIIrOI tubjecu, who received our established induction protocol 
(physic:iiD-chosen combinltiou of iall'lcervical or vqinal dinoprostone every six houn, anilcill 
rupture olmembnna (AROM). IIIII oxytocin infiasion). 
Our poup reponed ellldl-lnllysis of the published RCTs (S papers"u. l msncu•••• and 
one leur') or vqinal milaprollol venus c:ontemporuy comrol sroups (most indudins vqiall 
Uldlor cervicll commercill prostqlendifts). Over 600 subjec:ts receiving vaainal misaprostol hid 
been observed prospectively in such research.11 Misoprostol hu been effective. Tbcre wu more 
fiequat vqiall birth within 12 hours (Relative risk {b) 1.60, 9S% confidence intei'Yil (Cl) 1.21 
to 2.06) end within 24 hours (ltP. 1.16. Cl t .ll to l . .Sl). Oxytocin use was less (lUl O ..Sl, Cl 0.47 
to 0.61). No sipificant chlnp in Caesareans, low five minute Appr scores, or rate of neonatal 
acidosis wu (ound.11 
Oral Milopr01tol ror Ll.._ ladecdea 
An orelly administered Iabar induction qent would likely be annaive to both patients and 
laJib cere proviclen. Awidlnce ofimwnouslines in some panurients, and less frequent need Cor 
wain~~ aa1inll:iun miaht be llllic:ipated, and considered more client fiiendly. Greater fieedom Cor 
upriaht positionifta and ll1lbulatioD miaht even ficiliwe labor prosress. • 
Beceuse misoprosrol is ~ to be well tolerated orally when used for its primary 
ildic:llioa. the nw 1ement of upper~ dysfimc:tion, we studied the efl"ecriveneu, alety 
...Slide dcls ofmiloproltol• • on1..- for inducdon oflar. Althouah no infonnalion aists 
on cnllftilapiOIIOI phll1lw +" "'" • in third trimester prepu~CY, first trimester uterine contrlelion 
... fbllawina cnlldmiiUIJIIioa suaesc responsa simiJer to that in nonprearllllt use. After oral 
adminisllatioft in mila, the peek coacentnlion and half time of misoprostol acid. the ICIM 
meubolite. are 12 end 21 minutes respeclivety». 
We hew in pcesa2' 1ft ltCT ofonl misoprostol (SO ~• every four hours if needed) venus our 
lllndlrd eppte&h to tam libor iniM:cion {Jihyliciln chosen combirlllions or intrKerW:&I, or vqinal 
dinopiGIIUIW. clUe iiba..._ aa,racia idbsion, end AllOM). a The 275 women were I'1Ddomizal 
inlo ... bued on IMIUINa•--. Prellbor Npture of membranes (PilOM) bid oc:cumd in 56. 
In .........,, the time &om iadiiCiion to vqinll binh with oral misoprostol wu not sipificlndy 
dili!r.-lam dill wilh our ab"'""'d pniCGCOis. There were no clinically or Slltistically sipiftclnt 
di&iaw in lllllemalleCIODdlry ~ meuura (c..ran ...... &equency or epidural ..... 
paialll 11'1111111, or ....a naiiMI oftbe plecenta). Neonatal outcomes, inr.ludifta cord blood ICid 
.,_.....,,... na& ....._ 'nere wa no di1Ferwcc iA fiequalcy ofnwemal Gl side eft'ecls in 
the two 1f0UP1. Onl miloprallol may be a are. cost- effective iltemative to standud induction 
..-.with a hiah c1esree or,... •= c ptab:dity. 
We 1te unaware of adler publicllions usins oral misoprostol for term lebot induction with 
livinl fetuses. Npi et II u have ncendy reponed a double blind RCT with a sinJ1e 200 ~• oral 
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miloproiiOI dose vtra11 piiiCibo for ccnic:al priJnina. in PROM • tam. Twelve houn W.. m 
iallaavenoua oxytocin i-+"C'a protocol wu bepn. i!tbe putic:ipul was noa in proaaeaiw labor'. 
,.,.._IUIIjtcts receiwd onl miiDprostol. and 41 placebo. The Bishop score wu sipificandy 
in41o,.. widl nilopla.al (M).05). Tliny-fbur women Biven misoprollol went into labor without 
oaytocin. woupaed to 20 af*-._. piiCibo (P<O.OOI). lnleMI to anset of uterine ICtivicy llld 
diiMry wa bodllhorter wia Dloproscol (P<O.O I). Therw were three Caeslranl in acb paup. 
'Neanllll CIUialmll and Gl tallnnce _.. comparable. The lllthon concluded that a sirlale 200 ~• 
mitoprollol oral do• wa d'ediw for cerW:al primina. and may be eft'ective for labor induction. 
The onl riiDpiOitol piUIOCOIIIIII its purpose in our IIUdy .,. dift"erent &om that or the Rona 
Kaaa im ·a• s. 0.. ...._ CUIIIIIIIIive dole per IUbjec& for labor illimilar to dlcir 1inaJc doa 
It is reaauriftl that they did noclnd alipi&cant problem wfth acasiYe utcriae activity. 
Ius lbllnct hlljUil ...... lom V~ ora double blind RCT with oral misoprostol 
(50tal fNf1Y 6 houn) versas v.p.l clinoptostone (2mg every 6 houn), with study medication pven 
up to 4 doles. They found no cHaau in induction to delivay interval (37.9 z 41 hours venus 36.0 
z 75 houn), bul failed induclion was biper in the misoprostol aroup (16% versus l-Je. P<O.OOI). 
These induction to delivery in&ervals (not stated if cesareans were included in this analysis) are 
obviously lonaer than thole -.. 11 our center, so we eqerly await their complete manuscript 
pubticalion. 
The median PG COli ia our previous saudies1w wu SO.Jl for misoprostol and a conservative 
S70.00 for saudard therapy. Maximum PG exJ1CftSa for any sinale pllient were under S 1.00 and 
more tblll S110.00 for ......,.ol and standard therapy, respectively. 
Fetal Saldy luaa 
..._.. in labor induclion il die potential for excessive uterine activity which may interfere 
wilh utero: I ..a perfblioa lldl ci •ly to compromise the fetus. Becaule of confiasion llemmina 
tam vRid definitions of ·w Uleriae activity, CUftisD recommended a Slllldlnl tenninoloJY: 
h):patuuic ·a COIIIracliaa llllill mare.._ 90 seconds; tachysyllole • contnction hquenc:y anater 
than fift per ten mUuta; ll)pa • · •haiM • hypertonic contriCtioa or tachysystole with llle &tal 
halt nae clecelerltians or filii tldlyCIIdia. While t11i1 ta rnilioluai is m obvious imprcwement. it 
is 111\er* r'n lltlilrlly, willa • .....a to support it based on fetal or newborn outcomes. Thouah 
tbl; ' · lllip .,..._. • "'• .-..w&ic fetal han raae (FHR) IIIONtorina and fetal well beina 
is DOt one to one. ~ chan&a wociaaed with excessive uterine activity wamnt 
i•lltl1lion ect.to-.. IIIIRie ..mty, provide more direct uw 11111t of fetal well beiDa (f'elal 
blood amplina, adler biaph)'lic:al •aasnent), or removins tbe fetus liom this environment 
(dllivwy), if simple ......,.such • position change or maaemal O"fgeR .. pplemencllion ue not 
QNieeli .... 
Our metHIIIIylis" of dill hm cxiltina RCTs hu found tadlysystole sipific:anlly more 
hquent with miloprollol(la2.11. Cll.53 to l.ll), wfth uterine hypastina&laaion MUty 10 (Ril 
1.84, Cl 0.98 to 3.47). TNs lllltHnalysis included every vap.l misolJrostol protocol The 
IDIXilllum in it a ol tadlysyiiOic in any sinal• report was 37 pen:ent12 , and uaeriae 
h)peuf ••Ma 11 pen:aa. To place this in perspective. conaemporuy lhldies with oxytOcin 
induc:dons report tldlysyslole and uterine hypentimulllion of similar or pater ftequency.M.2t A 
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._. RCT report» &am die 111111ILIIhDnq fbund las llehysystole {7%) and hypentimulalion, than 
with a dinaprostone vqinal inlat. on dlanainl &om their oripw12 every three hours to ua every 
f'our hours proeoc:ol. 
Tbe Vancouver double bbd RCr• found uta'ine hypen1inulation rates of 5% with oral 
nilupa...U and 10% with vqiJIII clinoprostone. with f'ccal distress in t.bor oflJ% in both poups, 
ad c:euran rues or25% llld 22% (NS) -all reusurin& results for oral misoproscolllfety. 
When oxytocin inducdon results in uterine hypentimulation with nonreusurins FHR 
chanaes. dilconainuina the inftasian can reduce oxytocin blood levels quickly. Use of vqinal 
dinopronone pis or misoprostol is more problematic. Authorr' describe vqinl1 lavqe llld 
nmovina tablet remnams. however, intravenous p - adrenerJic qonist reaimens have been usecfl wilh....,... bene6cilllocalytic .....-. flllraw:naus tocolysis ia die apprcsch necessary with oral 
misoprostol. fon:ed emesis would likely be indl'ec:tive, and distasteful. We have never used 
intravenous tocolysis in more than 400 misoprosaol inductions. 
Despite these c:oncems ofpoaible uterine hyperstimulation. subaantive worrisome newborn 
outcomes (neonalaliCidosis, rneconMn aspia-.bon. and ACOG Binh Asphyxia criteriaz-.n) have been 
l"'l'e, • tJ IIUe. and nat clif&renl bec..n nisoprostolllld control groups. It is imperative that such 
ourcome cilia be c::ollecled in tblure tiUdies to quancitate more preciseJy potential risks of misoprostol 
(and trdtionalil)proKha). 
Pnlabor R•ptan oiMeallnMI (PROM) 
Approximately 1% of prepncies present with renn PROM. A Ianser PROM duration is 
thou&hl to be ala ci1rell with a tiat-risk oflnllemll and fecal infection. Over W/e of these women 
will beain labor spontaneoully within %4 hours. llld more than 9S8fe within 72 hours. The etiolol)' 
olPROM is not well understood. Ja 
Tbe usasment of suspedld PROM involves history and physical examination. lab testifta, 
lad ultrllound iJn1P1. A •erite !piCUium eum demoiiiUI!ina ftuid in th: vqina. which is both 
nitnzine posiliYe and f'crnina poli1iw. is diapotaic. N""mazine will detect alkaline lmlliotic ftuicl. 
whlnu the vqinal pH in PfiiiiiiiCY is 4.5-6.0. NitriZine can be falsely positive in the preiCftCe of 
blood. temaa. vqinilis IIIII .,,.. ; IE c IGiutions. The typical fcmina apparanc:e of ~~Miotic 8uicl, 
wh.• a fluid drop dries Oil a llide IIIII is viiUIIizld by microscope, is less often fibcly positive. 
1J11ruound can quulilll8 innulerinl amnioeic Ouicl volume. If' doubt remains followina these 
imleltiplionl. ab• •an fiX" llrdlcr luid leabae is appropriale.Ja 
Cancnl wilh IWub ... n.OM .-e related to ua incrased risk of maternal infection (IUCh 
cbaf • · iii~ pall-plltUID eradamltrilia lnd sepsis) lnd more seriously, ncoftllll inf"ection. Early 
induction to avoid tt.e CIDflllllic:.aions raises worry about increasin1 Caesarean births. There is 
cwauwny lbaul whllber to-...:. i111 5 ely or m1ft8P expectandy; or whether to use oxytocin 
or PG, ifiaduaion is cbolen. 
Sevtnllhldielliave ___.induction with oxytocin or PG's vs expec:unc rnanqerncnt. 
Thae IIUdies have been small and ,.......ly biued by the method of randomization. Neonatal 
outcomes were not IISated blind!y. Overview of these trials wu carried out in the Codnne 
Colllboruion Dllab .. • Prepancy lftd Childbinh Module. Induction aflabor with oxytocin wu 
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IIIOCialed witb biahcr c..... rata (typical OR. (95% Cl): us ( 1.37-2.50)) and toww rilt of 
MOIIIIIal in&clion (typical Oil (95% Cl); 0.27 (0. i2-0.59)) than expectant muapment. D In 
aia11 c:omp~~iaa induction with PGs with apecllllllllllllpiiiCftt. the 6ndinp .. ..-ed PGs 
would f8lll in a similar C •• l'lle (typical Oil (9S% Cl): 0. 91 (0.65-1.50)). and lower l'lle 
orendanwbitia(typic:al Oll(95% Cl): 0.31 (0.20-0.70))~t OveMews or fROM trials complrinJ 
oxytocin VI vqinll PGs IUIPil that iaducliaa of labor with PGs results in fewer Caauelnl 
(typical OR (95% Cl): 0.62 (0.42-0.91)». 
acc.Jy the TEJtMPROM TriaJIU' was published. This remarkable slUdy included 5042 
pllilnla &om 72 centers in Canada, Britaa. Australia. Sweden, Israel. and Denmark. Four poupt 
were compared 1) induc:tioft with oxytocin. :Z) induction with vaainaJ PO~ pl. 3) expec:tant care 
~ induction with oxytocin if needed. and •> expectllll care ~ induction with POE2 ael if needed. 
The primary outcome wu IIIICialll1 infection. AD in&nts were to have a CBC and blood c:u1ture 
performed and clinical "'" mcnt performed blind to lhe ueatment allocation. There wu no 
clitference in the rates or MOftllal infection (:Z.O - 3.0 %) or Caesarean secti\ln (approxima&ely 
10%). Sample size had been chosen to detect a 50'.4 reduction in an anticipated baseline neonatal 
infection l'lle or 4%. Because the Ktual baseline rate was less than 3%, lhe study power was 
un!ortunasely only 25%. The time to deiMry wu shortest in the induction with oxytocin sroup 
(P< 0.0001). There WU I tread toward redudion in chorioamnionitis and postpartum f'cwr in the 
oxytocin induced paup. OIMr secoadlly ouacome analyses .. gated less neonatalllltibiotic use 
and leu hquent neonatal inlenaiw care ldmiaion ror more than 24 hours 'with oxytocin 
induction. Thouah the numbln inwlved are small. aD f'our non-anomalous \)erinatal deaths were 
in the apec11nt poups (P • 0.125). Pllilnt lltiJ&ction wu hipest in the induceclpoup~. In one 
public:alion. the authors co heeled that iaduction with IV oxytocin wu the preferred choice. :n 
Anpably the plliealaf•fertion llld ~Kandary outcome analysis orTERMPROM 
sugac the approach ofi:JI 1 r.,. induction orlabor is unsurpassed. The option of oral apnt for 
llbor induction in tbis sihlllion bep fUrther evaluation. The existing published infonnalion fi'om 
Haft~ Kona 22 and our PROM stratum n is very preliminary. 
RESEARCH PROTOCOL 
........., lteHarU Q•~ 
This proposal seeks lladina ror two randomized controUed trials (R.CTs) to answer the 
f'oiJowina: 
RCTL 
RCTD. 
When compand with vllinal misoproSiol (50~ every rour. hours u needed) ror 
iDduc:tion otllbor at term with irlaact mcmbrues. does oral idminisaration differ by 
more than rour hours in time liom induction to vaainal birth' 
When c:orftl*'ed with our eaeblisbed inlravenous oxytocin labor inductian 
prococol far.....,.. rupcun of' membranes at term. does oral miJoprostol (50~ 
every fOur haun u needed) dift'cr by more than raur hours in time &om induCiion 
to vqinal birth? 
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I. Does onl misoprotaol induclion ofllbor increue hann to the newborn (u mcuured by 
cord blood acid bue lllllysis, and ACOG criteria ror birth uphyxia) or mother 
(Ciesarean. peripanum UIUIIIa or iataventioas)? 
2. Does oral misoproscol increase maternal Gl problems (vomiting or diarrhea)? 
3. What is the hquency of uterine tachysystole and hyperstimulation usoc:ialed with the 
scudy induction protocols (u well u in a poup of term parturients in spontiMOUS labor at 
term)? 
Ratioaale 
Our prior research has demonstrated cost-effectiveness and suuested safety first of 
Vl8iftll rnisoprostol and dlen oral misoprostol in comparison with an established and widely 
f'oDowed labor induction protocol. Before considering a more costly and ambitious multicenter 
trill on a more subslantive outcome such u Caesarean rate (2N • 3400 to detect a chanp &om 
12 to 9 %) or neonalal asphyxia (2N • SOJO to detect a change &om 2 to 1%), we feel fUrther 
raearch (&n euence pilot studies) is required to beUer define the appropriate interwntion to 
evaluale in such an cxerc:ise. Oral misoptosaol induction would be most innovative. 
The first RCT here pro.,ased wiU provide an assessment or oral misoprostol apinst 
vqinal miloptollol u the initial approach to term labor induction with membranes intact. There 
il no •ch publilhed trial to dale. A double blind comparison will penni& an unbiased usenmcnt 
of aU outcama. includina the occumnce or ex 11fve uterine activity. 
We feel the SKOnd RCT, with a clift'erent control poup is warranted. W&th Npaand 
lllllllbrana, vqinal piiCirnent, Mention, llld llbiOipCion ofa misoprostol tablet could Ill be 
pnlblemetic:. Our in1erpnlllion ofthe TERMPROM trial prompts us to choose traditional 
iaaav•IOUI oxytocin induaion for the comral. A double blind approach for this trial is possible, 
but not fasible, at this time in our center. · 
RCI' I· Onl verna Vqiul Miloprostol (Do•ble BUDd) 
S..ple Specillatioa 
Subjects wiD be ncruited &om those patieall who are placed on our hospital induction lisa 
&lr 1ft obsMtric or medical indication EJialllility criteria are preanam women upiUiicHl paur 
.... ]7 cmmpleted weeks with ........ intacc. and • sinal• live fetus or cephalic praentalion. 
Exdusian criteria are nonrassurifta feW ban rate (FHil) tndr.s. prior uterine surpry. 
lldla1 or lllljar fetaiiiiOmlly, SUipected c:llorioamnionitis, known hypersensitivity to misoprosaol 
or otber PGs. or c:ontrlindic:al to vqinal birth. 
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FoUowine approval of the attencfina physician. eliaible subjects wiD be approached by our 
raan:b nurse. an imrestiptor, or an obstetrical resident or Jlafrphysician familiar with the INdy. 
lnlormalion pampblets wiD be circulated to physic:iln oftk:a and prenatal education classes to 
inform women or our racan:h. Our research protocol and consent form has been approved by 
the Human lnvaaiption Committee. FICUity of Medicine. Memorial University ofNewf'aundlaDd. 
and HaJth Care Corporuion of St. John's Resan:h Committee. . 
To address in part iuua ofpneralizability and volumeer bias. demapaphic and au1come 
da&a wiU be coUected on parturients who are ineliiJible, or dcdine randomization. but allow 
confidenlial use of this information. 
Wath the cxceprion of the experimental manoeuvre. all upec:u ofparient care will be 
determined by the patient's own physician. If eliaibility criteria are met and informed consent 
obcained, allocation wiU be carried out. Group allocation will be wiped by openina the next 
sequentially numbered opaque envelope only when induction is to bqin. Envelopes will contain a 
cud indic:a&ins Shldy drug packap to be adminislered, which was determined using a computer 
aenented random sequence aftd prepared by uniwnity research personnel not involved in the 
IIUdy. Randomization wiD be blocked in aroups or four and suatified by cervical ripeness (Bishop 
score <7, or not). Study dnsa pacbaes wiD be pRpiRCl by pharmacy and comain eiaht doses 
{maximum dose per subject used in our prior research has been seven) of a desipa~ed packet 
containina powdered misoprostol or methyl cellulose (visually indistin,Wsh3ble), to be 
adminiaterecl by oral syrinp after diaolvina in 30 cc of waaer, or in a 5 cc syrinae c:onuinina 
hydroxyethyl pi for vqinal use. For a aiven subject either the oral powder or the vaainal syrinp 
will concain Ktive misoprostol Our phlrmlcy has developed this approach bued on a previoully 
publilhed protocol'. The oral pnparation will be ldminisaered to a subject, immediately after the 
vqia11 syrinae has been emptied inlo the vap.al poslerior fornix. We have succeafidly used 
these adminiSIIUicms in a number of patienu. This approach has been necessary u the c:osa of a 
pllcebo llblet &om the phum : 'rical manufaclurer hu been quoaed u in eccess of$200,000. 
A vaainal eum for cervical VI nent (Bilbap ICOI'e) and piiCiment of study medicalion 
(by a rllllt pllylician or raidenl) will occur immediately before randomizalion. Allsaudy 
induc:danl wiD be Cllried out oa ID inpltiem buis. with contiNaous electronic FHil and Ulerine 
CIDIIInCtion moai1orina unlil uterine ICiivity has resolved. or a mininum or 1 hour after lilY PG 
admilillrllion. Miloplosaollbldy drup wiD be npaaed at 4 hour intervals until one or the 
followinl occurs: proaaessiwlabar, contnctioa hquenc:y oftllree per 10 minutes. nonrassurina 
FHil tncina. or delivery. AD cllcilioRs with reprd to AR.OM. analpsia. epidural use. llld 
oxytoc:iD IUIIftlllll1ion will be mille by the lltlftdiaa physician. A alfphysiciu wiD ~ tbe 
palient WOre ach llllminillrllio of misoprosaol. The rationale for this schedule is our prior 
experience. aua This dose hqucncy will not be exceeded. Study dna& use !NilJ be clisconliiUed 
after Npture of membranes. Oxytocin aupenwion may not beain until 4 hours after 
dilconliradna misoprasaol. Intravenous oxytocin wiD beain at 2 miU/min and be inc:reued at 2 
miU/min inca ements every 3().6() milwtes. 
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Mac..W ud newbom outcome ...uures are required. All study subjects will remain in 
dleir IDOCIIed poup for outcome Ill II iaeul • Ill "intent to trell" analysis. 
The primary outcome ia the lime &om onset of induction to vaainal birth. Althouah 
con.nz may be abWned eulicr, ruadomizalion will not occur until the time induction is to 1Jeain. 
A di&renc:e of 240 minutes wu c:holcn u clinically imponant to detect, on the buis of a 
quellionnaire survey of prepant ud posq,utum pllients, nunins lnd physic:iu stafF. 
Secondaly outcomes include: 
I. Labor intervals to vqinal birth - induction to fi.dJ dilalion., duration of membrane rupture, 
llbor lllpl (fint. second and third). 
2. Labor intervals with Caesarean binh. 
3. Malcrnll incervencicms ud morbidity- frequency of IV use, Vlginal-exams (for study 
drup ud other}, oxytocin use, lllll1aia use (epidural, narcotic. general, other), 
nonreassurina FHR. fetal blood umplin& episiotomy, perineal laceration (depee}, incac:t 
perineum, manual ranoVII ofpllccnta, endometritis, fever >38 -con cwo oc:cuions more 
dian six houn apart. postp1rNm stay, estimaled peripanum blood loss. poscpartum 
haemofrhlae. blood transftasion. ocher sipificam illness and dCIIh. 
4. Binb route: Vlainal {spontaneous, vacuum or forceps}, and Caesarean. 
5. Frequency of uterine tacbysyscole (>6 coftCndions per 10 minutes). 
6. Malemal Sllis&ction with labor CVIIUIIed by questionnaire (Labor Agentry Scale"). 
7. Neonatal morbidity- coni uteay ICid bue analysis, Appr scores ac one and five minutes, 
meconium prior to birth. ACOG criteria for binh IXphysia [four findinp: profound 
metabolic or mixed 1cidvnia (coni artery pH less thin 7.00), 5 mimlte Appr scare orJ or 
laa. neoaatal neuroloaic lbaonnllity,lnd dysf\aftc:lion of one other lnajar body sysaem}. 
time ill intlftlive care and halpitaJ. sepsis. pneumonia. mcninaitis. antibiotic treacmenL. 
other sipifiCIIII i1lnca or deldl. 
1. MMimll G1 iatoleruot- hquency ofnausa, wmitina or clianhea by CU'IIIiWr NpOn 
... pllieat questiollnlire. 
Bllllinl demoplphic dala coUected on study subjects wiU include: indicalion for induction. 
ptrily, Bisbop scare. qe. liCe. heiaflt. weipt, poup 8 streptococcus (GBS) swus and neonllll 
bildlweiJfiL 
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The primary outcome measure rime &om induction to vapl&l binh. is a continuous 
vuilble. 
• (2 tliled) • 0.05 
p •0.20 
z. •1.96 
z, •0.84 
ct • standard deviation derived fi'om poolin1 of results &om our prior vaainal 
miloprostol cohort •• (511 minutes) and n IIUoprostol intlct membranes lh'ltWil 
21 (524 minutes). 
N (group) • 2 ( (Z. +Z,)oiAtjl 
•16 (usina PEPI. Version 2, 1995. Computer Proarams for 
Epidemioloaic Analysis. USD) 
2N •172 
Our prior SNdies •u• bad consistent overall Caesarean rues of 12.2 and 12. 4%. 
Combined. this rue is 12.3% with 99% CJ 1.8- 16.5%. Addifta 20% or 34 to the prior 2N would 
lllow for llllicipated Caesuan births in our sample. 
:. RCT I Sample Size • 206 
,......., 
1'111rw .. lppi'OXimacely 2600 annual binha II the Once General Hospital, SL John's, 
Newla """""d . nil provincill tatilry uait is lbe oaly binh cen1• within 100 lcilomecen for a 
....... ofov.l50,000. Our induclion rate is just over 20% Pvina approximalely 520 
inducliana ..... ,.,. Our pnvioulstudia enrolled 222 and %19 subj«ts respectMIIy 1' 11 for 
induc:aioa with intact mea1ibr&Mi in 6 months each. It should be quite feuible to complete this 
clinical trill in one year, linaaltaneously with RCT D. 
Dala AuiJiil 
Hypolbllil teslina wiD be pcrb1aed only on the primary CMCOme. Other c:ompuilona 
willie eanli du.SIIypathelis aa•llion. Prelet1iaa decilion _. ud hypodlaes to be lellld 
lhauld aiwiaai::e cilia clredPIIIId post hoc sipificuce biu. Analylil wiD be on 111 .. innna 10 
.._,.bail. t1le pnm.y outcome.......,., tm.10 vqinal birth. wiD be sipific:an& iCP<O.OS {U 
per ample a clfcrlluion) uliaa l*lllllllic llalialica (Student's t). 
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APPENDIX G: BUDGET 
CJedentieh: 
Dlali& 
• F...-u~-~~.· -"----":·--- .. ... 
• cau.:t _. callall1 . .. .... I8U I IUm l8d GUtliOIIIe dilL 
• laput~·-·;-. ,~.::- .. . .. 
• Jnfann p I lialjWIIdpnlllbaut nrilupi ....... PI a 0 .... !lin 
illduc:ID ......... ..__ . 
• Palticiplle in iDfarllled caa.lll PI I • 
• Adminileer pallpUtulft •~'•& lien • r Ndre. 
• EdeM •tellllrlina IIIII ........, _,lUCia u &mily pbyD ·Ins, ..... ._,, 
llld llbaur IDd *~~wry ........... - -.dy .. UIDUll. 
• Candnctlitnlule _._an ...._.IDpics. 
• Prepue ........... ie. llida. 
Sllarill: 
sJom •o 
136 
8r lit 
(25% Groll Slllly • CCP, PPP, UIC, WWC, Group. etc.) 2 woo 
T .... ....,_ M9MQIO 
Mataialud 
S.pp'n• ,.... ,_, CCIII ofNilaprollal. 
Calk I ?'": S0.77 Jp.lienl X 790..... - s 601.00 
GST(2.31%) • 14.04 
PST (12.14%) • 72 M 
$701.90 
Calf..,_: SIO.OO /pllilnl x 790 pllilala • $7,900.00 
GST (2.31%) • 112.49 
PST (12.14% x CIDit ofpllcebo) - • o•• 36 
S9,096.15 
CalctdadMI: loral prior to..... - s 50.00 
GST(2.31%) • 1.15 
PST (12,14% XCIDitof'apendlbler fJi ·~ 
s 57.57 
Ellimlle CIOil ofpllallllfa (S40fmal0). 
Oladlldlll: Iaiii prior 10.... - s 410.00 
GST (2.31%) • 11.09 
PST (12.14% X COlt otapendlble) • 61 §] 
$552.72 
l'rladJic: EJrimeted COlt ofphacac CJ?Jilla-
c.lc II'-~ 10.02/COfll X 4,000 capia • S 10.00 
GST (2.31%) • 1.15 
PST (12.14% X C1D1t af'prinlinl} • IQ 27 
s 92.12 
137 
Trawl: Trawl Car ..-• f • of......_llld aplalbw fbtunl nllled ~ 
opportunitia. 
£trimate trawl - s 2.000.00 
Tetalper,_.. s 62,341.26 
138 


